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  THE UNIVERSITY OF MANCHESTER 
ABSTRACT OF THESIS submitted by Dr Sai L Daayana for the Degree of MD and 
entitled Phase II trial of Imiquimod and HPV Therapeutic vaccination in patients with 
Vulval Intraepithelial Neoplasia   
Month and Year of submission                  September 2010 
Vulval intraepithelial neoplasia (VIN) is a distressing, premalignant condition, 
frequently associated with type HPV16 infection, with increasing incidence in younger 
women. Traditional surgical treatment is sub optimal.  Several different clinical 
studies influencing local and/or systemic immunity to HPV have been reported. 
 
Imiquimod, an immune response modifier can stimulate local innate immunity and 
also drive an adaptive immune response.  Therapeutic HPV vaccines are designed to 
generate cell-mediated immunity against HPV infected cells.  The rationale of this 
study was that local imiquimod treatment, in addition to having a direct effect on VIN 
could also provide an immunological platform for the therapeutic HPV vaccination to 
achieve an enhanced and durable response. In this phase II trial, we used a 
combination of imiquimod and vaccination with TA-CIN (HPV16 E6E7L2 fusion 
protein).  
 
Women with biopsy proven high-grade VIN were recruited. Imiquimod treatment for 8 
weeks was followed by three i.m. injections of TA-CIN. The objectives were to 
measure lesion size, histology, lesion HPV status, symptoms, immune responses 
before and after treatment as well as safety, toxicity, and tolerability. 
Lymphoproliferation to HPV antigens was used to analyse immunity to HPV before 
and after treatment. Local immune factors (CD4, CD8 and T regulatory cells) were 
assessed by immunofluorescence. 
 
74, 85 and 79% of women had a  50% reduction in the size of lesion and 32, 58 and 
63% had regression of VIN on histology at weeks 10, 20 and 52 respectively.  At 
baseline, 79% had moderate to severe symptoms compared to 21% at week 
52(P=0.01).  Of the women who showed histological responses at week 52, 5/10 also 
cleared their HPV 16 infection. Follow-up for an average of 15 months showed 84% 
of patients with a  50% reduction in lesion size.  Treatment was well tolerated.  
 
A significant post vaccination increase in proliferation to TA-CIN and its components 
was associated with histological responders (P=0.008) but not the non-responders 
(P=0.7). In the group as a whole, significant increases in the number of CD4, CD8 
and T regulatory cells (Treg) were evident by week 20 compared to baseline (P=0.03, 
P=0.01, P= 0.04 respectively); At week 20, the increased CD4 and CD8 density was 
significantly associated only with the histological responders (P=0.03; P= 0.03) while 
increased Treg density was associated with only non-responders (P=0.05). 
Intralesional Treg density was significantly higher in non-responders compared to 
responders pre and post treatment (P=0.01, 0.05 respectively).   
 
This study demonstrated that imiquimod followed by vaccination achieved 
histological clearance of VIN at 52 weeks in almost 60%.  Higher pre-existing and 
post-treatment levels of Treg cells were associated with a lack of treatment response. 
Lymphoproliferation of PBMC established that the vaccination was immunogenic and 
HPV 16 antigen specific. Importantly, these systemic immune responses to HPV 16 
antigens were significantly associated with treatment responders. 
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CHAPTER 1 
     INTRODUCTION 
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1.1 VULVAL (VULVAR) INTRAEPITHELIAL NEOPLASIA 
The term vulval (vulvar) intraepithelial neoplasia (VIN) was introduced in 1986 
to define squamous intraepithelial lesions of the vulva. The term VIN was 
coined by the International Society for the Study of Vulvovaginal Disease 
(ISVVD) and since adopted by the International Society of Gynaecological 
Pathology and the World Health Organisation. On histology VIN is described 
as disorder of cell maturation and nuclear atypia detected at various levels in 
the vulval epithelium [Buckley et al., 1984]. It is a non-invasive condition 
wherein the epithelial basement membrane is intact. Nevertheless, the 
condition is associated with an invasive potential.  
 
It has become increasingly clear that there are two distinct types of VIN, which 
differ from each other with respect to aetiology, pathogenesis and clinical 
picture.  Currently there are two different classifications of VIN, the WHO 
classification and the ISSVD classification. 
 
1.1.1 WHO CLASSIFICATION OF VULVAL INTRAEPITHELIAL 
NEOPLASIA 
 
WHO CLASSIFICATION [Wilkinson, 2003] 
 
VIN (warty/basaloid) with grades VIN1, VIN2 and VIN3 
 
VIN (simplex type) 
 
ISVVD CLASSIFICATION OF VULVAL INTRAEPITHELIAL NEOPLASIA 
Classification of VIN has evolved over several decades. International Society 
for the Study of Vulvovaginal Disease (ISSVD), have recently (2003) 
reclassified VIN into 3 categories: 
1. VIN, usual type (undifferentiated type), which can be further subdivided 
into 
a) VIN, warty type 
b) VIN, basaloid type 
c) VIN, mixed (warty / basaloid) type 
2. VIN, differentiated type 
3. VIN, unclassified type 
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The occasional example of VIN that cannot be classified into either the above 
two VIN categories (usual type and the differentiated type) may be classified 
as VIN unclassified type. e.g. the rare VIN of pagetoid type. 
 
In contrast to the WHO classification the ISVVD committee recommended 
revision of the traditional three-tiered grading system of VIN. As there is no 
evidence that the ‘VIN1-3 morphologic spectrum reflects a biologic continuum 
nor that VIN1 is a cancer precursor’, ISSVD recommended that ‘the term VIN 
should apply only to histologically high-grade squamous lesions (former terms 
VIN 2and VIN3 and differentiated VIN3)’. Further ISSVD proposed that 
‘histological changes previously described as VIN1 should be described either 
as flat condyloma acuminatum or HPV effect’.  
 
As per WHO recommended grading of HPV associated VIN, VIN grade 1 is 
defined as ‘maturation present in the upper two-thirds of the epithelium and 
the superficial cells contain variable but usually mild atypia which may include 
viral cytopathic effect’. If the full thickness of the epithelium has abnormal 
cells, VIN III, also called vulvar carcinoma in situ, is diagnosed. 
 
There is some debate as to which classification to follow and some 
histopathologists prefer to utilise the WHO classification in their diagnostic 
work.  
 
1.1.2 INCIDENCE  
 
VIN although not a very common condition, the incidence is increasing, more 
so in younger women. VIN has been identified as one of the twelve neoplasias 
whose incidence has increased in the developed countries [Akerman et al., 
2007b]. Studies have shown a nearly three-fold overall increase in the 
incidence of VIN across the world over the last twenty years [Herod et al., 
1996;Iversen and Tretli, 1998;Jones et al., 1997;Joura et al., 2000;Sturgeon 
et al., 1992]. The SEER (Surveillance, Epidemiology, End results) American 
cancer registry database reveals a 411% increase in the incidence of VIN 
from year 1973 to 2000, whilst the corresponding increase in vulval cancer in 
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the same time period has only been 20% [Akerman et al., 2007b]. The 
increase in the incidence of VIN, a precursor lesion in the majority of the 
cases of squamous cell carcinoma (SCC) of the vulva is expected to be 
followed by an increase in the incidence of invasive vulval cancer, but this has 
not been the case. As suggested by Akerman et al the unknowns of natural 
history of VIN and the effects of treatment may make any extrapolation 
hazardous. The disproportionate increase in the incidence of VIN in 
comparison with vulval cancer is thought to be due to an increase in the 
incidence of genital human papilloma virus (HPV) infections.    
 
Also, a study conducted in four hundred and five women diagnosed with VIN 
between the years 1962 and 2003 showed the mean age to decrease from 
fifty in the sixties to a mean age of thirty-nine in the subsequent years [Jones 
et al., 2005;Joura et al., 2000]. Lanneau et al identified fifty-six women under 
the age of forty-five years diagnosed with SCC of the vulva and observed that 
the incidence of both VIN and invasive SCC of the vulval had increased at the 
rate of 2.4% per annum; particularly in young women [Lanneau et al., 2009]. 
Increasing awareness of this condition among medical practitioners and 
increasing willingness by women to present with symptoms associated with 
VIN could also to a small extent have contributed to the rise in the detection of 
this condition.  
 
1.1.3 AETIOLOGY 
 
Aetiology of VIN is multifactorial and heterogeneous. The usual or 
undifferentiated type of VIN is more common than the differentiated and 
unclassified types of VIN. The usual or undifferentiated type is strongly 
associated with HPV infection of the female lower genital tract.  More than one 
hundred and thirty HPV genotypes have thus far been cloned from clinical 
lesions in the human beings. About thirty-forty HPV types are known to infect 
the genital tract, of which, about fifteen types are considered to be oncogenic 
and therefore high-risk. Usual or undifferentiated type of VIN was found to be 
associated with high-risk infection, HPV16 in about 78-90% of cases and less 
commonly with HPV 18 infection [Buscema et al., 1988;Ikenberg et al., 
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1983;Junge et al., 1995]. Meta- analyses of ninety-three studies of prevalence 
and type distribution of HPV in VIN using polymerase chain reaction (PCR) 
assays conducted across four continents demonstrated 85.3% HPV positivity 
in VIN 2 and VIN 3 lesions [De Vuyst et al., 2009]. A systematic review by 
Insinga et al of prevalence and attribution of HPV types among genital tract 
pre-cancers and cancers in the United States estimated that following 
multitype adjustment, which is adjustment for the presence of multiple HPV 
types in a single specimen, (n=503, 2 studies) HPV 16 was estimated to 
contribute to more than three quarters (77.7%) of VIN3 lesions. HPV 16, 33, 6, 
11 and 31 were the five most frequent HPV types detected, in order of 
prevalence, and multiple infections were observed in 5.8% of cases [Insinga 
et al., 2008]. A retrospective case-note study of long-term follow-up over a 
fifteen-year period of hundred and thirty-three women with biopsy confirmed 
VIN demonstrated that the number of women diagnosed with VIN had 
increased throughout the study period. Women who were HPV positive on 
biopsy sample taken from the VIN lesions were significantly younger than 
women who were HPV negative in the biopsy taken from the VIN lesions 
[Herod et al., 1996]. Skapa et al subjected two hundred and sixty nine vulval 
excision samples representing lichen sclerosus, lichen simplex chronicus, 
differentiated VIN, usual VIN, condyloma acuminata and squamous cell 
carcinoma to HPV typing. Different HPV profiles and differing frequency of 
multiple-type HPV infections were noted in women with high-grade usual or 
undifferentiated VIN compared to women with other types of vulval disorders 
[Skapa et al., 2007]. Presence of HPV infection appears to be the most 
influencing factor in the development of VIN. Infection with HPV on its own 
may not however cause VIN. It is presumed that associated factors that 
interfere with body’s immune system i.e. smoking, immunosuppression, and 
inherited immunity problems may also contribute to the disease, which will be 
discussed in the subsequent sections of the thesis.  VIN thus appears to be a 
component of multifocal HPV associated lower genital tract neoplasia as it is 
often multifocal and exhibits an obvious association with vulval warts, vaginal 
intraepithelial neoplasia (VAIN) and anal intraepithelial neoplasia (AIN).  
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The second and less common type of VIN, referred to as differentiated VIN 
(also known simplex VIN) is not associated with HPV infection but commonly 
arises from a vulval dystrophy, either lichen sclerosus or squamous 
hyperplasia.  Although Abel and colleagues first described features of this 
condition in the 1960’s, it is only in the recent years that the morphological 
features of differentiated VIN are made clear and the existence of this type of 
VIN stressed [Hart, 2001]. In a large study of five hundred and eighty women 
diagnosed with premalignant vulval conditions, only one hundred and seventy 
one were diagnosed with the usual (undifferentiated) type of VIN, nearly half 
the women were diagnosed with differentiated type of VIN and lichen sclerosis 
(two hundred and sixty one) and the remaining hundred and forty five women 
were diagnosed with squamous hyperplasia. The risk of squamous cell 
carcinoma of the vulva was also found to be significantly higher in the 
differentiated VIN group (85.7%) in comparison with the usual VIN group 
(25.7%) [Eva et al., 2009].  
 
1.1.4 CLINICAL FEATURES 
 
VIN lesions are polymorphic both in appearance and size. On inspection of 
the vulva, the lesions can be appearing to be unifocal, multifocal or diffusely 
scattered, with hypo or hyper-pigmented appearance (figure 1). On palpation, 
the lesions can be felt to be raised, rough surfaced or flat.  Majority of the 
lesions although are present on the inner aspects of the labia majora and 
minora, they can present anywhere on the vulva including the clitoral, 
periurethral and perianal aspects of the vulva (figure 2). Most lesions are 
symptomatic and cause the distressing symptoms of itch, soreness, irritation 
or discomfort. Asymptomatic lesions are uncommon and usually are detected 
incidentally when the woman is undergoing a gynaecological examination.  
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Figure 1 a – Unifocal VIN, 1b – multifocal VIN, 1c – multipigmented VIN, 1d – 
hyperpigmented VIN 
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Figure 2 Clitoral and Peri-urethral VIN 
1.1.5 NATURAL HISTORY OF VIN  
 
Studying the natural history of VIN is difficult, as most women diagnosed with 
VIN undergo treatment either for symptom relief or because malignancy is 
suspected. The more common HPV associated usual or undifferentiated type 
of VIN and the differentiated type of VIN which is not associated with HPV 
infection, are both likely to progress to pre-invasive early stromal invasion 
(ESI) of the vulva and invasive SCC of the vulva.  The rate of progression of 
VIN to invasive carcinoma is thought to be variable and about a tenth of the 
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proportion of cases are thought to progress to invasive carcinoma. 
Spontaneous regression of VIN is however uncommon and is thought to occur 
in less than 1.5% of patients [van Seters et al., 2005].  
 
1.1.6 MALIGNANT POTENTIAL 
 
The progression of grade 1 VIN to invasive vulval cancer is considered to be 
very low [Bancher-Todesca et al., 1997] in contrast to the clearly established 
progression of VIN3 lesions in 3-19% of cases to SCC of the vulva [Crum, 
1992;Herod et al., 1996]. In a retrospective study by Leibowitch et al, when 
seventy-eight specimens of SCC of the vulva were reviewed retrospectively, 
in most cases of SCC of the vulva, adjacent epithelium showed morphological 
changes of VIN or HPV changes in 22-67% of cases, VIN3 in 20-30% of 
cases, and lichen sclerosis in the nearby epithelium in 10-62% of cases 
indicating that in the majority of cases, a common factor plays a role in the 
development of pre-malignant and malignant lesions on the vulva [Leibowitch 
et al., 1990]. In some cases there is found to be a clinicopathological overlap 
between HPV associated and non-HPV associated SCC of the vulva. The 
majority of SCC of the vulval is found to be associated with vulval lichen 
sclerosis (differentiated VIN) but VIN is also adjacently found in a third of 
vulval carcinomas [MacLean, 2006]. Some studies have confirmed a 15-22% 
rate of occult carcinoma in histologically diagnosed VIN3 [Chafe et al., 
1988;Herod et al., 1996;Husseinzadeh and Recinto, 1999;Modesitt et al., 
1998a]. In a recent study by Eva et al greater than a thousand biopsy samples 
(n=1309) from five hundred and eighty women diagnosed with various pre-
malignant vulval conditions were studied and matched with prior, synchronous 
or subsequent diagnosis of SCC of the vulva. Among women diagnosed with 
the HPV associated usual or undifferentiated type of VIN, the rate of 
progression to SCC was found to be 25.7% in comparison to a markedly high 
85.7% risk of progression to SCC of the vulva, linked with differentiated type 
of VIN.  A large study based on the Netherlands Nationwide database of histo- 
and cytopathology conducted over a period of fourteen years concluded that 
overall percentage of the usual or undifferentiated type of VIN that were later 
diagnosed with SCC of the vulva was 5.7%, which was significantly lower than 
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the 32.8% risk of progression noted with the differentiated VIN. In addition, the 
time of  progression to SCC of the vulva for differentiated VIN was significantly 
shorter than the usual or undifferentiated VIN [van de Nieuwenhof et al., 
2009]. There is thus enough evidence to suggest that differentiated type of 
VIN is significantly more associated with vulval SCC than the usual type of 
VIN [Eva et al., 2009].  
 
In a retrospective case-note study of hundred and thirty-three women 
diagnosed with VIN, all of who underwent treatment for VIN, progression to 
invasive disease occurred in 7% of the cases [Herod et al., 1996]. Similarly, in 
a study of hundred and thirteen women diagnosed with VIN by Jones et al 
among the hundred and five women who received treatment for VIN, four 
women developed cancer (4/105), whilst among eight women who did not 
receive any treatment for VIN but were only clinically observed, seven women 
(7/8) developed cancer within eight years of clinical observation [Jones and 
Rowan, 1994]. Jones et al in their natural history and outcome study of four 
hundred and five women diagnosed with VIN concluded that untreated VIN in 
women over 30 years of age has an appreciable invasive potential [Jones et 
al., 2005].  
 
In a large review article on three thousand three hundred and twenty two 
women with VIN, only eighty eight women were found to not have undergone 
any treatment for VIN, of who, eight women (9 %)developed disease 
progression to invasion [van Seters et al., 2005]. The rate of progression of 
VIN to vulval SCC thus appears to vary from less than 5% to up to 20% as 
quoted in the above mentioned different studies and it appears that the 
untreated group carry a higher risk of progression to invasion. 
 
1.2 RISK FACTORS FOR DISEASE PROGRESSION IN WOMEN 
DIAGNOSED WITH VIN 
 
Many factors contribute to an increased risk of SCC of the vulva. Age has 
been shown to be one of these risk factors. It has been show that women 
aged forty or more are at an increased risk of HPV associated SCC of the 
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vulva compared to younger women [MacLean et al., 1993]. The incidence of 
HPV associated cancer is known to be much higher in the 
immunosuppressed, [Al Ghamdi et al., 2002;Brown et al., 2005;Buscema et 
al., 1980] further discussed in this manuscript. History of previous lower 
genital tract neoplasia i.e. pre-invasive and invasive disease of the cervix, 
vagina, vulva and anus, more so if the previous condition was treated with 
radiotherapy has also been shown to be a risk factor for VIN [van Seters et al., 
2005]. Proximity of the lesion to the anal margin and squamo-columnar 
junction (SCJ) has also been shown to be one of the risk factors [Buscema et 
al., 1980;MacLean et al., 1993]. p53 over expression has also been 
identified as one of the risk factors for progression of VIN to SCC of the vulva. 
 
p53 OVEREXPRESSION & VEGF EXPRESSION IN VIN  
 
The TP53 gene encodes the transcriptor factor p53, which plays a vital role in 
cell cycle regulation, tumour suppression and prevention of cancer. p53 gene 
mutation has been demonstrated in some cases of undifferentiated VIN 
[Almeida et al., 2004]. The immunoreactivity of mutated p53 is however non-
specific, as it is also known to be over expressed in HPV positive vulval 
cancer and vulval lichen sclerosis where p53 over expression has been used 
as a marker for invasion [Rolfe et al., 2003]. In one study of seventy-three 
cases of VIN only three women over expressed the p53 gene who were 
diagnosed with concurrent or previous vulval cancer [Rosenthal et al., 2003]. 
In another study of twenty women who underwent surgical treatment for VIN 
and were under regular clinical follow-up, p53 over expression was observed 
in ten out of twenty women. Interestingly, nine of these women subsequently 
developed disease recurrence and one woman developed SCC of the vulva 
[Almeida et al., 2004]. Vascular endothelial growth factor (VEGF) expression 
was found in 6% of cases of VIN and 92% of cases of SCC of the vulva and 
perhaps VIN expressing VEGF exhibits a greater risk of turning invasive 
[Lewy-Trenda et al., 2005].  
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1.2.1 SPONTANEOUS REGRESSION 
 
Literature about spontaneous regression of VIN is limited, mostly case reports 
and a retrospective case note review [Friedrich, Jr., 1972;Jones and Rowan, 
2000;Skinner et al., 1973]. In the literature thus far, the demographic and 
clinical traits of women in whom spontaneous regression occurred were very 
dissimilar to the routine. The patient group was much younger (mean age of 
19.5 years), non-white ethnicity that typically presented with symptoms in 
pregnancy or immediate post-natal period. So far, spontaneous regression 
has not been reported in any other patient groups.    In a recent, small two-
year prospective study, eight women who were newly diagnosis with VIN were 
kept under careful observation. Only women who consented to the ‘wait and 
watch’ policy were recruited into this study. Surgical treatment was exclusively 
considered when progression to invasive disease was suspected or for 
uncontrollable symptoms. Six of the eight women underwent surgical 
treatment very soon after recruitment and overall seven women underwent 
treatment within the two-year study period, majority for symptom control. No 
disease progression or spontaneous regression was observed in the 
remaining one participant demonstrating the chronic nature of the condition 
[McFadden et al., 2009].  
 
1.3 ASSOCIATION OF CIGARETTE SMOKING WITH VIN 
  
Clearly there are factors that drive the outcome of high risk HPV genotype 
infection towards a high-grade or a low-grade intraepithelial lesion. There is 
plenty of evidence for smoking to be one such factor. The number of 
cigarettes, years of smoking and early age of smoking initiation are all shown 
to be associated with increased risk of genital tract neoplasia. Cigarette 
smoking has been implicated both in the acquisition of high-risk HPV 
genotypes and the development of both high-grade intra-epithelial neoplasia 
and cancer of the lower genital tract [Sherman et al., 2008]. History of 
smoking at diagnosis was found to be an important risk factor in the 
progression of intra-epithelial neoplasia to cancer [Daling et al., 1992]. No 
such association between smoking and low-risk HPV genotypes was however 
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noted [Madsen et al., 2008]. In a recent study by Sherman et al women who 
smoked although were not at increased risk of becoming infected with high-
risk HPV genotypes, but were at a significantly increased risk of developing 
high-grade lower genital tract intra-epithelial neoplasia in comparison to non-
smokers [Sherman et al., 2008]. In a study of eighty women with histologically 
confirmed VIN3, women who smoked were not only more likely to be 
diagnosed with multicentric genital tract neoplasia but also were found to be 
thirty times more likely to have persistent disease in comparison to women 
who never smoked or women who quitted smoking following treatment for VIN 
[Khan et al., 2009]. Harris et al proposed that in cases of CIN, cigarette 
smoking may act by increasing cell turnover in the transformation zone of the 
cervix and supported their hypothesis by their findings of increased 
proliferation marker Ki-67 in heavy smokers [Harris et al., 2004]. A study by 
Goffin et al revealed an 8.7 fold (CI 2.0-38.4) increased association between 
smoking, HPV and active VIN status [Goffin et al., 2006]. Although there is no 
transformation zone in the vulva, the effects of tobacco smoking on intra-
epithelial lesions of the vulva may be due to the systemic effects of smoking. 
 
 
1.4 ASSOCIATION OF IMMUNOSUPPRESSION WITH VIN  
 
Immunosuppression has long been associated with an increased incidence of 
HPV associated intraepithelial neoplasia and its subsequent progression to 
malignancy. Higher incidence of persistent HPV infections and related HPV 
associated dysplasia in both the immunosuppressed transplant recipients and 
human immunodeficiency virus (HIV) infected individuals has been clearly 
shown [Bouwes Bavinck and Berkhout, 1997;Palefsky and Holly, 2003]. 
Strickler et al. studied the association between HIV-positivity, plasma HIV 
RNA level, CD4+ T lymphocyte count and the natural history of HPV infection 
or HPV reactivation in eighteen hundred and forty-eight HIV positive women 
and compared the findings with five hundred and fourteen HIV negative 
women. Both the groups were assessed at six-monthly intervals for the 
presence of HPV in the cervico-vaginal fluid by PCR and in the squamous 
intraepithelial lesions by Pap (Papanicoloau) smears.  In HIV positive women, 
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plasma HIV RNA levels and CD4+ T lymphocyte count in combination 
appeared to have a strong and significant association with the presence of 
incidental detection of HPV infection, some of which might represent 
reactivated HPV. Although an association between HIV co-infection and 
persistent HPV infection was also noted, this association was less strong in 
comparison to an incidental infection [Strickler et al., 2005]. Dedes et al 
studied thirty-one HIV infected women on retroviral therapy who were also 
diagnosed with vulval, vaginal and perianal intraepithelial neoplasia. A higher 
than average 65% developed disease recurrence and a third developed 
invasive cancer [Dedes et al., 2008]. Similarly, Brown et al in a retrospective 
case-note review of women diagnosed with vulval carcinoma before the age 
of forty noted an association between VIN progression to cancer, other HPV 
related diseases and the presence of an antecedent acquired immune 
deficiency syndrome (AIDS) defining illnesses. Intraepithelial neoplasia in HIV 
positive women was to be associated with high rates of recurrence and 
invasion despite treatment [Brown et al., 2005]. Koshiol et al. studied five 
hundred and twenty-two women who were HIV-seropositive and two hundred 
and seventy-nine women who were HIV-seronegative in their HIV 
Epidemiology Research Study (HERS, 1993-2000). They noted that high-risk 
HPV types had lower estimated clearance rates in comparison to low-risk 
HPV types, with no significant effect by the HIV serostatus on the clearance 
rate of the HPV infection [Koshiol et al., 2006].  
 
Meeuwis et al. in their study of two hundred and twenty four female renal 
transplant recipients on immunosuppressive therapy observed an increased 
propensity for development of pre-malignant and malignant lesions involving 
the skin and the female lower genital tract. In this group of women the 
increase in the incidence of CIN was two to six-fold, the increase in the 
incidence of carcinoma of the cervix was three-fold, but disturbingly the 
increase in the incidence of SCC of the vulva was fifty-fold [Meeuwis et al., 
2009].  
 
Aynaud et al conducted a retrospective study in hundred and six women who 
underwent laser treatment for ano-genital condylomatous lesions or ano-
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genital intraepithelial neoplasia and were followed-up for up to six months 
after treatment. Within this cohort, they compared immunocompetent women 
with those who were rendered immunosuppressed for therapeutic reasons 
and also with women who were immunosuppressed with HIV infection. Ano-
genital intraepithelial neoplastic lesions, in women, comprising CIN, VAIN, VIN 
and AIN were significantly more common in the HIV positive group (47.4%) in 
comparison to the immunocompetent group (20.2%) and this difference was 
statistically significant. As well, immunocompetent women and women who 
were immunosuppressed for therapeutic reasons more commonly presented 
with disease recurrence at follow-up in contrast to women who were 
immunosuppressed with HIV infection who presented with disease 
persistence [Aynaud et al., 2008].  
 
Immunosuppression, irrespective of the cause, in association with ano-genital 
HPV infection is characterised by persistent dysplasia and an increased risk of 
progression to malignancy [Ferenczy et al., 2003;Sillman et al., 1997].  
 
1.5 ASSOCIATION OF VIN WITH HUMAN PAPILLOMA VIRUS 
 
The lifetime risk of acquiring a genital infection on at least one occasion with 
an oncogenic strain of HPV is thought to be above 80% [Koutsky et al., 1988]. 
More than hundred and thirty HPV genotypes have thus far been cloned from 
clinical lesions of which, about thirty to forty types infect the epithelial and 
mucosal lining of the female ano-genital tract and other areas [Steben and 
Duarte-Franco, 2007]. The low risk HPV types, predominantly types 6 and 11, 
cause genital warts and about fifteen high-risk (oncogenic) types, 
predominantly types 16 and 18, infect the genital tract and contribute to a 
significant proportion of cases of CIN and VIN [Parkin and Bray, 2006].  
 
Incidental infection with HPV 16 is thought to occur in about 6% of the general 
population. Low risk HPV 6 or 11 infection was detected in 64.5% of VIN 1 
lesions and 29% of VIN 2 or 3; whereas, high-risk HPV 16 was detected in 
6.5% of VIN1 and 64.5 % of VIN2/3 [Garland et al., 2009]. HPV infection of 
the genital tract is often multicentric [Beckmann et al., 1991;van Beurden et 
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al., 1998]. Nearly one-third to a half of women with HPV positive high-grade 
VIN were shown to also possess CIN or other lower genital tract neoplasia 
[Hording, 1995;Jones and Rowan, 1994]. It has also been shown that up to 
76-94% of women with active VIN3 lesions harbour high-risk HPV types 
concurrently both on the cervix and on the vulva and the HPV types are 
usually concordant [Beckmann et al., 1991;Lijnen and Blindeman, 1994;van 
Beurden et al., 1998]. In another retrospective study of fifty-two women who 
were either previously treated for high grade VIN or were diagnosed with 
active VIN during the study period, high risk HPV DNA was detected at 
multiple sites on the vulva and also on the cervix. Past or current status of the 
disease was found not to have any effect on the presence of high risk HPV 
[Goffin et al., 2006].  
 
Insinga et al. conducted a systematic review on prevalence and attribution of 
HPV types among cervical, vaginal and vulval precancers and cancers 
[Insinga et al., 2008]. It was estimated that three thousand four hundred and 
ninety women in the USA would be diagnosed with vulval cancer in year 2007 
resulting in eight hundred and eighty deaths. HPV 16 (n=503, 2 studies) was 
estimated to contribute to more than three quarters (77.7%) of VIN3 lesions. 
Among vulval cancers, (n=197, 4 studies) only data for squamous cell 
carcinoma of the vulva were available. In this group, HPV types 16, 33, 6, 1 
and 31 were the five most frequent HPV types detected, in order of 
prevalence, and multiple HPV infections were observed in 5.8% of cases. 
Following adjustment for multiples types of HPV within the same lesion, HPV 
16 was found in nearly 50% of all the cases and in more than 75% of HPV-
positive cases. In another study of fifty-five women diagnosed with vulval 
carcinoma over a period of ten years by Monk et al, HPV prevalence within 
the lesions was described in relation to the patient’s age group.  The HPV 
positivity varied from 100% in the forty-five or younger age group to 71% in 
the forty-five to sixty-nine age group to 47% in women aged seventy years or 
more [Monk et al., 1995].  
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1.5.1 THE LIFECYCLE OF HPV  
Human papilloma viruses are epitheliotropic, non-enveloped, small, circular 
double-stranded DNA viruses that belong to the papilloma viridae family. HPV 
infections are not systemic; remaining at the site of initial infection, usually 
resulting in an asymptomatic infection, which often clears. Only a minority 
develop high-grade lesions [Kotloff et al., 1998].  
 
1.5.2 FUNCTION OF VIRAL PROTEINS 
 
The early (E) and late (L) proteins of the HPV have different functions in the 
life cycle of the virus. The following comprise the early and late viral proteins. 
E1 viral replication 
E2 viral replication and transcription 
E4 destabilization of cytokeratin network 
E5 mediated mitogenic signal of growth factors 
E6 cellular transformation 
E7 cellular transformation 
 
L1 major viral coat protein 
L2 minor viral coat protein 
 
1.5.3 INFECTION  
 
For epitheliotropic viruses such as the HPV, to cause an infection HPV 
requires access of infectious particles to cells in the basal layer of the 
epithelium. This requires a break in the stratified epithelium. It has been 
speculated that for the sustenance of infection the virus must infect an 
epithelial stem cell [Egawa, 2003]. On the vulva, stem cells are abundant 
within the hair follicles. HPV infection is thought to occur through micro trauma 
of the genital tract enabling access of the viral particles to target lymphocytes, 
probably the stem cells present in the basal layer of the epithelium.  
 
 
 
 44
1.5.4 GENOME MAINTENANCE 
 
Following infection, it is believed that the virus maintains its genome in the 
basal layer of the epithelium. It is generally thought that viral E1 and E2 
proteins are expressed whose function is to maintain the viral DNA as an 
episome and to facilitate correct segregation of genomes during cell division 
[You et al., 2004;Zhang et al., 1999]. The viral transforming proteins E6 and 
E7 are also expressed in the cells of the basal layer, though their role in 
genome maintenance is not as defined as the early viral proteins E1 and E2 
[Crum, 1998]. It is believed that viral genome is maintained in the basal layer 
at around 10-200 copies per cell and that viral early proteins (E6, E7, E1 and 
E2) are expressed at lower levels [De Geest et al., 1993;Stanley et al., 1989].  
 
1.5.5 PROLIFERATIVE PHASE 
 
In the uninfected epithelium, the process of terminal differentiation allows the 
basal cells to exit the cell cycle soon after migrating into the suprabasal cell 
layers. Changes that lead to natural terminal differentiation include the 
physical cross linking of keratin intermediate filaments, formation of cornified 
envelopes and secretion of lipids which together allow the epithelial surface to 
form a physical barrier against the microenvironment [Madison, 2003]. During 
papilloma virus infection, E6 and E7 are expressed in these cells, which are 
thought to have a synergistic effect. As a result, the restraint on the cell cycle 
progression is abolished and normal terminal differentiation is retarded 
[Sherman et al., 1997]. It has been shown that both E6 and E7 have functions 
that stimulate cell cycle progression and both can associate with regulators of 
cell cycle [Munger et al., 2001]. In addition, the association of E7 with 
members of the pocket protein family such as pRb, a negative regulator of the 
cell cycle that normally prevents S phase entry and other proteins involved in 
cell proliferation is well characterised. Despite the ability of E7 to stimulate cell 
proliferation during productive infection, only subsets of cells in the parabasal 
layers are mitotically active. The expression of cyclin E is absolutely 
necessary for S phase entry and is expressed during natural infection.  It 
appears that during natural infection the ability of E7 to stimulate S phase 
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progression is limited to the subset of differentiated cells, which express high 
enough levels of E7 to overcome the block to S phase entry. The viral E6 
protein complements the role of E7 and is thought to prevent the induction of 
apoptosis in response to unscheduled S phase entry mediated by the E7. 
Although the association of E6 with p53 and the inactivation of p53 mediated 
growth suppression and/or apoptosis is well been documented, E6 can also 
associate with other pro-apoptotic proteins including BaK [Thomas and Banks, 
1998] and BaX [Li and Dou, 2000]. The presence of E6 is considered as a 
predisposing factor in the development of HPV associated cancers allowing 
the accumulation of possible errors in host cell DNA to go unrestrained. The 
E6 protein of high-risk HPV types can also stimulate cell proliferation 
independently of E7. In addition to E6 and E7 it is thought that the other viral 
early proteins (i.e.. E1, E2, E4, E5) are expressed prior to the onset of 
genome amplification in order to ensure maintenance of the viral episome at a 
low copy number [Middleton et al., 2003].  
 
1.5.6 VIRUS SYNTHESIS 
 
Once viral genome amplification has been completed, papillomaviruses 
encode two structural proteins in the upper layers of the infected tissue, L1 
and L2. L2 is a minor coat protein but like L1 is produced in the subset of cells 
that express E4 [Doorbar et al., 1996]. The major capsid protein L1 is 
expressed after L2 allowing the assembly of infectious particles in the upper 
layers of the epithelium [Florin et al., 2002]. Papillomavirus particles comprise 
an approximate 8000 base pair genome within a capsid that contains 360 
copies of the L1 protein and probably 12 copies of L2 organised into a 72 
capsomere icosahedral shell [Modis et al., 2002]. The L2 protein accumulates 
at nuclear structures known as PML bodies during viral assembly and recruits 
L1 to these domains. It has been suggested that PML bodies may be the sites 
of papillomavirus DNA replication [Day et al., 1998;Swindle et al., 1999]. 
Although virus like particles can assemble in the absence of L2, the L2 protein 
is thought to enhance packaging and infectivity [Roden et al., 2001]. To be 
successful, the virus must eventually escape from the infected skin cell and 
survive extracellularly prior to reinfection. Papillomaviruses are non-lytic and 
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are not released until the infected cells reach the epithelial surface. 
Papillomaviruses are resistant to desiccation [Roden et al., 1997] and their 
extra cellular survival may be enhanced if they are shed from the epithelial 
surface within a cornified squame [Bryan and Brown, 2001]. The intracellular 
retention of papillomavirus antigens until the cell reaches the uppermost 
epithelial layers may compromise immune detection of the virus, particularly if 
the virus also has molecular mechanisms that limit the presentation of the viral 
epitopes to the immune system in the lower epithelial layers [Marchetti et al., 
2002]. Although the expression of viral proteins can inhibit expression of 
differentiation markers preventing the formation of normal cornified squames, 
[Doorbar et al., 1997] it has also been suggested that it is the viral E4 protein 
that contributes directly to virus egress in the upper epithelial layer by 
disturbing keratin integrity [Doorbar et al., 1991] and effecting the assembly of 
cornified envelope [Bryan and Brown, 2001;Lehr et al., 2004].  
 
1.6 IMMUNOEVASION, PERSISTENCE OF HPV INFECTION AND 
DEVELOPMENT OF NEOPLASIA 
 
1.6.1 IMMUNE EVASIVE STRATEGIES ADOPTED BY HPV 
 
Immune system plays an important role in controlling the spread of HPV 
associated infections. There is ample evidence to show that individuals with 
immune defects (i.e.. transplant receipts, HIV infected individuals and in some 
individuals with genetic defects in immune cell function) are particularly 
susceptible to HPV infection and can develop widespread lesions that are 
refractory to treatment. HPV is perfectly adapted to its natural host tissue, the 
differentiating epithelial cells of the skin or mucosa. Several factors minimise 
or prevent exposure of the virus to the immune system. HPV do not infect and 
replicate in antigen presenting cells (APC) nor do they lyse the keratinocytes. 
HPV replication and release does not cause cell death, as the differentiating 
keratinocyte is already programmed to die, and this “death by natural causes” 
does not present as a danger signal to the immune system. In addition, HPV 
suppresses the expression of several proinflammatory proteins that are crucial 
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in clearing infection and activating the cytotoxic T lymphocytes (CTL) involved 
in killing virus-infected cells. 
 
1.6.2 PERSISTENCE OF HPV INFECTION 
 
The frequent detection of HPV 16 DNA in the cervical lesions in the absence 
of any obvious disease may be explained by its presence in the latent state 
with only very few cells supporting the productive cycle during the epithelial 
cell differentiation. Following immune regression, papilloma virus DNA is 
thought to remain in the basal epithelial cells and then be reactivated when 
levels of immune surveillance decline. It has been suggested that latent gene 
expression is restricted to E1 and E2 proteins and that during this phase of 
the virus life cycle the E6 and E7 genes are not required [Zhang et al., 1999]. 
 
E6 and E7 proteins between high and low-risk HPV types are shown to be 
different, more of a quantitative rather than a qualitative nature. High-risk HPV 
types show more tendencies towards genomic integration, where as low-risk 
types are preferentially maintained as episomes – portions of genetic material 
that can exist independent of the main body of the genetic material [Arends et 
al., 1998].  
 
Genital infections with HPV are usually transient with the majority of 
individuals showing clearance of virus within a year of detection [Evander et 
al., 1995;Ho et al., 1998;Sellors et al., 2003;Woodman et al., 2001]. Only a 
minority of women appear to develop persistent infections with focally high 
levels of HPV DNA, a proportion of whom progress to developing high-grade 
disease and invasive carcinoma [Herrero et al., 2000].  
 
1.6.3 PROGRESSION OF PERSISTENCE HPV INFECTED LESIONS 
 
Considering the high prevalence of HPV infections in the human population, 
the number of lesions that progress to cancer is in fact very low. Key event in 
the progression of productive lesions to high-grade neoplasia may result from 
deregulation in the expression of the viral transforming proteins E6 and E7, 
 48
resulting in increased cell proliferation in the lower epithelial layers. Failure to 
restore the normal status and secondary mutations in the host cell DNA [von 
Knebel, 2002] retention of E6 and E7 genes and loss of E2 and E4 genes, 
which can exert a negative effect on cell growth, all these changes contribute 
and accompany the development of invasive cancer [Peh et al., 2004].  
 
1.6.4 REGRESSION OF HPV INFECTED LESIONS 
 
Despite the ability of the HPV to inhibit host defences, a successful immune 
response to genital HPV infections is established in most cases resulting in 
the regression of lesions. It has been suggested that in humans although 
about 80-90% of genital HPV infections resolve with time, in the remaining 10-
20% of cases, the individual does not become HPV DNA negative and 
develops persistent infection [Beckmann et al., 1991].  
 
1.7 HOST IMMUNITY 
 
There are two main arms to the immune response, which play a role in the 
natural clearance of infection, the innate and the adaptive immune responses. 
Protective immunity results from the interaction of the non-specific innate 
immunity and antigen specific adaptive immunity. Without the antigen non-
specific defence by the innate arm of the immune system, the adaptive arm of 
the immune response, which generates pathogen specific antibody and 
cellular effectors, is not activated and a pathogen can effectively hide from the 
host immunity.  The nature of HPV life cycle, where the local infection does 
not result in necrosis and the production of virus particles occurs only in cells 
that are terminally differentiated enables the virus to surreptiously take 
advantage of not been recognised by the innate division of the immune 
response and thus avoid potential immune control [Stern et al., 2000].  
 
1.7.1 INNATE IMMUNITY 
The innate immunity system senses tissue damage via signals from 
molecules, which would normally not be found exogenously. This involves 
production of immunoregulatory molecules such as cytokines (alpha, beta and 
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gamma interferons (   IFN), transforming growth factor beta (TGF), 
tumour necrosis factor-alpha (TNF-) and interleukins (IL-1, IL-6, IL-10, IL-12, 
IL-15), monocytes, macrophages, natural killer (NK) and antigen presenting 
cells (APCs), all of which have direct controlling effect on virally infected cells. 
The defence mechanisms involving these immunoregulatory molecules 
represents the first line of defence [Dermime et al., 2002a;Matzinger, 2002a]. 
In the female genital tract, dendritic cells (DC) or Langerhan cells (LC) are the 
antigen presenting cells (APCs) with the unique ability to take up and process 
antigens in the peripheral blood or tissues. The information acquired by these 
cells can shape the subsequent T cell mediated immunity by the adaptive 
immune response arm of the immune system into T helper (Th) type 1 or Th 
type 2 or T regulatory response [Kalinski et al., 1999;Wang et al., 2006].  
 
1.7.2 ADAPTIVE IMMUNITY 
 
The generation of an adaptive immune response is important in the long-term 
control of infection or tumour. The APCs activate a range of T lymphocytes. 
Th type 1 response will favour the production of cytotoxic T cell effectors 
which would be important in clearing any virally infected cells whilst a Th type 
2 response will facilitate the stimulation of B lymphocytes and their production 
of neutralising antibodies. With HPV infections, activated B-lymphocytes make 
antibodies against the viral capsid proteins or optimally activate cytotoxic T 
lymphocytes. The adaptive immune system is capable of generating antigen 
specific memory and can deliver long-term protection against subsequent 
HPV infection of the same type. Despite the ability of the HPV to inhibit host 
defences, a successful immune response to genital HPV infections is 
established in most cases. This is characterized by local cell mediated 
immunity that is associated with lesion regression and the generation of 
serum neutralizing antibodies directed against L1 protein displayed on the 
outer surface of the intact virus particle. However, serum neutralizing antibody 
levels following natural HPV infection, even at peak titres, are low [Carter et 
al., 2000]. Neutralising antibodies, although of uncertain significance in 
preventing infection or reinfection after natural exposure (prior infection) are 
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known to be highly protective after immunisation with HPV virus-like-particles-
based-vaccines [Einstein et al., 2009].  
 
Innate and adaptive immunity are not two separate entities because innate 
immunity controls both the development and nature of the adaptive immunity. 
APCs provide an important link between innate and adaptive immunity with 
dendritic cells acting as the most potent inducers of primary and secondary 
immune responses. Dendritic cells capture antigens, migrate to secondary 
lymphoid organs, and after maturation, they present the processed antigens to 
antigen-specific lymphocytes where clonal immunity is initiated. The innate 
activation of dendritic cells can trigger their differentiation into immunogenic 
APCs that are able to prime and expand naïve T lymphocytes. Therefore, 
activation or maturation of dendritic cells, as an essential component of the 
immune system, translates antigen-non-specific innate immune recognition 
into antigen-specific adaptive immunity. 
 
1.8 MAJOR HISTOCOMPATABILITY COMPLEX  
 
One method of identification of the antigen is by B-lymphocytes with their 
membrane bound antibodies, also known as B cell receptors. Whereas B cell 
receptors of B-lymphocytes can bind to antigens without much outside help, T 
cell receptors of T lymphocytes require presentation of the antigen. This is the 
primary role of major histocompatability complex (MHC) in the immune 
system. It is a very gene dense region, containing one hundred and forty 
genes and in the humans the MHC region is represented on chromosome 
number six. An individual is expected to have a maximum of eighteen MHCI 
or II alleles. There is however a high degree of MHC polymorphism in the 
general population.  
 
MHC proteins act as indicators, presenting fragmented pieces of an antigen 
on the host’s cell surface. Cancer cells and cells infected by a virus have a 
tendency to display unusual, non-self antigens on their surface. These non-
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self antigens, regardless of which type of MHC molecule they are displayed 
on, will initiate the specific immunity of the host’s body.    
 
MHC class I proteins are expressed on all the nucleated cells and present 
antigen fragments to the cytotoxic T lymphocytes and bind to the CD8 
receptor on the cytotoxic T lymphocytes.   MHC class I dependent pathway of 
antigen presentation is the primary way for a cell infected with virus to signal 
the influx of T lymphocytes. The subsequent fate of a virus-infected cell is 
almost always apoptosis, initiated by the cytotoxic T lymphocyte (CTL). 
 
MHC class II is expressed selectively on the APCs including macrophages, 
dendritic cells and B-lymphocytes. These cells present antigen fragments to T 
helper cells by binding to the CD4 receptor on the T helper cells. The antigen 
peptides presented by class II molecules are derived from extracellular 
proteins, hence the MHC class II dependent pathway of antigen presentation 
is called endocytic or exogenous.  
 
The sub-set of genes in the MHC region that encodes cell-surface antigen 
presenting proteins is referred to as human leukocyte antigen (HLA) genes. 
The nine classical MHC HLA genes are HLA-A, HLA-B, HLA-C, HLA-DPA1, 
HLADPB1, HLA-DQ-A1, HLA-DQB1, HLA-DRA and HLA-DRB1. The A, B and 
C genes belong to MHC class I, whereas the six D genes (HLA-DPA1, 
HLADPB1, HLA-DQ-A1, HLA-DQB1, HLA-DRA and HLA-DRB1) belong to 
class II. HLA has a critical role in the complex immunological processes that 
occurs between various cells in the body and the T lymphocytes.  
 
HLA down regulation when studied in relation to VIN and SCC of the vulva, 
poor response of VIN lesions to treatment has been attributed to HLA class I 
down regulation and reduced number of intralesional langerhan cells and CD8 
T lymphocytes. In 82% of cases of SCC of the vulval, total loss of HLA class I 
genes was observed [Abdel-Hady et al., 2001]. Abdel-Hady et al in their 
clinical study of photodynamic therapy for VIN observed that none of the 
women with HLA class I down regulation responded to the treatment in 
contrast to women who did not demonstrate HLA class I down regulation and 
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in 50% of women with HLA class I down regulation, VIN progressed to 
invasion [Abdel-Hady et al., 2001].  
 
1.9 CYTOKINES 
 
Cytokines are critical to the development and functioning of both innate and 
adaptive immune responses. They are secreted by immune cells in response 
to pathogens to cascade recruitment of more immune cells and increase the 
system’s response to the pathogen. The predominant producers of cytokines 
are helper T lymphocytes and macrophages.  
 
1.9.1 CYTOKINES STRUCTURAL CLASSIFICATION 
 
Based on their structure, cytokines have been classified into four types, the 
four -helix family comprising IL2, IFN and IL10 subfamilies, the IL-1 family, 
which primarily includes IL1 and IL18, the IL17 family (yet to be completely 
characterized, member cytokines have a specific effect in promoting 
proliferation of T lymphocytes that cause cytotoxic effects) and the 
chemokines. 
 
 
1.9.2 CYTOKINES FUNCTIONAL CLASSIFICATION 
 
Based on their function, type 1 cytokines enhance cytokine response (IFN , 
TGF  etc.) whereas type II cytokines favour antibody responses (IL4, IL10, 
IL13 etc.). Cytokines in one of these two sub-sets tend to inhibit the effect of 
those in the other. This has been an area of intense interest as dysregulation 
of this tendency is under intensive study for its possible role in the 
pathogenesis of autoimmune disorders. 
 
Other groups of cytokines include interferons (IFN) and chemokines. IFN  
and IFN  inhibit viral replication in infected cells, where as IFN  also 
stimulates APCs. Chemokines attract leukocytes to the sites of infection. 
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Some cytokines are predominantly inhibitory. For example, IL10 and IL13 
inhibit inflammatory cytokine production by the macrophages.  
 
1.9.3 CYTOKINE PRODUCTION PATTERN IN LOWER GENITAL TRACT 
NEOPLASIA  
 
Cytokines that modulate immunological control have long been speculated to 
be critical in regulating tumour growth. The type I cytokines IL2 and IFN  are 
immunostimulatory and capable of limiting tumour growth. The type 2 
cytokines IL4 and IL10 are immunoinhibitory and capable of stimulating 
tumour growth. In a study which looked into production of cytokines by 
peripheral blood mononuclear cells (PBMCs) in women with CIN, associated 
with localised or extensively spread HPV infection, thirty women with CIN and 
ten age and sex matched healthy control subjects were recruited. IL-2 
production by PBMCs in response to stimulation with soluble antigen or HLA 
all antigens was reduced in the group with extensive disease in comparison to 
the group with localised disease or healthy control subjects. With extensive 
HPV infection, the production of immunoinhibitory cytokines IL4 and IL10 was 
at its highest with a pronounced shift from type 1 immunostimulatory to type 2 
immunoinhibitory cytokine production [Clerici et al., 1997].  
 
1.10 T LYMPHOCYTES 
 
T lymphocytes play a vital role in the cell-mediated immunity. The presence of 
T cell receptor on their cell surface differentiates them from other 
lymphocytes. T lymphocytes are categorised into different subsets based on 
their function. The major subsets of T lymphocytes are: 
 Helper T lymphocytes (effector T lymphocytes or Th cells) 
 Cytotoxic T lymphocytes (Tc or CTLs) 
 Regulatory T lymphocytes (T regs) 
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1.10.1 HELPER T LYMPHOCYTES (effector T lymphocytes or Th cells)  
 
These cells arise in the thymus and have two important functions; stimulation 
of cellular immunity and inflammation, and stimulation of B-lymphocytes to 
produce antibodies. When Th lymphocytes are presented with both antigen 
and appropriate cytokines, they begin to proliferate and become activated. It is 
the nature of stimulation that determines which path they enter, leading to Th1 
or Th2 pathway. Th1 and Th2 cytokines are antagonistic in activity. The 
equilibrium between Th1 and Th2 activity may guide the immune response in 
the direction of cellular or humoral immunity. T lymphocytes are initially 
activated as Th 0 cells, which produce IL2, IL4 and IFN. The nearby cytokine 
environment then influences their differentiation into Th1 or Th2 cells. Th1 
cells produce IL2, IFN  and TNF, which activate CTLs and macrophages to 
stimulate cellular immunity and inflammation. Th1 cells also secrete IL-3 and 
GM-CSF (granulocyte macrophage-colony stimulating factor) to stimulate the 
bone marrow to produce more leukocytes. Th2 cells in turn secrete IL4, IL5, 
IL6 and IL10, which stimulates antibody production by the B-lymphocytes  
(Microvet). 
  
Specific CD4+T lymphocyte help is crucial for the development of cellular 
effector and humoral mechanisms against viral infections. For progressive 
HPV induced neoplasia, impaired responses against the viral antigens will 
result in unfavourable disease prognosis.  
 
1.10.2 CYTOTOXIC T LYMPHOCYTES  
 
A number of different cells in the immune system possess cytolytic activity 
against a broad range of cells. The most thoroughly studied of these cells are 
the cytotoxic lymphocytes. Cytotoxic large granular lymphocytes that 
spontaneously lyse certain tumour cells are called natural killer cells, 
important mediators of the first line defence mechanism, the innate immunity. 
These cells are unique in that no previous sensitisation is required for them to 
kill. Another type of killer cells are the lymphokine activated killer cells which 
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are known to lyse any type of cell and such cells are used in cancer therapy. 
Mechanism of action of these cells is however not yet very well understood. 
   
The last group of cytotoxic cells are the cytotoxic T lymphocytes, which kill 
infected, damaged or dysfunctional cells in an antigen-specific fashion and are 
believed to be essential for the elimination of virally or oncogenically altered 
cells. Although cytotoxic T lymphocytes are capable of lysing a wide range of 
target cells, an individual cytotoxic T lymphocyte is capable of lysing only 
those target cells that carry the appropriate antigen and therefore require prior 
sensitisation in order to function. These cells are thought to mediate graft 
rejection, mount responses against viral infections and intracellular bacterial 
infections, and play a major role in tumour destruction. 
Cytotoxic T lymphocytes are activated when cells infected with the virus or 
other pathogens via the antigen processing undergo degradation and release 
foreign proteins. Following activation, the cytotoxic T lymphocytes undergo 
expansion with the help of IL2, thereby enhancing the quantitative lymphocyte 
response to the target antigen. The primary mechanism through by which the 
cytotoxic T lymphocytes control infected cells is by killing them. The T 
lymphocyte receptor on the CD8 T lymphocytes possess a glycoprotein, CD8, 
which recognises a specific antigenic peptide bound to the MHC class I 
molecules. CD8 T lymphocytes can also suppress pathogens by other means 
such as release of chemokines and cytokines. Characteristically, an antigen- 
specific cytotoxic T lymphocyte response is in three stages. Stage one 
involves antigen specific proliferation of the T lymphocytes, stage two is 
acquisition of effector functions by the T lymphocytes resulting in elimination 
of the target cells and stage three is contraction of effector phase into 
maintenance phase, in which, the surviving antigen specific T cells develop 
into the long-lived memory CD8+ T cell population [Kaech et al., 2002;Ahmed 
and Gray, 1996;Sprent and Surh, 2002;Wong and Pamer, 2003].  
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1.10.3 REGULATORY T LYMPHOCYTES (suppressor T lymphocytes) 
 
These cells are a specialised subpopulation of T lymphocytes that act to 
suppress activation of the immune system and thereby maintain immune 
system homeostasis and tolerance to self-antigens. These cells are potent 
immune regulators. Regulatory T lymphocytes come in many forms, CD4, 
CD25, FoxP3CD4 (CD4+CD25+ regulatory T lymphocytes or T regs), CD8 
and other T lymphocytes types that have suppressive function. 
CD4+FoxP3CD4+ regulatory T lymphocytes (T regs) have been referred to as 
naturally occurring regulatory T lymphocytes to distinguish them from 
suppressor T lymphocyte population generated in vitro. 
 
T regs are capable of mediating peripheral tolerance to auto antigens and 
regulation of T lymphocyte responses directed to foreign antigens. A proposal 
for the existence of two general subsets of CD4+CD25+T regulatory cells has 
been made; naturally occurring and induced, that not only differ in their 
mechanism of action but also in their origin, development and activation 
requirements [Piccirillo and Shevach, 2004]. FoxP3CD4 is a member of the 
forkhead / winged helix family of transcription factors critically involved in the 
development and function of CD4+CD25+ T regulatory cells and is also a key 
regulator of immunosuppression. It is a nuclear product and not expressed in 
the cell cytoplasm or on the cell surface. Expression of this single transcription 
factor causes a developmental switch in naïve T lymphocytes to a suppressor 
cell phenotype, more commonly referred to as regulatory T lymphocyte. 
FoxP3CD4 expression was previously thought to be restricted to T 
lymphocytes. The discovery of FoxP3CD4 as a specific marker for T 
regulatory cells led to an outburst of research on the biological activity of 
regulatory cells. 
 
The immunosuppressive cytokines TGF  and IL10 have also been implicated 
in enhancing the regulatory T lymphocyte function. A large number of 
FoxP3CD4 expressing T regulatory cells are found within the MHC class II 
restricted CD4 expressing CD4+ helper T lymphocyte population and express 
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high levels of IL 2 receptor alpha chain (CD25). In addition to the FoxP3CD4 
expressing CD4+CD25+, there also appears to be a minor population of MHC 
class I CD8+ FoxP3CD4 expressing regulatory T lymphocytes. Prior to the 
identification of FoxP3CD4, these two cell surface markers CD4 and CD25 
were used to identify and define this population and thus these cells are often 
referred to as CD4+CD25+ regulatory T lymphocytes. As defined by CD4+ 
and CD25+ expression, regulatory T lymphocytes comprise about 1-2% of 
CD4+ helper T lymphocytes in humans. T regulatory cells prevent migration of 
effector immunocytes to the target organs and inhibit their cooperation with 
APCs.   
 
1.11 THE ROLE OF REGULATORY T LYMPHOCYTES IN 
IMMUNOSUPPRESSION, INFECTION & CANCER 
 
Regulatory T lymphocytes having CD4+ CD25+ FoxP3CD4+ (T regs) or 
CD4+IL10+(Tr1) phenotype are found to be capable of inducing anergy 
toward self and allo-antigens thereby playing an important role in 
autoimmunity, tolerance of allografts, pregnancy and in the development of 
cancer. In human cells, alteration in the number of T regulatory cells, in 
particular, those expressing FoxP3CD4 has led to a variety of conditions. 
Humans with mutations in FoxP3CD4 gene suffer from a severe and rapidly 
fatal autoimmune disorder known as Immune dysregulation, 
polyendocrinopathy, enteropath X-linked syndrome (IPEX). 
 
T regulatory cells are shown to make up for a large fraction of CD4+ T 
lymphocytes in the normal human skin [Hirahara et al., 2006;Sather et al., 
2007]. Skin is a complex immunological organ subjected to constant exposure 
to microbial flora and antigens. In cases of deregulated immunity in the skin, 
many common inflammatory and allergic disorders could arise. Recent studies 
have confirmed FoxP3CD4 expression in the tumour cells indicating malignant 
transformation of healthy cells can induce FoxP3CD4 expression [Ebert and 
Groh, 2008]. Tumours induce or recruit T regs to disable immune priming and 
hinder the function of antitumour effectors. 
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1.12 T LYMPHOCYTES IN VIN  
 
Alteration in the local immune environment is thought to play a role in the 
development of pre-malignant vulval lesions and persistent disease in chronic 
conditions like VIN is thought to be due to non-functional T lymphocytes 
[Tindle, 2002]. In the vulva, CD8 T lymphocytes are shown to be predominant 
in the epidermis, whilst in the dermis, both the CD4 and CD8 T lymphocytes 
are equally distributed [Abbas and Janeway, Jr., 2000]. Gul et al have 
suggested that increase in CD8 T lymphocyte count is the initial local immune 
response in low grade VIN and that this protective cytotoxic CD8 lymphocyte 
activity is lost as VIN progresses. It has also been speculated that CD8+ T 
lymphocytes present in high grade VIN, especially in non-responders could be 
functionally inactive [Gul et al., 2004]. Similarly, when prognostic significance 
of tumour infiltrating lymphocytes (TIL) in gynaecological and other cancers 
were evaluated, CD8+ T lymphocyte infiltration was associated with better 
prognosis [Curiel et al., 2004;Piersma et al., 2008;Wolf et al., 2007]. Other 
studies have suggested that inadequate generation of tumour specific CD4 T 
lymphocytes in the VIN lesions can result in an inability to reject a tumour by 
the host [Greenberg, 1991]. Studies on advanced cancer however have 
demonstrated that a decrease in the ratio of CD4:CD8 in the tumour infiltrating 
lymphocytes is a very likely indicator of disease progression [Igarashi et al., 
1992;Sheu et al., 2001].  
 
In high-grade VIN, even when cytotoxic T lymphocytes are generated, T 
regulatory cells with immunosuppressive properties are found to dominate the 
lesion environment and counteract the beneficial defence response of the 
cytotoxic T lymphocytes [Kobayashi et al., 2004;Stanley, 2008a].  
 
In a study of thirty-eight women with HPV 16 positive high-grade squamous 
intraepithelial lesions of the lower genital tract, HPV 16 specific T lymphocyte 
responses were absent in the circulation of the majority (nearly 60%) of the 
patients.  Any obvious HPV 16 specific T lymphocyte activity was in patients 
with persistent or recurrent high-grade disease, however, in the majority, the T 
lymphocyte response was not associated with secretion of pro-inflammatory 
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cytokines resulting in lack of cellular immunity [de Vos van Steenwijk PJ et al., 
2008]. In fact, HPV derived lesions were found to be having significantly 
higher number of infiltrating lymphocytes and T regs in comparison to other 
tumours like colon cancer, melanoma of the skin and bronchial carcinoma 
[Loddenkemper et al., 2009].  
 
In a study of fifty-one women with active high-grade VIN by van Seters et al 
tissue samples obtained from the VIN lesions were compared with vulval 
samples obtained from nineteen healthy controls for HPV DNA, T 
lymphocytes and various other immune markers. In the epidermis of the VIN 
tissue sample, the cytotoxic CD8+T lymphocytes were significantly lower than 
in the control group. No significant changes were observed for the helper 
CD4+ T lymphocytes or the regulatory T lymphocytes between both the 
groups. In the dermis, however, of VIN patients, elevated number of both 
helper and cytotoxic T lymphocytes were present in the VIN group in 
comparison to the control group. In summary, high risk HPV associated usual 
or undifferentiated type of VIN lesions are characterised by an 
immunosuppressive state in the epidermis. In the dermis, however, 
inflammatory activity is reflected by the influx of helper and cytotoxic T 
lymphocytes suggesting that the cellular immune response to viral HPV 
infection occurs in the dermis of VIN patients [van Seters et al., 2008a].  
 
1.13 TREATMENT OPTIONS FOR VIN   
Current treatment for ano-genital neoplasia fall into five main categories, 
surgical excision, laser ablation, cytotoxic agents, photodynamic therapy and 
immunomodulators. The latter three treatment options are currently 
experimental. 
 
1.13.1 SURGICAL EXCISION AND LASER ABLATION 
 
The traditional treatment options for treatment of VIN and in fact most HPV 
related disease rely primarily on surgical excision or laser ablation of the 
lesions. Surgical excision and laser ablation although have been the standard 
and traditional methods of treatment, both these options are unpopular with 
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patients and physicians alike. Consequently and not uncommonly, a number 
of women diagnosed with VIN do not undergo any treatment and opt for the 
policy of conservative (wait and watch) management with regular clinical 
follow-up.   Surgical treatment for VIN is usually reserved for symptom control 
or to rule out malignant transformation.  
 
The basis of surgical treatment is complete elimination of the lesion. 
Excisional surgery is more suitable for small, unifocal lesions, however results 
in scarring, positive margins if incompletely excised and therefore a risk of 
recurrence. Routine vulvectomy is no longer considered to be an acceptable 
treatment option for VIN. On the other hand, multiple excisions for multifocal 
disease can result in significant disfigurement of the vulva. Although methods 
have evolved for rebuilding the defects associated with extensive vulval 
surgery, surgical mutilation of the vulva is best avoided if possible. For VIN 
affecting the clitoris, treatment in the form of partial or total clitoral amputation 
affects quality of life and sexual function. Although some recent studies have 
advocated skinning clitorectomy with either a thin skin flap or split-thickness 
skin graft as a sound organ-sparing alternative for clitoral amputation in the 
treatment of clitoral VIN [Terlou et al., 2009]. Skinning vulvectomy in place of 
surgical excision has also been recommended for high grade VIN and in a 
small study of twenty one women with high-grade VIN who underwent this 
procedure with minimal post operative complications and good cosmetic 
outcome, the treatment was considered successful with no disease 
recurrences [Ayhan et al., 1998]. Although such surgical advances show 
promise, are technically demanding and require surgical expertise with 
multidisciplinary involvement. 
 
Laser treatment of VIN lesions in the form of carbon di oxide (CO2) surgical 
laser ablation can be easily and precisely performed in an outpatient clinical 
setting with good functional and cosmetic outcome. Following laser ablation 
however the area takes a long time to heal and does not provide a tissue 
sample for histo-pathological analysis. Laser ablation treatment is more 
suitable for superficial lesions in the non-hair bearing areas of the vulva due to 
the limited depth of CO2 laser beam penetration.  
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1.13.1.1 RECURRENCE OF VIN   
 
Both surgical excision and laser ablation are associated with high rates of 
disease recurrence. In a study of one hundred and thirty three women 
diagnosed with VIN who were followed up for a period of fifteen years, by 
Herod JJ et al histological or symptom recurrence occurred in 48% of women 
within four years of treatment. The rate of recurrence was significantly higher 
following laser ablation (75%) compared to following surgical excision (45%) 
[Herod et al., 1996]. In a retrospective study by Ahr et al of sixty-eight women 
diagnosed with VIN 3, the aim of which was to study the risk factors for 
recurrence of VIN, by univariate analysis, HPV positivity and 
immunosuppression due to positive HIV status correlated with VIN recurrence. 
In addition, a resection margin of less than five millimetres (mm) was also 
significantly associated with disease recurrence. On multivariate analyses 
HPV positivity, immunosuppression due to positive HIV status and resection 
margins less than five mm were all found to be independent risk factors for 
recurrence of VIN. No significant association however was noted with age of 
the woman or multifocality of the disease [Ahr et al., 2006]. Jones et al in their 
study of natural history of VIN in four hundred and five cases of high grade 
VIN from 1962 to 2003 observed that with both surgical excision and laser 
ablation treatment options, recurrence rate was high with no less than half the 
treated group needing at least one further treatment, more so in those cases 
where the surgical excision margins were positive [Jones et al., 2005]. Li et al. 
studied twenty-four women diagnosed with VIN3 between 1992 and 2002, all 
of who underwent surgical treatment. One-third underwent extended local 
excision whilst the rest underwent simple vulvectomy. Positive surgical 
margins correlated with disease recurrence in three women (12.5%) who 
developed disease recurrence [Li et al., 2005]. Herod et al. with a view to 
study the long-term outcome of VIN conducted a retrospective case-note 
study on hundred and thirty-nine women with a primary diagnosis of VIN over 
a fifteen-year period.  86% underwent surgical treatment, 48% of who 
developed disease recurrence (histological, symptom or both) within four 
years of undergoing primary treatment. Treatment with laser ablation was 
associated with much higher rate of disease recurrence at 70% [Herod et al., 
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1996]. In another long-term outcome study of sixty-five women diagnosed with 
high grade VIN over a period of ten years from 1989 to 1999 by Sykes et al, 
84% of women underwent surgical treatment, a staggering 65% of who were 
found to have positive surgical margins and 51% warranted further surgical 
treatment for persistent or recurrent disease [Sykes et al., 2002]. Similar 
results were noted in another retrospective study of hundred and one women 
diagnosed with VIN3 by McNally et al. over a period of sixteen years from 
1981 to 1997, 78% of who underwent surgical excisional treatment. Over a 
period of a mean follow-up period of thirty-six months, 38% of women required 
at least one further surgical treatment for recurrent disease. Smoking, 
multifocality, presence of HPV and positive surgical margins although were all 
linked with disease recurrence, although the association was not statistically 
significant [McNally et al., 2002]. In a study by of sixty-five women diagnosed 
with high-grade VIN over a period of ten years from 1989-1999, 65% of 
women who underwent surgical treatment (84%) had positive surgical 
excision margins. Similar to the findings in other studies, 51% required further 
treatment [Rodolakis et al., 2003].  
 
The recurrence rates with both surgical excision and laser ablation are 
probably high because these therapies target the visible lesion and the latent 
HPV infected keratinocytes may persist. Targeted anti-viral therapy may 
actually be of more value.  
 
1.13.2 PSYCHOLOGICAL MORBIDITY ASSOCIATED WITH VIN  
 
Surgical treatment is mutilating and even after extensive surgery, recurrences 
are common. Considerable emotional trauma with extensive surgery, 
especially in younger woman is very likely, increasing the risk of developing 
psychosexual disease. Surgical treatment of VIN affects quality of life [Zhang 
et al., 2009]. Theusen et al in their study of selected eighteen women 
diagnosed with VIN who were aged sixty or less, all of whom underwent 
surgical excisional treatment for VIN, found that older age and more extensive 
vulval surgery were more likely to be associated with poorer sexual function 
[Thuesen et al., 1992]. Other studies have confirmed an accentuated 
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psychosexual morbidity associated with VIN but however, could not relate it to 
the extent of the surgical treatment. Shylasree et al recently reported the 
results of a questionnaire study of eighty-two women diagnosed with VIN, of 
whom forty-four were sexually active at the time of the study.   The design of 
the questionnaire enabled quantification of demographic, psychological and 
disease related factors and related their effect on quality of life outcomes. In 
this study, duration of disease, presence of symptoms and the number of 
treatments did not have a measurable impact on the quality of life [Shylasree 
et al., 2008]. In another study of forty-three women diagnosed with VIN all of 
whom underwent excisional surgical treatment for VIN, neither VIN grade, 
location of surgical excisional scar nor time since surgical excision correlated 
with sexual function or quality of life [Likes et al., 2007]. Both the studies 
however clearly showed an increased psychological morbidity in women 
diagnosed with VIN compared to women with no VIN. In an attempt to assess 
women’s perception of vulval appearance and sexual function following 
surgical excision for VIN, seventy women responded to a questionnaire study 
by Fong et al and only 3% expressed dissatisfaction [Fong et al., 2008]. A 
similar study by Mc Fadden et al in eight women diagnosed with VIN scored 
poorly on quality of life and sexual functioning, although this did not appear to 
be due to depression or anxiety [McFadden et al., 2009]. Although the 
evidence for psychosexual consequences of HPV-related genital warts and 
intraepithelial lesions is limited, it is convincing.  
 
1.13.3 MEDICAL MANAGEMENT OF VIN 
 
The chronic natural history associated with difficult symptoms, unacceptable 
treatment options with a constant fear of disease recurrence and impending 
malignancy beg for effective strategies in the management of VIN. Surgical 
morbidity, loss of body image and sexual dysfunction associated with these 
procedures have clearly made the conventional treatment sub optimal and 
unacceptable driving the need for medical management [Likes et al., 
2007;Shylasree et al., 2008]. Increasing incidence in younger women as well 
justifies a more conservative approach in the management of VIN. It is also 
certain that surgical treatment for VIN is associated with high rates of disease 
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recurrence. In fact, treatment for VIN is known to be associated with higher 
rates of recurrence in comparison to CIN or VAIN [Hillemanns et al., 2006]. 
Anatomical location of the disease and multifocality of the lesions probably 
result in incomplete surgical excision and positive excision margins 
contributing to a high risk of disease recurrence. On the other hand, disease 
recurrence does not seem to be influenced by positive surgical margins alone 
as extensive surgery with clear surgical margins does not necessarily appear 
to evade the development of recurrent VIN. Failure to eradicate the HPV 
infection and not the radicalism of treatment adopted appears to be 
contributing to persisting infection and recurrence of genital tract neoplasia.  
 
Agents that perhaps enhance or induce strong cell mediated immune 
responses to HPV related disease hold promise for treatment and reduction of 
future recurrences [Gastrell and McConnell, 2001;Modesitt et al., 1998b]. 
Choosing the best therapeutic approach is however challenging.  
 
 
1.13.4 INVESTIGATIONAL TREATMENT OPTIONS FOR VIN 
 
VIN is one condition where the need to develop non-invasive, durable 
treatment option is pressing. In addition to various cytotoxic agents, some of 
which have a proven role in the management of dermatological conditions and 
condylomatous lesions, there is a role for toll like receptor agonists, 
photodynamic therapy and therapeutic HPV vaccination, either as solitary 
treatment or in combination. 
 
 
1.13.4.1 CIDOFOVIR 
 
Cidofovir is an acyclic nucleoside analogue with a broad-spectrum anti-viral 
activity against broad range of DNA viruses, including HPV.  The mechanism 
of action is thought to be apoptosis of infected cells. Due to its antiviral and 
anti-proliferative activity topical cidofovir has been used in viral infections like 
resistant herpes simples, ano-genital condyloma and to a limited extent, in 
ano-genital intraepithelial neoplasia. Tristram et al. conducted a pilot study in 
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twelve women of whom ten were evaluable to assess the usefulness of topical 
cidofovir in women diagnosed with ano-genital neoplasia. Four women 
showed histological and viral disease clearance whereas three women made 
a partial clinical response [Tristram and Fiander, 2005]. Topical cidofovir may 
have a place in the management of VIN. Cidofovir has increasingly been 
advocated in the management of anogenital condylomata acuminata 
[Coremans and Snoeck, 2009] and further studies (unpublished) are 
underway  evaluating its efficacy in VIN. 
 
1.13.4.2 INDOLE-3-CARBINOL (I3C) 
Indole-3-carbinol (I3C) a phytochemical (naturally derived product) derived 
from cruciferous vegetables has been shown to be anti-carcinogenic and anti-
estrogenic. Oral treatment with I3C has been shown to increase the anti-
proliferative metabolite 2-hydroxyestrone and decrease the potentially 
carcinogenic metabolite 16-alpha-hydroxyetrone in the serum.  I3C has shown 
efficacy in the casuing regression of CIN lesions in a small randomised 
controlled trial in thirty women who received oral I3C [Bell et al., 2000]. There 
was significant regression of CIN in women who received I3C compared to 
women treated with a placebo. One other study has been reported where I3C 
was used in twelve women with histologically proven high-grade VIN. 
Significant improvement in symptomatology and lesion size was noted. 
Histological response was however absent at six months [Naik et al., 2006].  
 
1.13.4.3 RETINOIDS & INTERFERON 
Anti-neoplastic lesions such as retinoids (RA) and interferon (IFN) have been 
reported to be active against a variety of tumours and HPV related lesions 
[Slotman et al., 1988;Vilmer et al., 1998]. Retinoids (RA) are important for 
regulation of cell growth, differentiation and apoptosis and have been 
successfully used in the treatment of various dermatological disorders. In a 
preliminary study of two women with high-grade VIN, following application of 
retinoid cream, an improvement in their symptoms and the appearance of the 
lesion was observed, however, biopsy of the lesion did not confirm histological 
disease resolution. In another small-randomised double-blind crossover trial, 
IFN  was compared with IFN  with nonoxyl-9 and showed 67% response in 
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all patients, independent of the addition of nonoyxl-9. Although the results 
from these studies appear promising, the efficacy cannot be determined until 
large preferably placebo controlled studies with more participants are 
conducted.  
 
1.13.4.4 5- FLUOROURACIL 
5-Fluorouracil (5-FU) is a pyrimidine analogue and although has many 
mechanisms of action, mainly blocks the transport of extracellular thymidine, 
thereby inhibiting the thymidine salvage pathway. 5-FU is available as a 
topical preparation but there is some hesitation in advocating this preparation 
for VIN due to the severe inflammation it causes. In a small case-series where 
topical 5-FU was administered for VIN, although a 50-60% clinical response 
was observed, treatment was associated with significant desquamation, 
inflammation and painful ulcerations and treatment was poorly tolerated 
[Sillman et al., 1985].  
 
1.13.5 IMMUNOTHERAPY 
 
In the management of any chronic condition, to enhance the cellular immunity 
and eradicate persistent infection, single or combination immune modulating 
therapies that incline the balance in favour of host effector response and away 
from immune regulatory and immune evasive mechanisms may be the key. 
The aim of immunotherapy for VIN is to enhance the natural immune 
response against HPV.  There is a significant role for the development of 
immunotherapeutic modalities as treatment options for HPV associated 
intraepithelial neoplasia. It has been postulated that the induction of a local 
inflammatory environment, which stimulates immature tolerising dendritic cells 
to become activated dendritic cells in combination with enhanced cytotoxic T 
lymphocyte responses against HPV proteins, might provide a superior 
approach to treating established HPV infection.  
 
 HPV suppresses the expression of several proinflammatory proteins that are 
crucial in clearing infection and activating the cytotoxic T lymphocytes 
involved in killing virus-infected cells. Immunosuppression has been shown to 
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be a risk factor for increased incidence and progression of HPV associated 
lower genital tract neoplasias [Bouwes Bavinck and Berkhout, 1997;Palefsky 
and Holly, 2003]. Immune equilibrium permits the persistence of HPV infection 
due to immunoevasive nature of the HPV virus. Despite HPV’s ability to inhibit 
host defences, however, a successful immune response to genital HPV 
infections is established in most cases. A certain proportion of HPV related 
intraepithelial neoplasia does undergo immune-mediated regression.  
 
Immunotherapy or immunotherapies (combination treatments) that tip the 
balance of this equilibrium in favour of the host effector response and away 
from the regulatory T lymphocyte and viral evasion strategies may be the key 
to enhancing the cell mediated immunity required to eradicate persistent HPV 
infection and established disease. There has been increasing focus on 
immunotherapy as alternative treatment option for VIN. 
 
In this unit, previously, solo PDT and therapeutic HPV vaccination trials were 
conducted when some clinical response was observed [Davidson et al., 
2003a;Davidson et al., 2004;Martin-Hirsch et al., 1998]. Since, encouraging 
data for toll like receptor agonists like imiquimod in the management of VIN 
has emerged (table 1). One of the potential combination therapies that meet 
the criteria of ideal immunotherapy is to combine a topical immune response 
modifier with a therapeutic HPV vaccination. This is the approach that we 
propose to follow in the clinical trial discussed in this thesis.  Immunotherapy, 
if successful, should effectively be a suitable alternative option by addressing 
the local lesion, causal HPV infection and all the lesions associated with HPV 
infection irrespective of their location, inducing long lasting immunity and thus 
preventing recurrences. 
 
1.13.5.1 TOLL LIKE RECEPTORS  
 
Toll like receptors (TLRs) are a class of surface molecular proteins that play 
an important role in the innate immune system. TLRs are considered to be the 
key molecules that alert the immune system to the presence of microbial 
infections. Once the microorganisms have breached the physical barrier such 
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as skin or mucosa, they are recognised by the TLRs that function as primary 
sensors for the innate immune system to recognise pathogen associated 
molecular patterns that are expressed on the microorganisms and mediate the 
production of cytokines necessary for the development of effective immunity. 
 
Thirteen TLRs have thus far been identified in the human population (TLR1 to 
TLR13) [Chuang and Ulevitch, 2000;Du et al., 2000;Tabeta et al., 2004]. TLRs 
are very specific in their function and for most of the TLRs, ligand recognition 
specificity has been established. TLRs bind and become activated by different 
ligands, which are located on different organisms or structures. Since 
research has identified the TLRs, it has sparked interest in the therapeutic 
manipulation of the innate immune system. TLR agonists are being developed 
as treatment options for infectious diseases, viral infections, allergies, cancer 
and also as adjuvants for vaccines in various preventive and therapeutic 
treatment strategies. It is believed that with increasingly impressive safety 
record and efficacy of the TLRs, their applications are likely to increase in 
future [Meyer and Stockfleth, 2008].  
 
It has been shown that HPV type 16, the most carcinogenic type among the 
high risk HPV interferes with the innate immunity by affecting the expression 
of TLR. TLR7 lies in close proximity to another family member, TLR8 on the 
human X chromosome. TLR7 and TLR8 agonists are known to activate 
dendritic cells and thereby elicit T helper 1 and CD8 positive T lymphocyte 
responses. Activation of TLR7 and/or TLR8 agonists is therefore a 
prospective therapeutic opportunity for the treatment of various viral 
infections. And also, this ability of the TLR7 and TLR8 agonists to elicit T 
helper responses has been exploited to enhance the efficacy of vaccines by 
including them as adjuvants in some cancer trials [Craft et al., 2005]. TLR7 
specific agonists have been shown to activate plasmacytoid dendritic cells, B-
lymphocytes and induce mainly IFN and other IFN-regulated cytokines. 
TLR8 specific agonists have been shown to activate myeloid dendritic cells, 
monocytes, and monocyte derived dendritic cells leading primarily to the 
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production of proinflammatory cytokines, such as TNF and IL-12 [Gorden et 
al., 2005].  
 
Using TLR7 deficient mice and HEK293 cells transfected with human TLR7, 
Hemmi et al. demonstrated that TLR7 is involved in the recognition of the 
imidazoquinoline compounds imiquimod (R837) and the related compound 
resiquimod (R848) [Hemmi et al., 2002]. Both human TLR 7 and human TLR 
8 proteins sense imidazoquinolines. Infection of the human primary 
keratinocytes with HPV16 E6 and E7 recombinant retroviruses inhibits TLR 9 
transcription and hence the functional loss of TLR 9 regulated pathways and 
this effect of HPV 16   on TLR 9 was also demonstrated in vivo in cervical 
carcinoma patients. E6 and E7 proteins from low risk HPV type 6 were unable 
to down-regulate the TLR 9 promoter. On the contrary, E6 and E7 proteins of 
the high risk HPV 18 exhibited reduced efficiency when compared to HPV16 
in inhibiting TLR 9 transcription. This is presumed to be a novel mechanism 
used by the HPV 16 to suppress the host immune response. Deregulation of 
the TLR 9 transcription provides evidence that abolishing the innate 
responses may be a crucial step involved in the carcinogenic events mediated 
by the HPV [Hasan et al., 2007]. Trials are underway to further assess the 
function of TLRs in various infectious and neoplastic conditions. 
 
1.13.5.1.1 IMIDAZOQUINOLINES 
Imidazoquinolines are double cyclic organic molecules that are able to 
activate TLRs and therefore induce immune modulatory cytokines. 
Imidazoquinoline compounds and derivatives are often used as the active 
components of antiviral and anti allergic creams [Hemmi et al., 2002;Peet et 
al., 1985]. The two imidazoquinoline compounds, imiquimod and resiquimod 
are low molecular weight immune response modifying drugs that have 
demonstrated effective anti-viral and anti-tumour properties. 
 
1.13.5.1.2 IMIQUIMOD & RESIQUIMOD 
The mechanism of action of imiquimod although appears to be multimodal, it 
mainly acts by amplifying the anti-tumour immune responses through the 
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TLRs 7 and 8 proteins on the dendritic cells [Hemmi et al., 2002]. Imiquimod 
and its homologues are shown to activate macrophages and other immune 
cells via binding to cell surface receptors like TLR7, thereby inducing 
secretion of pro-inflammatory cytokines, predominantly IFN-, TNF and IL-12. 
This locally generated cytokine surge encourages a Th1 cell mediated 
immune response with generation of cytotoxic T cells [McInturff et al., 
2005;Stanley, 2002]. Histological examination of the inflammatory cell infiltrate 
of different superficial malignant tumours when treated with the imiquimod 
cream revealed the prevalence of T helper lymphocytes with significant 
infiltration of CD8 + cytotoxic lymphocytes [Wolf et al., 2007].  
 
Natural killer (NK) cells are notorious for their preferential ability to lyse virally 
infected cells and spare uninfected cells. People deficient in NK cells are 
known to suffer from recurrent viral infections [Biron et al., 1989;Orange, 
2002].  Hart et al following their in vitro studies on NK leukaemia cell lines, 
discuss the role for TLR agonists in the activation of NK cells and demonstrate 
that the relative contribution of both direct and indirect mechanisms of 
activation of human NK cells varies for specific TLRs. TLR3 has been shown 
to be directly activated on the resting NK cells, while the activation of TLR7/8 
is mediated primarily through accessory mechanisms such as release of IL-12 
and IFN- [Hart et al., 2005].  
 
Dumitru et al in their in vivo mice studies and in vitro human studies reported 
enhancement of natural killer cytotoxicity by theTLR7/8 agonist and also 
concluded that IFN- dependent functions of natural killer cell populations 
appear essential for TLR7/8 agonist associated cancer immunotherapy. The 
long lasting activation of natural killer cells was determined by the sustained 
expression CD69, an activation marker for natural killer cells [Dumitru et al., 
2009].  
 
A novel mechanism of action of imidazoquinolines has recently been 
described which has important physiological relevance and allows strategies 
to be developed for use of these agents. In invitro cultures using pancreatic 
and colorectal cancer cells as well as squamous cancer cells from head and 
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neck, where the immune system and TLRs were eliminated, the 
imidazoquinolines were found to up regulate the opiod growth factor receptor 
OGFr. This results in retardation of cell proliferation at the G1-S phase of the 
cell cycle. This is novel and exciting knowledge of the mechanism of action of 
imidazoquinolines [Zagon et al., 2008].  
 
Resiquimod is thought to be a more potent analogue of imiquimod. It is known 
to be having a mixed TLR7 and 8 activity and has been evaluated in the 
clinical trials for topical use in herpes simplex viral infections and hepatitis C 
infections with some success [Miller, 2008].  
 
1.13.5.1.3 IMIQUIMOD IN HUMAN STUDIES 
The US Food and Drug administration (FDA) first approved topical imiquimod 
treatment in 1997 for genital warts. Imiquimod is currently an FDA approved 
treatment option for HPV induced warts, actinic keratosis and superficial basal 
cell carcinoma (BCC). It is the first TLR agonist approved for these 
dermatological conditions [Miller, 2008]. Imiquimod is generically marketed as 
5% Aldara cream for topical usage. To supplement the clinical applications of 
topical imiquimod, as a topical immune response modifier attracting the local 
immune markers to the site of application and inducing an immunological 
memory, numerous uses outside the licensed indications of warts, actinic 
keratosis and BCC have been proposed and practised.  
 
1.13.5.1.4 IMIQUIMOD FOR THE TREATMENT OF VIN 
Amongst the investigational medical treatment options for VIN, imiquimod is 
the most studied drug. The initial case-reports of imiquimod for VIN were 
published in the year 2000. The literature on the clinical efficacy of imiquimod 
in the treatment of VIN consists mainly of case reports and observational 
studies. Recently, two randomised trials of imiquimod for VIN have been 
published [Mathiesen et al., 2007;van Seters et al., 2008b].  
 
The first publication describing the use of imiquimod in VIN was in the year 
2000 by Davis et al who reported a case series of four women diagnosed with 
VIN3 all of whom responded to imiquimod. The maximum allowed dose was 
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up to three applications per week until the lesions clinically disappeared or for 
a maximum of sixteen weeks. Two women developed recurrence at one year 
follow-up [Davis et al., 2000]. In another retrospective case-note review by 
Diaz-Arrastia et al. eight women with recurrent high-grade vulval intraepithelial 
neoplasia were treated with topical imiquimod, three times per week for six to 
sixteen weeks. Of the seven women evaluable for treatment response, three 
of who were immunosuppressed (HIV positive), four women achieved a 
complete clinical and histological response; two women attained partial clinical 
response and in one woman VIN progressed to invasive disease. This group 
was clinically followed for a mean of thirty-three months, when two women, 
both of who were HIV positive developed disease recurrence. Women with 
recurrent VIN were again treated with imiquimod, resulting in a complete 
clinical response. In this group, pre and post treatment RNA levels of 
interferons when assessed, an increase in 2,5 oligoadenylate synthetase RNA 
expression was seen after therapy. This is an IFN induced enzyme activated 
by the double stranded RNA which is believed to lead to inhibition of protein 
synthesis, which may be part of the antiviral function of the interferons [Diaz-
Arrastia et al., 2001].  
 
Case-reports of individual cases of successful treatment with imiquimod of 
bowenoid papulosis (VIN3) of the vulva [Petrow et al., 2001], VIN3  in a 
woman on immunosuppressant treatment following a lung transplant [Travis et 
al., 2002] and another case of high grade VIN which vulvar-pemphigus as a 
side effect of imiquimod  treatment have been reported in the literature 
[Campagne et al., 2003]. Todd et al published the first prospective trial of 
imiquimod for VIN in 2002. They reported on an uncontrolled, observational 
study of fifteen women with VIN3 who underwent treatment for sixteen weeks 
with a thrice-weekly imiquimod cream application regime. In four out of fifteen 
women clinical improvement was detected and in three women, post-
treatment biopsies were negative for VIN. Thrice weekly drug application was 
limited by the side effects of imiquimod. At five months post treatment visit, all 
the four women who had demonstrated a clinical response relapsed with 
biopsy proven recurrent VIN [Todd et al., 2002]. In 2003, van Seters et al 
published the results of their pilot study of topical imiquimod treatment of 
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fifteen women with multifocal VIN2 or 3. In this study the length of treatment 
varied between six and thirty-four weeks. Based on the complete response 
defined as complete disappearance of all the visible lesions and a partial 
response as 25% reduction in the lesion size criteria, four women (27%) made 
a complete response and nine women (60%) made a partial response to 
treatment. Eleven women (85%) benefited from symptom relief. Two out of 
fifteen women discontinued imiquimod treatment because of severe side 
effects associated with the imiquimod treatment [van Seters et al., 2008b].  
 
In 2002 Jayne et al published a retrospective review of thirteen women with 
VIN 2 or 3 treated with imiquimod. They reported eight (62%) complete 
responses and four partial responses (31%); in this study partial response 
was defined as at least 75% reduction in the lesion size. Two of the partial 
responders were found to have invasive disease in their residual lesions. This 
group therefore concluded that any residual disease three months after 
completion of imiquimod trial treatment should be surgically excised and the 
excision sample subjected to histopathological analysis [Jayne and Kaufman, 
2002]. In 2004 Wendling et al published a prospective uncontrolled study of 
twelve women with VIN treated with imiquimod for up to seven months. They 
accounted three histologically confirmed complete responses and four partial 
responses, defined as at least a 50% reduction in the lesion size. Three out of 
twelve women withdrew because of the severe side effects associated with 
imiquimod cream [Wendling et al., 2004]. More recently Le et al reported a 
prospective uncontrolled study of imiquimod for VIN2 and 3. Twenty-three 
women were recruited and responses were evaluable in seventeen of them. 
The duration of treatment was for sixteen weeks. Complete response defined 
as VIN1 or less on histology was reported in nine women (53%) and partial 
response in five women (29%) at completion of treatment with no available 
long-term follow-up data [Le et al., 2007]. Mathiesen et al. in 2007 used a 
prospective, randomised, double blind, placebo controlled study model of 
topical imiquimod treatment for VIN. Twenty-one and ten women were 
randomised to the treatment and the placebo arms respectively. Treatment 
entailed thrice weekly imiquimod applications for sixteen weeks. 81% of 
women in the treatment group demonstrated a complete response and 10% 
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showed a partial response to treatment compared to no responses in the 
placebo group. All the responses were evaluated by histo-pathological 
analysis of biopsies taken two months after completion of trial treatment.   
Long-term results are not available for this trial, which has demonstrated an 
overall excellent response to imiquimod treatment [Mathiesen et al., 2007]. 
van Seters et al. conducted a randomised, double blind placebo controlled 
trial for VIN with imiquimod in fifty-two patients. Treatment regime comprised 
twice-weekly imiquimod applications for sixteen weeks. 81% of women 
showed a  25% response to treatment in the imiquimod arm of the trial 
whereas none in the placebo arm of the trial showed a response. On further 
analysis, the rates of histological regression of VIN, HPV clearance and 
density of intralesional immune cell infiltrates (CD4, CD8) was significantly 
different in the imiquimod group when compared to the placebo group. A 
significant improvement in the symptoms was also seen in the imiquimod 
group.  Twelve month follow-up data is available when one in the imiquimod 
arm and two women in the placebo arm were diagnosed with invasive disease 
[van Seters et al., 2008b]. Iavazzo et al published a review article assessing 
the safety and effectiveness of 5% imiquimod cream in the treatment of VIN 
and VAIN. Drawing a conclusion from the seventeen identified articles, (one 
randomised controlled trial, ten case series, six case reports), complete lesion 
regression was observed in 26% to 100% of patients, partial lesion regression 
in 0% to 60% of patients and disease recurrence was confirmed in 0% to 37% 
of patients.  The most common side effects remarked were local burning and 
soreness, but not severe enough for patients to warrant treatment 
discontinuation [Iavazzo et al., 2008]. There is thus abundant clear evidence 
in the literature for imiquimod treatment of VIN.  
 
Making direct comparison between different studies is complex due to the 
inconsistency in the definition of ‘treatment response’. Frequency of 
imiquimod cream application varied from once a week to up to three times 
week and the total treatment duration also varied from eight weeks to six 
months in different studies. In most trials, with the background knowledge of 
the side effects associated with imiquimod use, to improve treatment 
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compliance, a dose-escalating regime was practised, whereby; application 
frequency is gradually increased from once a week to a maximum of three 
times a week over a three-week period. In spite of the wide variation in the 
reported response rates (27%-82%) between the published studies with lack 
of follow-up data for most studies, imiquimod as a treatment option for VIN is 
emerging.   
 
In terms of cost of topical imiquimod cream for treatment of VIN, it is a more 
economical treatment option compared to surgical treatment options of 
surgical excision or laser ablation. Imiquimod is marketed as Aldara cream in 
5gm sachets, is easily available in most hospital pharmacies due to its already 
FDA approved licensing status and the cost of imiquimod 5% cream when 
applied three times a week over an eight week period amounts to less than 
two hundred Great British pounds (imiquimod summary sheet). Imiquimod 
cream is also suitable for self-application and the treatment does not warrant 
hospitalisation at any point.  Compliance is however an issue with imiquimod 
treatment due to treatment related side effects.  
 
 
1.13.5.1.5 SIDE EFFECTS ASSOCIATED WITH IMIQUIMOD 
 
Topical imiquimod application stimulates local immunity and induces the 
release of interferon  and IL-1, resulting in a pseudo-influenza like syndrome. 
Most patients experience localised oedema, erythema, skin peeling, 
ulceration, crusting consequently resulting in soreness and burning. Some 
patients also experience systemic side effects   such as flu like illness, fever, 
lethargy and feeling weary. The side effects are known to subside within a 
short period of discontinuation of the drug. Interestingly, in immunocompetent 
patients, the intensity of local reaction to topical imiquimod treatment has 
been found to be directly proportional to the degree of clinical response when 
imiquimod was used for the treatment of FDA approved conditions such as 
actinic keratosis, warts and basal cell carcinoma. In the literature, there is one 
adverse event reported in a sixty-year-old woman who developed multiple 
 76
pemphigus like lesions during imiquimod treatment for BCC.  Systemic 
absorption of the drug and/or enhanced cytokine synthesis was thought to be 
the likely reason for this type of reaction. To avoid such a reaction, the authors 
recommend using low doses of imiquimod when treating large or multiple 
lesions [Bauza et al., 2009].  
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STUDY HISTOLOGY 
AT Wk 0 
No: of 
patients 
LENGTH 
OF 
TREATMEN
T 
SIDE-
EFFECTS 
RESULTS FOLLOW-UP 
Retrospective case-series[Diaz-
Arrastia et al., 2001] 
 
High-grade 
VIN 
N=8 6-16 weeks  No VIN – 2 
PR - 1 
22 to 42 months; 
1recurrence at 15 
months 
Case-report [Petrow et al., 2001] 
 
Bowenoid 
papulosis 
N=1 8 weeks  No VIN 18 months 
Prospective uncontrolled[Todd et 
al., 2002] 
 
VIN3 N=15 16 weeks 11 reduced 
freq of 
application 
No VIN – 3 
PR - 1 
1 Month; 3 
recurrences 
Case-series [Davis et al., 2000] VIN3 N=4 16 weeks  No VIN - 4 12 months; 2 
recurrences 
Retrospective case-series 
[Jayne and Kaufman, 2002] 
VIN2/3 N=13 Mean 33 
months 
1 withdrawn 
due to side-
effects 
8 – CR 4 
PR 
 
55 months 
Prospective uncontrolled [Travis 
et al., 2002] 
VIN3 N=1 8 months    
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Case-report [Campagne et al., 
2003] 
 
High-grade 
VIN 
N=1 8 weeks Vulval 
pemphigus 
No VIN 18 months 
Prospective uncontrolled [Buck 
and Guth, 2003] 
VAIN 2/3 N=42    1 week to 6 months 
Prospective uncontrolled 
[Wendling et al., 2004] 
Undiff VIN N=12 Up to 7 
months 
mean 5 
months 
3 
withdrawals 
due to SE 
3 – no VIN 
4 PR 
16 months 
Prospective uncontrolled 
[Marchitelli et al., 2004] 
Bowenoid 
basaloid 
VIN2/3 
N=8 Up to 16 
weeks 
  Mean 22 months 
Retrospective case review 
[Haidopoulos et al., 2005] 
VAIN 2/3 N=7 8 weeks   18 months 
Prospective uncontrolled [van 
Seters et al., 2002] 
VIN2/3 N=15 6-34 months 2 
withdrawals 
due to SE 
4-CR 9-PR  
Prospective uncontrolled [Le et VIN2/3 N=17 16 weeks 8 dose 9 CR, 5-  
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al., 2006] reductions PR 
Prospective uncontrolled [Le et 
al., 2007] 
VIN3 N=33 16 weeks   Median 16 months 
Randomised double-blind 
placebo controlled trial 
[Mathiesen et al., 2007] 
VIN2/3 N=31; 21- imiq 
10 - placebo 
  81% 
histology 
response 
12 months 
Randomised double-blind 
placebo controlled [van Seters et 
al., 2008b] 
VIN2/3 N=52; 26-
imiquimod; 26 
- placebo 
16 weeks  81%  
25% 
reduction 
in lesion 
size 
Median 12 months 
Table 1 Studies of imiquimod treatment for vulval intraepithelial neoplasia, PR – partial response; CR – complete response; SE – 
side-effects 
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1.13.6 PHOTODYNAMIC THERAPY 
 
 
Photodynamic therapy (PDT) is based on the principle of combination of light 
at a certain wavelength with the photosentising drugs with the intention of 
damaging the tumour tissue. In response to the tissue damage and cell death 
induced by the PDT, acute inflammation results by various mechanisms. The 
APCs that produce IL12, crucial for the release of IFN secreting effector T 
lymphocytes, are activated. The resulting effects on the cytokine expression 
incorporate an increase in IL-6 production and a decrease in IL-10 production. 
In addition to the enhanced invasion and infiltration of the tumour by the 
leukocytes and expression of heat shock proteins, which aid in protein-to-
protein interactions. Singlet oxygen (Reactive oxygen species-ROS), are 
generated after the activation of the photosensitiser with the PDT light at an 
appropriate wavelength. The singlet oxygen released is thought to either 
modify the cellular function or induce cell death by necrosis or apoptosis 
[Banchereau and Steinman, 1998;Canti et al., 2002;Castano et al., 
2006;Manetti et al., 1993;Matzinger, 2002a;Matzinger, 2002b].  
 
1.13.6.1 THE SCIENCE OF PDT 
PDT involves the preferential accumulation of the photosensitiser in the target 
tissue with precise illumination. The light penetrates the tissue and causes 
excitation of the photosensitiser. Activation of the photosensitisers is a 
prerequisite to successful PDT. A particular wavelength of light is needed for 
each photosensitiser to maximise penetration through the tumour and cause 
excitation of the photosensitiser. 
 
Photosensitisers have a stable electronic configuration, which is in a singlet 
stage in their lowest or ground state energy level. Following absorption of a 
photon of light of specific wavelength, a molecule is promoted to an excited 
state, which is also a singlet state, and which is short lived. Photosensitiser 
returns to the ground state by emitting a photon (fluorescence) or by internal 
conversion with energy loss as heat. 
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There are two mechanisms by which the triple state photosensitiser can react 
with bio molecules. These are known as type1 and type 2 reactions. Type 1 
reaction involves electron / hydrogen transfer directly from the photosensitiser, 
producing ions / electrons from the substrate molecules to form free radicals. 
These radicals then react rapidly usually with oxygen resulting in production of 
highly reactive oxygen species (the super oxide and peroxide anions). These 
radicals thus released attack cellular targets.  
 
Type 2 reactions produce the electronically excited and highly reactive sate of 
oxygen known as singlet oxygen. Direct interaction of the excited triple state 
photosensitiser with molecular oxygen (which unusually has a triplet ground 
state) results in the photosensitiser returning to its singlet ground state and 
the formation of singlet oxygen.  
 
In PDT, it is difficult to distinguish between the two reaction mechanisms. It is 
possible that the mechanism of damage is dependent on both the oxygen 
tension and the concentration of the photosensitiser involving both the type 1 
and type 2 reaction mechanisms. PDT is thought to achieve cytotoxic effects 
through photo damage to sub-cellular organelles and bio molecules.  
 
1.13.6.2 PHOTODYNAMIC THERAPY FOR VIN 
The distinctive properties of PDT make it an attractive treatment option for 
superficial epithelial disorders including VIN. Martin-Hirsch et al. in 1998 first 
reported a study of eighteen women with high grade VIN treated with PDT 
with 5- amino-laevulinic acid (5-ALA) as the photosensitiser. In the first ten 
women who received 50J/cm2 of PDT, two clinical responses were observed. 
In an attempt to improve the clinical responses, the PDT dose was increased 
to 100J/cm2 in the subsequent eight recruits, of whom three women (37%) 
showed a clinical response. Overall, 89% of women reported symptom relief 
[Martin-Hirsch et al., 1998]. Hillemanns et al. in 2000 reported a study of 
twenty-five women (total one hundred and eleven lesions) diagnosed with VIN 
of different grades. 5-ALA was used as the photosensitising agent and 
100J/cm2 of laser light PDT was used. In this study, complete clinical 
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response was seen in 52% of women. Pigmented and hyperkeratotic lesions 
were found to be associated with a poorer response to PDT. Treatment was 
poorly tolerated under local anaesthesia warranting general or regional 
anaesthesia in the majority (80%). This group reported excellent cosmetic 
outcome with minimal side effects and tissue destruction with PDT 
[Hillemanns et al., 2000]. Kurwa et al. in 2000, in a study of six women with 
high grade VIN resistant to standard surgical treatment reported a poor 
response to single episode ALA PDT [Kurwa et al., 2000]. Fehr et al. in 2001 
reported a complete response rate of 73% in fifteen women diagnosed with 
high grade VIN who underwent treatment with 120J/cm2 laser light PDT. 
Unexpectedly the procedure was well tolerated in an outpatient setting and 
only three disease recurrences were observed over a twelve-month follow-up 
period [Fehr et al., 2001]. Campbell et al. in 2004 evaluated the role of 
systemic photosensitiser Foscan, as a substitute to topical photosensitiser in 
six women with high grade VIN with some success. As systemic 
photosensitisers warrant a much shorter light exposure, it is sited as an 
advantage over PDT using topical ALA. The drawback however with systemic 
photosensitiser is the prolonged photosensitivity lasting for up to one to two 
weeks after treatment completion requiring a strict light protection regime 
[Campbell et al., 2004]. Olejek et al. in 2008 who conducted a PDT trial with 
topical ALA in twenty women diagnosed with VIN reported a higher reduction 
in subjective symptoms in comparison to histological improvement following 
PDT [Olejek et al., 2008].  
 
Abdel-Hady et al. considered exploration of immunological and viral factors 
associated with responsiveness of VIN to PDT. Treatment response was 
found to be associated with a post-treatment surge in the intra lesional 
cytotoxic T lymphocyte density and this was significantly higher in the clinical 
responders compared to the non-responders. None of the women who 
demonstrated HLA class I down regulation responded to PDT treatment and 
in fact in 50% of them VIN progressed to invasive disease [Abdel-Hady et al., 
2001].  
 
 83
1.13.7 THERAPEUTIC HPV VACCINATION 
 
Therapeutic vaccination programmes independently or in combination with 
other treatment modalities are expected to have the potential to prevent 
progression of low-grade disease to high-grade disease, regress the existing 
lesions, prevent the spread of metastatic cancer and also prevent recurrences 
following treatment [Chu, 2003;Stanley, 2003].  
 
Understanding HPV biology has helped researchers to use the virus as a 
model for the development of not only prophylactic vaccines, but also 
therapeutic vaccines. The preventative HPV vaccines rely upon generation of 
the neutralising antibodies, which prevent or neutralise the biologic activity of 
the virus. On the other hand therapeutic HPV vaccines aim to eliminate the 
HPV infection by inducing a virus-specific cellular immune response. The 
close association of VIN with high-risk HPV such as the oncogenic HPV types 
16 and 18 provides a role for therapeutic HPV vaccines in the management of 
VIN. Therapeutic HPV vaccines if successful, are expected to offer women 
already diagnosed with pre-invasive HPV lesions, who obviously have by now 
acquired the HPV infection, a therapeutic response of the lesions to the 
vaccination and expectantly this applies to more advanced disease also. 
Therapeutic vaccines also represent an attractive treatment alternative for 
many pre-invasive and invasive diseases primarily because of their ability and 
specificity to generate immunologic memory, which is important for controlling 
recurrences. The key objectives with therapeutic vaccination programme are 
controlling the progress of established disease and prevention of disease 
recurrence.  
 
1.13.8 DEVELOPMENT OF THERAPEUTIC HPV VACCINES 
 
The advantages of HPV as a model system stems from the fact that a limited 
number of proteins are encoded by the HPV genome that can be potentially 
targeted by the vaccines, and also for the reason that the expression of 
certain viral proteins is restricted during different stages of the HPV infection. 
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Immunologically, in an outline, the role of therapeutic HPV vaccines is to 
generate cell mediated immunity against HPV infected cells that express early 
viral proteins such as E6 and E7, reverse the immune suppressive 
microenvironment of the local HPV infection and allow the cytotoxic killer T 
lymphocytes to access the infected, neoplastic cells. The efficacy of 
therapeutic vaccines may thus depend on formulations that not only generate 
effective immune responses but also overcome the systemic and local 
immune evasion mechanisms adopted by the HPV infection and the 
progressing infection. Development of a therapeutic HPV vaccine can 
therefore be technically challenging.   
 
In the design of therapeutic vaccines, the choice of target antigen(s) is a very 
important consideration. HPV vaccines directed against tumour specific 
antigens of the HPV, in general, focus on the E6 and E7 proteins; the main 
oncogenes necessary for the growth and progression of HPV infected cells. 
E6 and E7 oncogenes are particularly appealing in the development of 
therapeutic HPV vaccines not only because of their functional role in the 
neoplastic process but also because both these proteins are co-expressed in 
HPV lesions. Natural immune responses to both these antigens, although 
limited, have been identified in the presence of HPV positive lesions.    
 
1.13.8.1 THERAPEUTIC HPV VACCINES 
The development of therapeutic HPV vaccines has been brisk in the last two 
decades. A variety of therapeutic HPV vaccines have been tested in clinical 
studies. Therapeutic HPV vaccines are currently administered under close 
observation as investigations products and are not as yet approved or 
licensed for regular clinical use.  
 
An ideal therapeutic HPV vaccine, in addition to being safe and effective, must 
also possess numerous other properties. It must be multivalent, offer long 
lasting protection, preferably not require booster immunisations, and be cheap 
and easily available.  
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Therapeutic HPV vaccines thus far have included fusion proteins used alone 
or with the addition of an adjuvant, encapsulated polynucleotides, protein with 
adjuvant, recombinant viruses, DNA constructs, dendritic cells and chimeric 
virus like particle (VLP) constructs as shown in the table 2. Some of these 
vaccines have been tested in healthy individuals, and some in a spectrum of 
HPV associated disease cohorts like patients with lower genital tract 
neoplasia (CIN, VAIN, VIN, AIN) or end-stage cervical cancer. Early clinical 
trials were conducted in patients with late-stage HPV 16 associated cervical 
cancer. Despite obtaining positive pre-clinical data, evidence of benefit 
measured in clinical and immunological terms, in women with late stage 
cervical cancer was limited. It was then concluded that women in late stages 
of cervical cancer, however, could anyhow be immunocompromised due to 
the terminal cancer and also due to the treatment received for the cancer 
[Borysiewicz et al., 1996;Ferrara et al., 2003;Frazer, 2004;Kenter et al., 
2008;van Driel et al., 1999]. In addition, the fact that end stage cervical 
cancers commonly have mutations in genes involved in antigen processing 
and presentation was thought to be interfering with development of an 
immune response to therapeutic HPV vaccination [Brady et al., 2000;Evans et 
al., 2001]. More recently, the therapeutic HPV vaccination studies have been 
conducted in patients with pre-invasive HPV associated conditions as shown 
in the table 2.   
 
1.13.8.2 PRE-CLINICAL DATA 
Studies of canine oral papillomavirus infections, which are usually benign and 
self-limiting have shown that immune responses to two early viral proteins, E2 
and E6 correlate with lesion regression [Jain et al., 2006]. Rabbit oral 
papillomavirus infections and cottontail rabbit papillomavirus infections are 
self-limiting in most strains. Chronic infection, however, can lead to localised 
skin cancers which have been shown to respond to immunotherapy with 
therapeutic HPV DNA vaccination [Brandsma et al., 2007]. Similarly, several 
HPV positive murine tumours have shown susceptibility to a range of HPV 
antigen specific vaccinations [Frazer, 2004;Kanodia et al., 2008].  
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The following types of therapeutic HPV vaccines have been evaluated 
successfully in clinical studies in humans.  
 
 
1.13.9 TYPES OF THERAPEUTIC HPV VACCINES 
 
1.13.9.1 TA-HPV 
TA-HPV is a recombinant vaccinia virus expressing HPV 16 and 18 E6 and 
E7 proteins. This vaccine was studied in eighteen women diagnosed with 
HPV 16 positive high-grade VIN. A single dose of the vaccine was 
administered intramuscular (i.m). Overall, post vaccination, thirteen women 
demonstrated HPV 16 specific systemic immune responses. Partial clinical 
response was observed in eight out of thirteen women (62%) and reduction of 
HPV viral load in six out of eight women who made a clinical response and six 
out of ten women who did not make a clinical response. Women who made a 
response to the treatment were found to have significantly higher levels of 
lesion associated helper, cytotoxic and CD1a immune cells in comparison to 
treatment non-responders.  This group hypothesized that enhanced local 
immune infiltration may play a critical role in the potential responsiveness to 
therapeutic vaccine therapy in HPV associated neoplasia [Davidson et al., 
2003a].  
 
1.13.9.2 ZYC-101a 
ZYC-101a is a DNA vaccine synthesised from some proteins containing 
cytotoxic T lymphocyte epitopes against E6 and E7 oncoproteins of HPV 
types 16 and 18. This vaccine was tested in a multicentre randomised double-
blind placebo controlled trial in women with confirmed high-grade CIN. 
Women were randomised to either a placebo or 100mcg dosage of ZYC-101a 
or 200-microgram dosage of ZYC-101a. The aim of the study was to 
histologically confirm resolution of CIN on a cone biopsy of the cervix 
performed six months after the scheduled three-i.m doses of the vaccine.  Of 
the one hundred and twenty-seven evaluable study participants, the 
proportion of women whose CIN resolved on histological analysis was higher 
in the vaccine group, not influenced by the dose of the vaccine, compared to 
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the placebo group (43% vs. 27%), however, this was not statistically 
significant. Interestingly, in the vaccination arm of the trial, women under the 
age of twenty-five years were found to have a greater lesion resolution than 
the older counterparts.  ZYC101a vaccine was well tolerated by the patients 
and its activity was not restricted to HPV 16 or HPV 18 positive lesions and 
cross-protection against other HPV types was also observed [Garcia et al., 
2004]. 
 
1.13.9.3 TA-CIN 
TA-CIN is a protein-based vaccine, developed by Xenova. It is a single fusion 
protein comprising HPV 16 L2, E6 and E7 proteins. The choice of these 
antigens has been based on therapeutic vaccination studies in animal models. 
van der Burg et al. in 2000 studied the effect of then a newly designed TA-CIN 
vaccine in a pre-clinical mouse model. TA-CIN was shown to elicit HPV 16 
specific cytotoxic T lymphocytes, helper T lymphocytes and antibodies in the 
mouse HPV16 TC-1 tumour xenograft model. Proof-of-principle experiments 
demonstrated that treatment with TA-CIN prevented tumour outgrowth and 
also extended symptom-free survival in mice. In fact, one vaccination with TA-
CIN on the same day of challenge with TC-1 tumour cells protected mice 
against tumour growth demonstrating the capacity of TA-CIN in inducing 
effective anti-tumour immunity [van der Burg et al., 2001]. More recent primate 
in vivo data have shown that administration of HPV 16 L2, E6 and E7 fusion 
protein can effectively neutralise not only HPV16 but also other high-risk HPV 
genotypes including HPV types 6, 11, 18, 31, 45 and 58. Vaccination with L2, 
E6 and E7 fusion protein completely prevented tumour growth after challenge 
with HPV16 transformed TC-1 tumour cells [Karanam et al., 2009].  
 
HPV oncogenes E6 and E7 are known to be expressed throughout the HPV-
associated disease process and offer to be attractive targets for 
immunotherapy, as they are exclusively expressed in virally infected 
neoplastic cells. The addition of L2 capsid protein to the fusion protein was of 
therapeutic interest, as L2 protein has been shown to induce neutralising 
antibodies and offer cross-protection against the other HPV types. In addition, 
it was also found to be highly effective in promoting tumour rejection in 
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animals when compared to L1 protein, with massive infiltration of lymphocytes 
into the tumours [Jarrett et al., 1991].  
 
In a phase I double blind, placebo-controlled, randomised, dose escalating 
trial of three dose levels of TA-CIN, at the doses of 26, 128, 533 g of TA-CIN 
per dose, TA-CIN was found to be safe and immunogenic in a dose 
dependent manner. Forty healthy volunteers tolerated the i.m.administered 
TA-CIN well with no side effects. No serious adverse events were noted 
during the study period. Vaccination with TA-CIN induced proliferative T 
lymphocyte responses in the majority (25 out of 32) of the healthy volunteers 
following three doses of the vaccine. Six out of sixteen volunteers who 
received the highest dose of TA-CIN (533 g) revealed a lymphocyte 
proliferative response to TA-CIN after only one dose of the scheduled three-
dose vaccination regime with TA-CIN, unlike the volunteers who received 
lower doses of the vaccine or the placebo.  L2, E6 and E7 specific antibody 
response and positive T lymphocyte responses were nevertheless seen in all 
the volunteers who received the active vaccine and not the placebo. 
Antibodies specific to the E6 and E7 components of the TA-CIN were however 
found to dwindle after the last dose of the vaccination. It was hence suggested 
that sustained boosting of the immunity with the TA-CIN may be sub-optimal 
[de Jong et al., 2002].  
 
1.13.9.4 TA-CIN / TA-HPV IN A PRIME BOOST REGIMEN 
Pre-clinical studies in the mice showed that vaccination with TA-CIN followed 
by vaccination with TA-HPV stimulated greater T lymphocyte response than 
any other combination of these two vaccines [van der Burg et al., 2001]. The 
context of this notion led to a study in humans where TA-CIN was 
administered together with TA-HPV in a heterologous prime-boost regimen.  
 
Davidson et al conducted a study in ten women with HPV 16 positive high 
grade VIN, who were initially primed with TA-HPV and then received three 
booster immunisations with TA-CIN. 90% of women demonstrated HPV 16 
specific proliferative T lymphocyte and/or serological responses following 
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vaccination. In addition, three women also demonstrated lesion shrinkage with 
some symptom relief, but no correlation between clinical and immunological 
responses was observed. TA-HPV boosting with TA-CIN also failed to 
demonstrate any significant additional CD8 T lymphocyte responses or clinical 
improvement [Davidson et al., 2004].  
 
Smyth et al. studied TA-CIN followed by the TA-HPV vaccine, in a prime boost 
regime fashion in twenty-nine women with high grade AGIN. Three i.m doses 
of TA-CIN at four weekly intervals were administered followed by a single 
dermal scarification with the TA-HPV vaccine. The prime-boost regimen was 
significantly immunogenic in all the women. This was confirmed by checking 
immunogenicity against the test and control antigens pre-vaccination and at 
different post-vaccination time-points by the lymphoproliferation assays. 
Almost a third showed a three-fold change in the TA-CIN specific proliferation 
response at one or more time-points following the vaccination.  In addition 
vaccination also was found to result in induction of antibodies against 
individual HPV 16 E6 and E7 oncoproteins. Clinical response was slightly 
short of immunological response at 21%. In nineteen out of twenty-nine 
women (65%), no disease progression or regression was observed during the 
study period of twelve weeks. Disease progression was however noted in four 
women (14%) during this period. The prime boost regimen, accordingly 
although positively immunogenic for both cellular and humoral immunity in 
women with AGIN, this study showed no clear-cut association between 
induction of HPV 16 specific systemic immunity and clinical outcome [Fiander 
et al., 2006;Smyth et al., 2004].  
 
1.13.9.5 CHIMERA VLP 
HPV 16 L1E7 chimeric virus-like particles (CVLP) consist of a carboxy-
terminally truncated HPV16L1 protein fused to the amino-terminal part of the 
HPV 16 E7 protein and self-assemble by recombinant expression of the fusion 
protein. The CVLP are able to induce L1 and E7 specific cytotoxic T 
lymphocytes. The first therapeutic trial to determine the therapeutic potential 
of this vaccine was by Kaufmann et al. in a randomised, double-blind placebo 
controlled trial in thirty-nine women diagnosed with mono-HPV 16 infected 
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high-grade CIN. Volunteers were randomised to receive either a 75g dosage 
of the vaccine or 250g dosage of the vaccine and four doses in total were 
scheduled. The vaccine was well tolerated and no major side effects were 
observed. In addition to cellular immune responses, antibodies with high titres 
against HPV 16L1 and low titres against HPV 16E7 proteins were also 
detected. The immune responses between lower and the higher concentration 
of the vaccine were comparable. Histological regression to CIN or no CIN was 
seen in 39% of vaccine recipients and 25% of the women who received 
placebo treatment. In addition, 37.5% of women in the vaccine group were 
HPV16 DNA negative compared to 14% in the placebo group, at week 48. It 
was observed that between the groups receiving vaccine or placebo 
treatment, although the trend towards clinical and histological response was 
only clearly obvious at week 48, the disparity in the HPV 16 DNA status was 
evident from week 24 onwards, signifying that histological responses probably 
follow HPV DNA clearance [Kaufmann et al., 2007].  
 
1.13.9.6 HEAT SHOCK PROTEIN (SGN-00101)  
Einstein et al. studied this novel therapeutic vaccine consisting of a fusion 
protein containing an M.bovis BCG heat shock protein (Hsp 65) covalently 
linked to the entire sequence of HPV 16 E7 protein. Fifty-eight women with 
biopsy proven high grade CIN were recruited into two cohorts, with thirty-one 
and twenty-seven women in each of the cohorts. The purpose of the study 
was to establish the efficacy of the vaccine and study clinical response rates 
at long term follow up. Following three doses of the vaccination at a dose of 
500g per vaccine at monthly intervals, a large loop excision of the 
transformation zone of the cervix or a cone biopsy of the cervix was then 
performed in all the women. On histological analysis of the resected cervical 
specimen, 22% were found to have achieved complete resolution of CIN on 
histological analysis, 55% achieved partial resolution to a lower CIN grade, 
19% were found to have stable disease and in 4%, disease progression was 
confirmed. At a cellular level, there was significant association between 
induction of local inflammation, immune cell infiltration and histological 
response. The Hsp component of this vaccine which targets HPV 16 E7 
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oncoprotein has also been shown to be efficacious against HPV types other 
than HPV 16 alone suggestive of a possible cross-reactive function [Einstein 
et al., 2007].  
 
Roman et al. studied the role of this same vaccine Hsp (SGN-00101) in 
women with high grade CIN. Twenty-one women received four injections of 
HPV 16 Hsp E7 fusion protein at a dose of 500 g per dose, three weeks 
apart, following which a large loop excision of the transformation zone of the 
cervix was carried out for histological analysis. 35% were found to have 
completely cleared the CIN on the loop biopsy specimen. 55% had stable 
disease with no disease progression or regression. Immune responses were 
measurable in nine out of seventeen women (53%) tested. Five out of seven 
women who made a complete histological response also demonstrated 
immune responses. The vaccine at the given dose and schedule resulted in 
lesion regression with corresponding immune responses. This group 
concluded that enhancing the immunogenicity of the vaccine in any way might 
enhance clinical and histological responses [Roman et al., 2007].  
 
1.13.9.7 VACCINIA VIRUS – MVA – E2 
This is a recombinant vaccinia virus expressing bovine papilloma virus (BPV) 
E2. Gracia-Hernandez al. conducted a phase II clinical trial in women with 
HPV positive high grade CIN. Thirty four women received this therapeutic 
vaccine at the concentration of 10(7) virus particles per dose injected directly 
into their uterus once every week for six-weeks. Twenty women who 
underwent cone biopsy of the cervix for high grade CIN were recruited to the 
control arm of this trial. In the group who received the vaccination, complete 
histological clearance of CIN was demonstrated in 59% of women and a 
greater than 50% reduction in the size of the lesions was noted in another 
32%. All the women who received the vaccine developed antibodies against 
the MVA E2 vaccine and were also shown to generate specific cytotoxic 
cellular immune response. In addition, HPV DNA viral load was significantly 
reduced in the vaccinated group. In comparison, in the group who underwent 
cone biopsy of the cervix, on histological analysis, CIN was found to be 
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completely excised in only 80% of women.    Specific cytotoxic cellular 
immune activity was also absent and predictably, there was no effect of the 
cone biopsy on the HPV viral load.   At twelve-month follow-up, three out of 
twenty women treated with cone biopsy of the cervix developed lesion 
recurrence in comparison to none in the vaccinated group [Garcia-Hernandez 
et al., 2006].  
 
1.13.9.8 LONG PEPTIDE VACCINE  
van Driel et al. conducted a phase I / II trial with HPV 16 E7 peptide 
vaccination in nineteen patients diagnosed with HPV 16 positive cervical 
carcinoma who were also refractory to the conventional treatment. This study 
proved that HPV 16 E7 peptide vaccination was feasible with no major side 
effects or serious adverse events in women who were immunocompromised 
and terminally ill with cervical cancer [Ressing et al., 2000;van Driel et al., 
1999].  
 
In another phase I toxicity assessment study, Kenter et al. studied the 
therapeutic HPV vaccine consisting of the complete set of long overlapping 
peptides of the oncogenic proteins E6 and E7 of HPV16 virus in formulation 
with Montanide ISA-51 adjuvant. A similar patient cohort to van Driel et al, 
comprising forty-three women with histologically proven advanced or recurrent 
carcinoma of the lower genital tract who ran out of any feasible options for 
further therapeutic treatment were recruited into this trial. Vaccines were 
administered subcutaneously four times at three weekly intervals. In this study 
the vaccine proved safe and highly immunogenic. Unsurprisingly, no 
therapeutic responses were observed [Kenter et al., 2008].  
 
1.13.10 LONG PEPTIDE VACCINE IN THE MANAGEMENT OF VIN 
 
Kenter et al. further studied the immunogenicity and efficacy of a synthetic 
long peptide therapeutic HPV vaccine in women diagnosed with VIN who 
were otherwise healthy, different to their previous cohort of terminally ill 
women diagnosed with end-stage cervical cancer. The vaccine consisted of 
nine HPV 16 E6 and four HPV 16 E7 synthetic peptides dissolved in 
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dimethylsulfoxide and emulsified with incomplete Freund’s adjuvant. Twenty 
women with high grade VIN were vaccinated on three or four occasions at 
three weekly intervals. At twelve months of follow-up, 79% demonstrated 
objective clinical response (47% complete clinical response and 32% partial 
clinical response). Symptom relief was noted in 63% of women. All the women 
who made a complete clinical response continued to be in remission at 
twenty-four month follow-up visit as well. Systemic HPV 16 specific T 
lymphocyte proliferative responses to HPV 16 E6, E7 or both proteins were 
detectable in 85% of women after the last dose of the vaccination schedule. 
Also, lymphocyte proliferation responses were accompanied by the production 
of both T-helper type 1 and type 2 cytokines. Post hoc analysis suggested that 
women who made a complete response at three months had a significantly 
stronger IFN associated proliferative CD4 positive T lymphocyte responses 
and a broad CD8 positive T lymphocyte response in comparison to women 
who did not make a clinical response. In the majority of the women assessed 
(twelve out of fourteen), proliferative responses were even detectable one to 
two years after completion of the vaccination programme [Kenter et al., 2009].  
 
DNA therapeutic HPV vaccines have been shown to generate effective 
cytotoxic T lymphocyte activity and also antibody responses by delivering 
foreign antigens to antigen presenting cells that stimulate helper and cytotoxic 
T lymphocytes. Naked DNA plasmid vaccines are shown to be relatively safer 
with ease of administration compared to live viral or bacterial vectors [Kim et 
al., 2008]. In addition, DNA vaccines are easy to prepare on a large scale with 
high purity and stability.  There however appears to be a need to develop 
strategies to enhance the potency of therapeutic HPV DNA vaccines. Clinical 
efficacy and HPV specific immunogenicity have both been shown to be sub-
optimal in clinical trials that have advocated DNA vaccines in comparison to 
long peptide therapeutic HPV vaccines (table 2).  
 
  
 

 95
STUDY DELIVERY SYSTEM ANTIGENS DISEASE GROUP IMMUNOG
ENICICTY 
CLINICAL OUTCOME 
Open-label phase I/II 
uncontrolled trial 
[Borysiewicz et al., 1996] 
Vaccinia virus (TA-
HPV)  
E6, E7 fusion 
protein 
Late stage cervical 
cancer (n=8) 
CTLs (1/18) 
Ab (3/18) 
Outcome not 
demonstrated 
Open-label uncontrolled 
trial [van Driel et al., 1999] 
Peptide oil/plus water 
adjuvant 
E7 peptides Refractory cervical 
cancer (HPV-16+, HLA-
A201 (n=19) 
CTLs 2/19 stable disease 
Open-label uncontrolled 
trial [Frazer, 2004]  
Protein/algammulin 
adjuvant 
E7-GST fusion 
protein 
Cervical cancer (n=24) Ab, DTH No alteration in natural 
h/o disease 
Open-label uncontrolled 
trial HPV-16+ [Muderspach 
et al., 2000] 
Peptide plus IFA E7 A0201 peptide VIN, CIN HPV 16+ HLA 
A2 (n=18) 
CTLs 10/16 
no DTH 
3/18 – CR 
6/18 - PR 
Open-label uncontrolled 
trial [Zhang et al., 2000] 
VLPs L1 Genital warts (n=33) Ab, DTH 25/33 - CR 
Double-blind placebo 
controlled trial [de Jong et 
al., 2002] 
Fusion protein TA-CIN 
(no adjuvant) 
HPV 16 L2, E6, 
E7 fusion-protein  
Healthy volunteers 
(n=40) 
Ab, T 
lymphocyte, 
IFN, 
ELISPOT 
No HPV infections 
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Open-label uncontrolled 
trial [Goldstone et al., 
2002] 
HSP fusion protein 
(HSP-E7) 
HPV 16 E7 
peptide 
Genital warts (n=22) Not done 3- CR, 10 - PR 
 
Open-label uncontrolled 
trials[Garcia et al., 
2004;Klencke et al., 
2002;Sheets et al., 2003]  
Encapsulated 
polynucleotides ZYC 
101 
HPV 16 E7 Anal, cervical dysplasia; 
HPV 16+, HLA-A2 (anal 
n=12, cervical n=15) 
ELISPOT; 
E2 specific 
immunity 
Regression of AIN: 
3/12-PR; CIN: 5/15 CR 
Multi-centre double-blind 
randomised placebo-
controlled trial[Garcia et 
al., 2004;Frazer, 2002]  
Encapsulated 
polynucleotide ZYC 
101 
HPV 16 E7 
peptide 
CIN2/3 any HPV type 
(n=127) 
ELISPOT, 
induction of 
E2 specific 
immunity 
Lesion regression 
higher in <25yr; not 
restricted to HPV 
16/18 lesions 
Randomised placebo 
controlled trial [Frazer, 
2004]Frazer 2002  
Protein/Iscomatrix 
adjuvant (E6, E7-IMX) 
HPV 16 E6, E7 
fusion protein 
CIN (n=31) Ab, DTH, 
CTLs  
7/14 – CR 7/14 - PR 
Open-label uncontrolled 
trial [Davidson et al., 
2003a] 
Vaccinia virus (TA-
HPV) 
E6, E7 fusion 
protein 
VIN (n=18) Ab, CMI PR- 8/18; loss of viral 
load in 12/18 
Open-label uncontrolled 
trial[Baldwin et al., 2003]  
Vaccinia virus (TA-
HPV) 
E6,E7 fusion 
protein 
VIN (n=12) CTL, 
ELISPOT 
CR-1/12; PR-5/12;T  
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cell specific 
responses  
-6/10 
Open-label uncontrolled 
trial[Ferrara et al., 2003]  
Dendritic cells HPV 16 E7, HPV 
18 E7 
Cervical cancer stage IV 
(n=15) 
Ab, 
ELISPOT 
No objective clinical 
response 
Non-randomised phase II 
prime boost vaccine trial 
[Fiander et al., 2006] 
L2, E6, E7 Fusion protein 
L2, E6, E7 (TA-
CIN) 
VIN (n=27); VAIN (n=2)  CR-1/29; PR – 5/29; 
15/29 – symptom 
response 
Open-label phase II 
uncontrolled clinical trial 
[Garcia-Hernandez et al., 
2006] 
BPV E2 Vaccinia virus 
(MVA-E2) 
CIN, vaccine arm (n=34) 
CIN, cone biopsy arm 
(n=20) 
Ab against 
MVA E2, 
CTL, viral 
load 
Histological response 
20/34 in the vaccine 
arm 
Open-label phase II 
uncontrolled clinical trial 
[Roman et al., 2007] 
Hsp-7 (SGN-00101) E7 CIN (n=21) CTL, HPV 
testing 
CR-35%; PR-5%, SD-
55%; disease 
progression-5% 
Randomised placebo-
controlled trial [Kaufmann 
et al., 2007] 
Chimeric virus like 
particle (CVLP) 
HPV 16 L1E7 
protein 
CIN2/3; HPV 16 only 
(n=39) 
Ab, CTL 39% no VIN in 
vaccinated vs. 25% no 
VIN in placebo, 59% of 
responders became 
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HPV 16 DNA negative 
Open-label uncontrolled 
trial [Kenter et al., 2008] 
Peptide Montanide 
ISA-51 adjuvant 
HPV 16 E6 
combined or 
separated from 
HPV 16 E7 
overlapping long 
peptides 
End stage cervical 
cancer (n=35) 
ELISPOT Immunity against E6 in 
pt vaccinated with E6, 
E7 at the same site; > 
response to E7 in pt 
vaccinated with E6 in 
one limb and with E7 
in a diff limb 
Open-label uncontrolled 
trial [Trimble et al., 2009] 
DNA vaccine Sig-E7 (detox)-
HSP70 fusion 
protein 
CIN2/3 HPV 16+ (n=15) ELISPOT No VIN in 33% in the 
highest dose cohort, 
new responses  
Open-label phase II 
uncontrolled clinical trial 
[Kenter et al., 2009] 
Long peptide vaccine  HPV-16 E6,E7 in 
Freund’s adjuvant 
VIN3 (n=20) HPV 
specific T 
lymphocyte 
responses 
CR-20%; PR-40; all pt 
has vaccine induced T 
cell responses 
Table 2 – Studies of therapeutic HPV vaccination for lower genital tract neoplasia 
CTLs – cytotoxic T lymphocytes; DTH – delayed type hypersensitivity; CIN – cervical intraepithelial neoplasia; VIN – vulval 
intraepithelial neoplasia; VAIN – vaginal intraepithelial neoplasia; AIN – anal intraepithelial neoplasia; HPV – human papilloma 
virus; Ab – antibody; CMI – cell mediated immunity; IFN - interferon gamma; BPV – Bovine papilloma virus; VLP – virus like 
particles; CR – complete response; PR – partial response
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1.13.11 IMMUNOTHERAPY – COMBINATION TREATMENT 
 
Combination immunotherapies in theory might prove to be superior to solo 
medical management by modulating the immune responses in more than one 
way. For instance, in some clinical trials for certain chronic conditions, 
imiquimod treatment induced T helper 1 response and the imiquimod primed 
effector cells were then boosted with other immunotherapeutic modalities or in 
some cases, the treatment at this stage was completed with the established 
method of treatment for that specific condition as described below. 
 
 
1.13.11.1 IMIQUIMOD IN COMBINATION THERAPIES  
 
Imiquimod is clearly shown to potentiate innate immune mechanism and then 
drive the adaptive immune response towards the T helper 1 or cell-mediated 
pathway and inhibit the T helper 2 pathways.  To take advantage of this 
aspect of imiquimod treatment, many trials have been conducted where, for 
clinical conditions that are usually resistant to the standard treatment, topical 
imiquimod was recommended as a compassionate treatment.  
 
A case of complete remission of nodular basal cell carcinoma was reported 
following treatment with topical imiquimod 5% cream and PDT [Devirgiliis et 
al., 2008]. Martinez Gonzalez et al remarked a rapid total response achieved 
in a patient with chronic, resistant mycosis fungoides to imiquimod and 
systemic interferon  2a as spectacular [Martinez-Gonzalez et al., 2008]. 
Bassukas et al. attempted a trial combination of imiquimod and cryotherapy 
for the treatment of lentigo maligna and observed an enhanced treatment 
response. According to the authors, the rationale to use imiquimod, as an 
adjunct to cryotherapy was to reinforce apoptosis of the tumour cells and build 
up an imiquimod induced cascade of potent tumour-destructive immune 
responses [Bassukas et al., 2008]. The efficacy of imiquimod in combination 
with 5-Fluorouracil (5FU) when considered in forty-eight women with actinic 
keratosis, clearance of lesions was found to be relatively rapid and the 
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combination treatment was also convenient in comparison to solo treatment 
with imiquimod or 5-FU [Price, 2007].  
 
1.13.11.2 IMIQUIMOD IN COMBINATION THERAPY FOR VIN  
 
1.13.11.2.1 IMIQUIMOD & PDT 
 
The first published study of combination immunotherapy for VIN was by 
Winters et al. In this study, twenty women diagnosed with high grade VIN 
were subjected to a treatment combination of topical imiquimod and 5 ALA-
PDT. Topical imiquimod was used as a neo-adjuvant treatment for eight 
weeks in a dose escalating fashion. This was followed by two sessions of 5 
ALA-PDT, the PDT sessions spaced a month apart. 80% of the women found 
the combination of imiquimod and PDT treatment bearable. A clinical 
response rate of 55% was observed at week 52, the study primary end-point. 
Also, 65% of the women were asymptomatic following treatment in 
comparison to 5% who were asymptomatic when the trial commenced. 
Nineteen out of the twenty participants remained under clinical follow up for 
more than two years after the trial completion. Reassuringly, all the 
participants who made a response to the study treatment remained in clinical 
remission at follow-up. In fact, one woman who was considered to be a partial 
clinical responder during the trial was in fact found to have completely cleared 
the lesion at follow-up. This study exemplifies the longevity of response 
achieved with combination treatment of imiquimod and PDT. The authors 
consider that imiquimod establishes a favourable microenvironment 
enhancing the immunological effect of PDT. Women who completed the 
scheduled treatment experienced better treatment outcome and compromised 
imiquimod and / or PDT treatment resulted in less positive results. Clinical 
responses accomplished in this trial were comparable to the results achieved 
in other clinical trials of solo imiquimod treatment where treatment schedule 
was as prolonged as sixteen weeks to six months. In fact, enhanced clinical 
response rates were observed in this trial in comparison to PDT alone trials 
for VIN [Winters et al., 2008].  
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2.1 STUDY PROTOCOL 
2.1.1 IMIQUIMOD IN COMBINATION WITH THERAPEUTIC HPV 
VACCINATION FOR THE MANAGEMENT OF VULVAL INTRAEPITHELAIL 
NEOPLASIA – STUDY PROTOCOL 
 
This thesis portrays an open, uncontrolled phase II trial of twenty women 
diagnosed with high grade VIN. The study scheme was to consider the 
combination of topical imiquimod cream and intramuscular administration of 
TA-CIN therapeutic HPV vaccination in a sequential fashion in women 
diagnosed with VIN grades 2 or 3. The aim of the study was to detect an 
effective and non-invasive treatment option for VIN, which also contemplates 
preservation of vulval architecture, establishes longevity of response and 
reduces recurrence rate. 
 
2.1.2 HYPOTHESIS 
 
Immune response modifier imiquimod and therapeutic HPV vaccination have 
both a recognised role in the management of VIN in a clinical trial setting. With 
imiquimod treatment, compliance with the treatment schedule is an issue due 
to prolonged recommended periods of treatment (sixteen weeks to six 
months) coupled with severe local and systemic side effects. In the previous 
TA-HPV or TA-CIN therapeutic HPV vaccination clinical trials of VIN or AIN, 
majority of patients’ demonstrated symptom response with a reasonable 
proportion also displaying objective clinical responses. In most of these 
studies, it was frequently observed that enhanced local infiltration of helper 
and cytotoxic T lymphocytes often corresponded with clinical response to 
treatment.  
In this study, the rationale behind using a combination of imiquimod and TA-
CIN was that a short course of imiquimod in addition to having a direct effect 
on VIN by stimulating a local immune response would also provide an 
immunological platform for the therapeutic HPV vaccination to achieve an 
enhanced response rate than that achieved in the previous solo vaccination 
trials.  
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2.1.3 PRIMARY STUDY OBJECTIVE  
 
The primary objective of the study was to evaluate the objective (clinical) 
response of VIN to treatment with imiquimod followed by vaccination with TA-
CIN. 
To assess the primary objective, the lesions were mapped and the marker 
lesions were identified at the baseline. The extent of the disease was 
assessed visually supported by the direct measurement of the marker 
lesion(s) with the aid of the colposcope on the standard vulvoscopy chart at 
the time of baseline assessment and then repeated at every clinic visit for the 
duration of the study. For each marker lesion, the longest perpendicular 
dimensions were measured. In addition, medical photographers from the 
medical illustration department took photographs of the lesions at baseline 
(week0), after imiquimod (week10), after the third and final dose of the TA-
CIN vaccination (week20) and at follow-up clinic visits (weeks 26 and 52). 
 
2.1.3.1 DEFINITION OF CLINICAL RESPONSE 
 
Clinical response was defined as reduction equivalent to or greater than 
50% in the size of the lesion(s). All the measurements were made during 
vulvoscopy examination by the same clinician, to avoid inconsistency. 
Complete clinical response (CR) was defined as total clearance of the 
lesion(s). Partial clinical response (PR) was defined as reduction in the size 
of the lesion(s) equivalent to or greater than 50% but less than 100%. Stable 
Disease (SD) was defined as less than 50% reduction in the size of the 
lesion(s) or less than 25% progression in the size of the lesion(s).  Disease 
Progression was defined as 25% or more increase in the size of the lesion(s) 
 
2.1.4 SECONDARY STUDY OBJECTIVES  
 
The secondary study objectives were to evaluate histological response, 
symptom response, HPV response, safety, toxicity and tolerability of the 
treatment regime and also to evaluate, characterise and quantify immune 
response to the treatment. 
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2.1.4.1 Histological response to treatment was assessed by taking 4 mm 
punch biopsy(s) of the marker lesion(s) with Keyes punch biopsy forceps 
under local anaesthesia (5 ml of bupivicaine 0.25%). Biopsy was taken 
following imiquimod treatment at week10, after the three doses of TA-CIN 
vaccination at week20 and repeated at the week 52, the study primary end-
point.  The biopsy sites were sealed with Monsel’s (ferric subsulfate) 
haemostatic solution, which is our normal practice.  In cases of excessive 
bleeding uncontrolled with the Monsel’s solution, an absorbable suture was 
placed taking sterile precautions. The biopsy sample was sent in formalin for 
histopathological analysis by a dedicated histopathologist with special interest 
in gynaecology cancer. The same team of histopathologists consistently 
reviewed all the biopsy specimens taken from the trial participants. 
 
Definition of Histological Response 
Complete regression of high grade VIN (VIN 2 or 3) to no VIN on 
histopathology of the punch biopsy of the index lesion was defined as 
histological response. 
 
2.1.4.2 Symptom responses were evaluated from patient’s symptom diary 
that was given to them at the beginning of the trial, where women were 
expected to document the symptoms that occurred during the treatment in a 
visual analogue scale structure. Women were instructed to take this diary to 
each of the clinic visits for closer monitoring of symptoms.  
 
At each clinic visit, trial participants were also systematically questioned if they 
have felt any pain, itching, redness, discharge, and / or any other symptoms 
over the last seven days. Those who experienced any of these symptoms 
were asked to grade the symptoms into none, mild, moderate and severe 
categories. Symptoms which did not interfere with everyday life were classed 
into none or mild categories whereas symptoms which got in the way of 
everyday life were classed into the moderate or severe categories. 
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Definition of Symptom Response 
Regression of symptoms from the ‘moderate’ or ‘severe’ category to the ‘mild ‘ 
or ‘none’ categories was defined as symptom response. 
 
2.1.4.3 HPV response was evaluated by exploration of the different HPV 
genotypes in the biopsy sample of the index lesion at different time-points. 
This was facilitated by Reverse Line Blot Assay (RLBA) analysis of a small 
section of the punch biopsy taken from the index lesion at baseline (week 0), 
post imiquimod (week 10), post vaccination (week 20) and the primary end-
point (week 52). 
 
Definition of HPV Response 
Clearance of HPV 16 from the biopsy site in somebody who was previously 
positive for the presence of HPV 16 was considered to be HPV response. 
 
The emphasis for measurement of local immune responses was on helper 
(CD4), cytotoxic (CD8) and regulatory T lymphocytes (Tregs), by using the 
immunofluorescence technique on frozen tissue sections acquired from the 
punch biopsy of the index lesion. HPV specific systemic T lymphocyte 
immune responses were assessed by lympho-proliferation assays and 
neutralisation antibody assays.     
 
2.1.5 SAFETY AND TOLERABILITY 
 
To evaluate the safety, toxicity and tolerability of both imiquimod and TA-
CIN treatment, in addition to the regular clinical assessment, to confirm 
general well-being during the course of the trial, urinalysis (to check for the 
presence of any protein, blood, leucocytes, glucose, ketones, nitrites and 
urobilinogen) and blood samples for full blood count (FBC), renal function 
tests (U&E) and liver function tests (LFT) were carried out serially at baseline 
(week 0), post imiquimod (week 10) and following the final dose of the 
vaccination at week 20. All the samples were processed at the biochemistry 
laboratory, St Marys hospital.   The intention was to follow-up clinically 
significant values until the end of the study period.  
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During every immunisation, adrenaline (1mg), chlorpheneramine (2.5-5.0mg) 
and hydrocortisone (100mg), in pre-filled syringes, and cardio-pulmonary 
resuscitation equipment was made immediately available for management of 
anaphylaxis.  
 
Local reaction to TA-CIN was described as an extensive area of redness and 
swelling which becomes indurated and involves most of the antero-lateral 
surface or a major part of the circumference of the upper arm. General 
reaction to TA-CIN was described as fever equal to or more than 39.5C 
within 48 hours of dosing, anaphylaxis, bronchospasm, laryngeal oedema, 
generalised collapse or convulsions. 
 
At all clinic visits following vaccination with TA-CIN, women were asked to 
give details of all injection site reactions that occurred since the last visit in the 
symptom diaries provided to them. The policy was also to monitor any local or 
systemic adverse events by keeping a full record of each adverse event and 
intercurrent illness, whether believed to be related or unrelated to the 
treatment. This record would include date and time of appearance and 
resolution of any adverse event, intensity, seriousness, attributability to trial 
medication, and action taken (appendix 1). 
 
2.2 METHODS 
 
2.2.1 IMIQUIMOD TA-CIN TRIAL PROTOCOL 
Ethical approval was obtained from the University of Manchester Ethics 
committee on the 8.10.2004 and the Central Manchester Local Research 
Ethics Committee – reference number – 05/Q1404 / 172 on 19.10.2005. The 
study was registered with the European Clinical Trials Database EudraCT No 
2005-001824-35. The Medicines and Healthcare Products Regulatory Agency 
(MHRA) approved the trial and issued the clinical trials authorization number 
(CTA) 01501/0003/001-000. 
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Volunteers were recruited from the gynaecology, colposcopy and the vulva 
clinics at St Marys Hospital, Manchester. St Marys hospital is a tertiary referral 
centre for women diagnosed with vaginal or vulval intraepithelial neoplasia. 
Some volunteers were referred from other district general hospitals. Women 
with newly diagnosed or recurrent VIN were invited to participate in the trial. 
The following inclusion and exclusion criteria applied:  
 
2.2.1.1 INCLUSION CRITERIA 
 Female aged 18-70 years 
 Non-child bearing or using effective contraception 
 Patients with VIN3 or AIN3, histologically confirmed by biopsy within 
the previous three months 
 Given written informed consent 
 Patients must have at least one lesion of sufficient size to allow 
biopsies to be taken on three occasions and for disease evaluation to 
be performed. (It is estimated that a lesion of approximately 1 cm 
diameter would be sufficient.) 
2.2.1.2 EXCLUSION CRITERIA 
 
 Any patient who has received active treatment for VIN3 or AIN3 in the 
previous four weeks prior to enrolment 
 Any patient with VAIN3 requiring treatment 
 Any patient who has received HPV vaccine in the past 
 Any patient with known immunodeficiency 
 Any patient who is planning pregnancy, pregnant or breast feeding 
 Any patient receiving immunosuppressive therapy 
 Any patient with clinically significant abnormal serum biochemistry, 
haematology 
 Any patient with evidence of ongoing infection 
 History of severe allergy 
 History of severe adverse reaction to any vaccine 
 Receipt of blood or blood products in the last three months 
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 Women whose last cervical smear was abnormal. If their last smear 
was more than three years ago, it must be repeated at screening 
 Any patient who either has ano-genital carcinoma or who, in the 
investigator’s opinion, is at high risk of developing ano-genital 
carcinoma over the next six months 
 
2.2.2 TEST AGENTS 
Imiquimod (Aldara TM) is provided in 10 mg sachets containing 12.5 mg of 1-
(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine. Each gram of the 5% 
cream contains 50 mg of imiquimod in an off-white oil in water vanishing 
cream base consisting of isostearic acid, acetyl alcohol, stearyl alcohol, while 
petrolatum, polysorbate 60, sorbitan monostearate, glycerine, xanthum gum, 
purified water, benzyl alcohol, methyl paraben and propyl paraben.    
TA-CIN is an HPV16 L2E7E6 fusion protein formulated in 5mM glycine buffer 
containing 0.9mM cysteine. Each vial consisted of 0.5 ml of TA-CIN at the 
dose of 128 g/ml, stored at –20 C. 
 
 
 
2.2.3 PROTOCOL 
 
2.2.3.1 SCREENING VISIT 
 
The trial was discussed with potentially eligible patients in the clinic and they 
were given the patient information sheet to read at home. If willing to 
participate, they were then invited to the trial clinic for a screening 
appointment where the eligibility to participate was verified by a clinical 
examination, urinalysis and blood tests. Women were asked to provide a urine 
sample in a sterile container. This was tested for the presence of any blood, 
leukocytes, protein, glucose, ketones, nitrite, bilirubin and urobilinogen (dipstix 
urinalysis). The sample was sent for urine microscopy and culture sensitivity 
to the microbiology department at St Marys hospital if the dipstix urinalysis 
was indicative of possible infection. Venous blood was drawn for full blood 
count (5ml) and serum biochemistry (5ml). A punch biopsy of the lesion was 
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taken at this stage if it was not already carried out in the last three months, to 
establish the diagnosis of high grade VIN.  A detailed medical history was 
obtained at this stage to make certain all the inclusion and exclusion criteria 
were met.   
 
2.2.3.2 RECRUITMENT - WEEK 0 – COMMENCE IMIQUIMOD TREATMENT 
 
Twenty-five women met the inclusion criteria and agreed to participate in the 
trial. Five women subsequently changed their mind regarding trial 
participation. At the recruitment visit women were asked to sign two copies of 
the written consent form, one for them to keep and one to be kept with their 
medical notes. A separate consent form was used for the photographs 
whenever required. Women were identified by a study code number that 
began with IT (abbreviation for Imiquimod TA-CIN). Vulvoscopy was then 
carried out and the longest dimensions of the index lesion(s) measured 
followed by a photograph of the lesion.  One 4mm punch biopsy of the index 
lesion was obtained a small fragment of which was sent in a dry pot to the 
virology department for HPV typing. The rest of the biopsy was snap frozen in 
liquid nitrogen and transported to the Paterson Institute for Cancer Research, 
Manchester, either in liquid nitrogen or dry ice to be stored at -80C prior to 
obtaining sections. Forty ml of blood was drawn into a universal container with 
heparin (6000 iu heparin / 20 ml blood) and transported to the Paterson 
Institute for Cancer Research for further processing.  
 
The colposcope in the clinic is equipped with live image capturing facility, 
which enabled women to visualise the lesions on the screen. The areas that 
needed imiquimod application were shown to the patient on the screen and 
the method of application demonstrated. Women were advised to apply 
imiquimod for eight weeks in total, in a dose-escalating manner, one 
application in the first week, two applications in the second week followed by 
three applications a week, for the next six weeks. This regime was used to 
minimise the side effects and improve tolerance to the imiquimod treatment. In 
addition to the manufacturers information leaflet about Aldara (imiquimod) 
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cream, an additional information sheet specifically designed for the trial 
purposes was provided to the patient. Women were instructed to use the 
required number of sachets to cover all the lesions. In most cases, one sachet 
sufficed for one application. Each woman was provided with a box of twelve 
sachets.  Women were advised to apply the imiquimod cream at bedtime on 
clean affected areas, wash hands after application and if necessary, to wear 
only cotton loose fitting underwear. They were instructed to wash the cream 
off the next morning and carry on with their routine daily activities. They were 
instructed to refrain from sexual intercourse on the days of imiquimod 
application. In addition, they were advised to keep the symptom diary whilst 
on treatment. It was advised not to commence the imiquimod application until 
ten days after the recruitment visit to allow the biopsy site to heal. The general 
practitioner and the referring clinician were informed of the patient’s 
participation in the trial.  
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Figure 3 a, b: Method of assessing the size of the lesion on vulvoscopy 
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SCHEDULE CHART 
 Screening 
Wk 
0 
Wk 
1 
Wk 
4 
Wk 
10 
Wk 
14 
Wk 
18 
Wk 
20 
Wk 
26 
 
Wk 
52 
Consent X         
 
Medical 
History 
X         
 
Photograph  X   X   X X X 
Vulval biopsy  X   X   X  X 
FBC, serum 
biochemistry, 
urinalysis 
X    X   X  
 
Blood for 
immunological 
assay 
 X   X   X  
 
Commence 
Imiquimod 
  X       
 
Vaccination     X X X   
 
Table 3 Trial Schedule Chart The participant in total made nine visits to the 
hospital over a period of twelve months. Biopsies were taken on four 
occasions and bloods on three occasions in total. 
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2.2.3.3 WEEK 4 – REVIEW IMIQUIMOD TREATMENT 
Women were advised to attend the clinic four weeks into the imiquimod 
treatment primarily to ascertain tolerance to the imiquimod treatment, to 
discuss an altered application regime if necessary and to suggest coping 
mechanisms for any intolerable side effects. Any requirement for analgesia 
was discussed, if necessary, prescriptions were arranged for oral analgesics, 
anti-histamines to relieve local itch related to VIN, and bedtime sedatives to 
those who requested.  Vaseline gauze dressings (gelonet), local anaesthetic 
creams and gels were also provided. Every possible attempt was made to 
help women persevere with the treatment. An assessment of the dosage of 
imiquimod used per application was made and a further prescription provided 
if necessary.  
 
At this stage, most of the participants had an inkling of what to expect over the 
next four weeks. Some women preferred to use the cream during daytime for 
various reasons and some participants felt they could not cope with three 
applications per week due to the side effects. A further appointment to attend 
the clinic two weeks after completing the imiquimod treatment (week 10) was 
scheduled. 
 
2.2.3.4 WEEKS 10, 14 and 18; ASSESSMENT OF RESPONSE TO 
IMIQUIMOD TREATMENT, ADMINISTRATION OF TA-CIN VACCINATION 
 
A complete clinical assessment with accurate measurement of the lesion(s) 
took place at week 10, with the clinical findings supplemented by 
photographs. Symptom response was assessed by asking the patient and 
also by reviewing their symptom diaries. Two punch biopsies were obtained to 
assess histological, HPV and local immune responses. It was attempted to 
take the biopsies close to the original biopsy site to allow comparison. 
Urinalysis and blood tests were repeated. Forty ml of venous blood was again 
drawn for immunological assays.  
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The TA-CIN vaccines were stored in the pharmacy at -20C and were 
obtained on a named / patient based prescription and dispensed only to the 
clinic staff. The vaccine following defrosting at room temperature for up to 
thirty minutes, the vial was gently inverted about five times before drawing up 
the dose. Using a 25G (orange) needle and 1ml syringe, 0.5 ml (128 g/ml) of 
the clear defrosted solution was drawn and administered intramuscularly into 
the deltoid muscle within two hours, under aseptic precautions.  Women were 
advised to wait in the clinic area for about twenty minutes to make sure they 
suffered no immediate adverse effects due to the vaccination. 
 
TA-CIN vaccination was similarly repeated at weeks 14 and 18.  
 
2.2.3.5 WEEK 20 
A complete clinical assessment with accurate measurement of the lesion(s) 
for a third time took place again at week 20, with the clinical findings 
supplemented by photographs. Symptom response was assessed by asking 
the patient and also by reviewing their symptom diaries. Two punch biopsies 
were again obtained to assess histological, HPV and local immune responses. 
It was attempted to take the biopsies close to the original biopsy site to allow 
comparison. Urinalysis and blood tests were repeated. Forty ml of venous 
blood was again drawn for immunological assays. This week marked 
completion of trial treatment and an appointment was made for week 26, to 
assess the overall clinical response to treatment. 
 
2.2.3.6 WEEK 26 
A complete clinical assessment with accurate measurement of the lesion(s) 
for the fourth time took place again at week 26, with the clinical findings 
supplemented by photographs. Symptom response was assessed by asking 
the patient and also by reviewing their symptom diaries.  
 
2.2.3.7 WEEK 52 
The final assessment was made at twelve months from the start of treatment, 
the primary end-point. A further assessment of clinical and symptom response 
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was made at this stage. In the absence of any apparent VIN on vulvoscopy, 
one punch biopsy was taken from the site of the original biopsy at recruitment. 
If however VIN was suspected on vulvoscopy, a punch biopsy was taken for 
histological diagnosis. A fragment of the punch biopsy was forwarded to the 
virology department for HPV typing. 
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Figure 4 – Appearance of the vulva in patient 10 at wk 0 (a), wk 10 (b), wk 20 
(c) and wk 52 (d). A clinical record of the same lesions based on vulvoscopy 
appearance is shown in figures 5 (a, b, c, d) 
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Figure 5(a) – Appearance of vulva patient 10, wk 20 . (corresponding to figure 
4a) 
 
 118
 
 
 
Figure 5(b) – Appearance of vulva patient 10, wk 20 . (corresponding to figure 
4b) 
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Figure 5(c) – Appearance of vulva patient 10, wk 20 . (corresponding to figure 
4c) 
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Figure 5(d) – Appearance of vulva patient 10, wk 52 . (corresponding to figure 
4d) 
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2.2.4 STUDY SAMPLES 
2.2.4.1 PATIENT BLOOD SAMPLES 
 
Forty millilitres of peripheral venous blood drawn from each patient at weeks 
0,10 and 20 in a pre-heparinised tube (6000 iu of heparin / 20ml blood) were 
further processed at the Paterson Institute for Cancer Research. Lymphocytes 
from the blood were separated in the following manner. 
 
2.2.4.2 LYMPHOCYTE SEPARATION 
Heparinised blood was layered onto lymphoprep lymphocyte separation 
medium (LSM, Nycomed, Amersham) and centrifuged at 800g (units of times 
gravity - g) at 20°C for twenty minutes in Mistral 30001 centrifuge 
(acceleration at 5 and brake at 0). Peripheral blood mononuclear cells 
(PBMC) were collected from the LSM interface and washed with phosphate 
buffered saline (PBS) twice and then centrifuged for ten minutes, twice at the 
speed of 350g and 200g respectively. Aliquots of plasma and red blood cell 
pellets were labelled and stored at -20°C. Plasma was spun at 3000 rotations 
per minute (rpm) for 10 minutes to sediment any contaminated red blood cells 
and the supernatant was aliquoted. PBMC were counted in a Neubauer’s 
chamber and were frozen at the concentration of 107 cells / ml in 10% 
dimethyl sulfoxide (DMSO) in foetal calf serum (FCS, TCS biologicals) and 
stored in liquid nitrogen at -80 C until required. 
 
2.2.4.3 PATIENT BIOPSY SAMPLES 
Snap frozen biopsies were stored at -80°C prior to sectioning. They were 
embedded in optimum cutting temperature embedding compound (O.C.T), 
and sectioned by a cryostat to seven-micron sections and placed on 
aminopropyltriethoxysilane (APES)-coated slides, two-sections per slide. 
Slides were labelled and stored at -20°C until required.  
 
2.2.4.3.1 DNA EXTRACTION FOR HPV TESTING  
Two dedicated virologists at the virology department, St Marys Hospital, 
carried HPV detection and genotyping. DNA extraction was carried out as 
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follows; biopsy samples were first digested in proteinase K lysis buffer 
containing 10mM Tris/Hcl ph 8.3; 1mM EDTA; 0.5% Triton X 100, 0.001% 
SDS and 250µgms/ml of proteinase K (the volume of lysis buffer was decided 
empirically depending on the size of the biopsy). Following digestion at 37°C 
overnight with constant rotation the DNA was extracted using the MagnaPure 
Total Nucleic Acid Extraction protocol. Extracted DNA was stored at -70°C 
prior to testing. 
 
2.2.4.3.2 HPV GENOTYPING (ROCHE REVERSE LINE BLOT ASSAY) 
HPV detection and genotyping was carried out using the prototype reverse 
line blot assay kindly supplied by Roche. This assay is designed to amplify 
and detect 27 HPV genotypes. In order to assess DNA integrity, this assay 
also amplifies and detects a fragment of the human β-Globin gene. Testing 
was carried out according to the manufacturer’s instructions. A 50µl volume of 
extracted DNA was amplified using the PGMY primer PCR reagents provided 
by Roche on a 9700 thermocycler. Following amplification, biotinylated PCR 
product was denatured and captured onto nylon strips coated with the HPV 
type specific oligonucleotides. By the reverse blot strip analysis; genotype 
discrimination of the multiple HPV types can be accomplished in a single 
hybridisation and wash cycle. Twenty- seven HPV probe mixes, two control 
probe concentrations, and a single reference line were immobilised to 75- by 
6- mm nylon strips. Each individual probe line contained a mixture of two 
bovine serum albumin-conjugated oligonucleotide probes specific to a unique 
HPV genotype. The genotype spectrum discriminated to this strip includes the 
high-risk, or cancer-associated, HPV genotypes 16, 18, 26, 31, 33, 35, 39, 45, 
51, 52, 55, 56, 58, 59, 68 (ME180), MM4 (W13B), MM7 (P291), and MM9 
(P238A) and the low risk, or non-cancer associated genotypes 6, 11, 40, 42, 
53, 54, 57, 66, and MM8 (P155). The primary advantage of the strip-based 
detection system is the ability to rapidly genotype the HPVs present in the 
genital samples with high sensitivity and specificity, minimizing the likelihood 
of misclassification. Immobilised product was visualised using streptavidin-
horseradish peroxidase-mediated colour precipitation as described previously 
[Gravitt et al., 1998].  
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2.2.5 DOUBLE IMMUNOFLUORESCENCE STAINING OF SPECIMENS 
 
The characterisation of the local immune environment in the punch biopsies 
was by double immunofluorescence staining of the tumour infiltrating 
lymphocytes using a combination of antibodies against CD4, CD8 and 
FoxP3CD4. The reagents and methods used to identify CD4, CD8 and Tregs 
required optimisation. This part of this chapter describes the optimisation 
procedures for these reagents.   
 
Antibodies were tested initially on sections of the human tonsil, acknowledged 
for their abundance of various types of T lymphocytes at different 
concentrations for optimisation. For the detection of CD4 lymphocytes, two 
different antibodies were tested, Mouse Monoclonal primary (EDU-2) to CD4 
(Ab 1246) and Abcam and Mouse Monoclonal Primary (B379) to CD4 (Ab 
8476).  The background was felt to be high with three washes in the 
methodology and this led us to increase the washes at all stages of the 
protocol to five times. 
 
Following identification of the optimal antibody, the appropriate concentration 
and the best method, the antibodies alone and in combination were then 
tested and optimised on the VIN sections.  
 
The following antibodies at the following concentrations were used in 
this study for the immunofluorescence labelling of the CD4, CD8 and 
FoxP3CD4 lymphocytes.  
 
Double fluorescence labelling of CD4+FoxP3CD4+ lymphocytes was carried 
out with mouse IgG1 anti-FoxP3CD4 (eBioscience) antibody, at a 
concentration of 1:50 and mouse IgG2a anti-CD4 (Abcam) antibody at a 
concentration of 1:100 and detected respectively using goat antimouse IgG1 
Alexa Fluor 488 at a concentration of 3 µl/1000µl and goat antimouse IgG2a 
Alexa Fluor 546 at a concentration of 3 µl/1000µl (Invitrogen) respectively. 
CD8+ lymphocytes were detected using Rabbit anti-CD8 (Abcam) antibody at 
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a concentration of 1:100 and detected using Goat anti Rabbit-IgG Alex Fluor 
488 at the concentration of 3 µl/1000µl. 
 
2.2.5.1 CD4 ANTIBODY - Mouse Monoclonal Primary (EDU-2) to CD4 (ab 
1246) - Abcam 
Immunogen – Human T lymphocytes 
Species Reactivity – Reacts with human, not yet tested in other species 
Cellular localization – Type 1 membrane protein 
Store at +4 degrees C, Clonality – monoclonal, Clone number – EDU-2 
Isotype – IgG2a, Purity – IgG fraction 
Storage Buffer – PBS, 0.5% BSA, 0.2% Sodium Azide 
Form – liquid, Concentration – 0.20mg/ml 
 
2.2.5.2 CD4 ANTIBODY - Mouse Monoclonal Primary (B379) to CD4 
(ab8476) – Abcam  (tested but sub-optimal) 
Immunogen:  CEM cells, reacts with human  
Specificity: human CD4 antigen 55kD glycoprotein 
Tested applications – flow cytometry, ICC/IF, IHC-frozen 
Recommended dilution – for IF 5-20 µg/ml  
Cellular localization – type1 membrane protein, raised in mouse 
Clonality – monoclonal, clone number –B379, Isotype – IgM 
Concentration 0.4mg/ml 
 
2.2.5.3 CD8 ANTIBODY - Rabbit polyclonal to CD8 (ab4055) – Abcam 
Immunogen – Synthetic peptide comprising the 13-C terminal amino acids of 
the cytoplasmic domain of CD8 alpha chain. 
Species reactivity – Reacts with human and Sheep, Not yet tested in other 
species 
Recommended dilutions: Immunohistochemistry – 1/50 – 1/100 for 30min at 
RT 
Positive Control: Tonsil 
Cellular localization: Type 1 membrane protein (isoform 1) and secreted 
(isoform2) 
Store at +4 degrees C, Concentration  - 0.100 mg/ml. 
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2.2.5.4 FoxP3CD4 ANTIBODY - Affinity purified anti-human FoxP3CD4, 
catalogue number; 14-4777 - E-bioscience 
Formulation: Phosphate buffer pH 7.2, 150mM Nail, 0.09% NAN3 (3 
subscript), Store at 4 degrees C, Clone: 236A/E7, Isotype: Mouse IgG1 
This antibody has been reported for use in intracellular staining followed by 
flow cytometric analysis, immunoblotting (WB), and immunohistochemical 
staining of frozen and paraffin embedded sections. 
Storage buffer – 50mM borate, 150 mM Nacl, 20% glycerol and 0.05% sodium 
azide Ph-8.0, liquid form, concentration 0.400mg/ml, storage +4 degrees 
Clonality – polyclonal, Isotype – IgG, Purity – IgG fraction 
Storage Buffer – PBS with sodium azide 
 
2.2.5.5 Control Antibodies 
Antibody for negative control for CD4 – goat anti-mouse IgG2a at a 
concentration of 200mg/l 
 
Antibody for negative control for CD8 – goat anti-rabbit IgG at a concentration 
of 100mg/l 
 
Antibody for negative control for FoxP3CD4 – goat anti-mouse IgG1 at a 
concentration of 200mg/l 
 
 
2.2.5.6 Secondary ANTIBODIES - Molecular Probes - Labelled Goat Anti-
Mouse Isotype-Specific Antibodies 
Storage – 2-6C, Protect from light 
Working concentration – 1-10 microgram/ml 
Molecular Probes’ fluorescent goat anti-mouse isotype-specific antibodies are 
prepared from affinity-purified antibodies that react with the Fc portion of the 
heavy chain of mouse IgG of the appropriate isotype. The Alexa Fluor dyes to 
which these antibodies are conjugated provide for extraordinarily bright 
antibody conjugates.  
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 2.2.6 DOUBLE IMMUNOFLUORESCENCE LABELLING TECHNIQUE   
 
Double immunofluorescence staining allows concurrent staining of two 
different antibodies. The following combination of antibodies was attempted in 
this study; CD4 + FoxP3CD4; CD8 + FoxP3CD4 and CD4 + CD8. The 
procedure of double immunofluorescence labelling includes slide fixation, 
blocking the non-specific binding of the antibodies, permeabilization of the 
cell membrane to target any intracellular antigens (FoxP3CD4 in this study), 
incubation with the primary antibodies followed by incubation with the 
secondary antibodies.  
 
2.2.6.1 FIXATION 
Slides stored at -20 C were allowed to come to room temperature, which 
usually took about fifteen minutes. Slides were labelled with the patient 
number, date and the antibodies tested. In the meantime, acetone used as 
the fixative, was pre-cooled at -20C for thirty minutes. Slides were fixed with 
the pre-cooled acetone fixative for ten minutes at room temperature followed 
by air-drying for an additional ten minutes. The slides were then rinsed and 
hydrated in phosphate buffered saline (PBS) for twenty minutes.  As the 
sections were never exposed to formalin, the process of antigen retrieval was 
not required. 
 
2.2.6.2 BLOCKING 
Sections were then incubated in PBS +10% Horse serum for thirty minutes 
followed by PBS+1% Horse serum for another thirty minutes, at room 
temperature to block unspecific binding of antibodies. The sections were 
outlined with PAP pen (special marking pen that provides a thin film of 
hydrophobic barrier when a circle is drawn around a specimen on the slide) 
and the section incubated (1ml of antibody solution for each section) with the 
first surface / membrane primary antibody (CD4, CD8 or the control antibodies 
in this study) in PBS + 1% horse serum in a humidified chamber for one-hour 
at room temperature.  
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2.2.6.3 PERMEABILIZATION 
 
The first primary antibody solution (CD4 or CD8) at this stage was decanted 
and the sections were washed in PBS + 0.1% Triton-X-100. This step was 
carried out as the subsequent target protein (FoxP3CD4 or the control 
antibody) is expressed intracellularly. Triton-X-100 is considered to be a very 
popular detergent for improving the intracellular penetration of the antibodies. 
 
The sections at this stage were incubated with the intracellular primary 
antibody (FoxP3CD4) in the medium of PBS + 1% horse serum + 0.1% Triton 
X-100 at 4C overnight in a humidified chamber.  
 
2.2.6.4 WASHES FOLLOWING INCUBATION WITH THE PRIMARY 
ANTIBODIES 
The following morning, antibody was decanted and the slides were washed in 
PBS + 0.1% Triton-X-100 at room temperature five times, each wash lasting 
for five minutes.  
 
2.2.6.5 SECONDARY ANTIBODIES 
 Fluorescent secondary antibodies were used in the medium of PBS + 1% 
horse serum at the concentration of 3 l/ ml. The slides were incubated at 
room temperature very stringently in the dark for an hour.  
  
2.2.6.6 WASHES FOLLOWING INCUBATION WITH THE SECONDARY 
ANTIBODIES  
 Following decanting of the secondary antibodies, slides were washed again 
for five times in PBS + 0.1% Triton-X-100 in dark, each wash lasting for five 
minutes.  
 
2.2.6.7 SLIDE PREPARATION 
About 20 l of DAPI (4’6-diamidino-2-phenylindole – fluorescent stain that 
binds strongly to the DNA. DAPI has the ability to pass through an intact T 
lymphocyte membrane, stains the nucleus and emits blue emissions) was 
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poured onto each of the sections and incubated in the dark for fifteen to 
twenty minutes. The slides were then dipped in 1% TBS (Tris buffered saline) 
briefly followed by quick gentle air-drying in the dark.  A drop of the anti-fade 
and the mounting medium (ProLong Antifade Kit) was then placed on the 
section and the slides were fixed with a coverslip. Once dry, the slides were 
stored in the dark at 4 C until microscopy of the immunofluorescence labelled 
sections was carried out. 
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Figure 6 – Immunofluorescence labelling of cell nuclei with DAPI, helper T cells with CD4, cytotoxic T cells with 
CD8 and regulatory T lymphocytes with FoxP3. (Pt IT 1, wk 20) 
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 Figure  
Figure 7 – Double 
Immunofluorescence 
labelling of cell nuclei with 
DAPI (blue), helper T 
cells with CD4 (red) and 
regulatory T lymphocytes 
with FoxP3 (green) (Pt IT 
9, wk 0). This is a 
composited image of 
double 
immunofluorescence 
labelling of regulatory T 
lymphocytes where the 
green stain of the 
cytoplasm is surrounded 
by the red CD4 stained 
cell membrane. 
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 6 –
Figure 8 – Double 
Immunofluorescence 
labelling of cell nuclei with 
DAPI (blue), helper T cells 
with CD4 (red) and 
regulatory T lymphocytes 
with FoxP3 (green) (Pt IT 
11, wk 10). This is a 
composited image of 
double 
immunofluorescence 
labelling of regulatory T 
lymphocytes where the 
green stain of the 
cytoplasm is surrounded 
by the red CD4 stained 
cell membrane. 
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Figure 9 – 
Immunofluorescence 
labelling of cell nuclei with 
DAPI (blue), helper T 
cells with CD4 (red) and 
regulatory T lymphocytes 
with FoxP3 (green) (Pt IT 
5, wk 0). The extreme 
right lower quadrant 
depicts a composited 
image of the DAPI (blue), 
CD4 (red) and FoxP3 
(green) where the double 
immunofluorescence 
labelling of FoxP3 is 
shown. 
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Figure 10 – 
Immunofluorescence 
labelling of cell nuclei 
with DAPI (blue), helper 
T cells with CD4 (red) 
and regulatory T 
lymphocytes with FoxP3 
(green) (Pt IT 9, wk 0). 
The cell counting feature 
of the Image J Analysis 
software was used to 
count the numbers of the 
representative cells. In 
this figure, the red dot 
represents a FoxP3 
positively stained cell 
and the yellow dot 
represents a CD4 
positive cell. 
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Figure 11 – 
Immunofluorescence 
labelling of cell nuclei 
with DAPI (blue), helper 
T cells with CD4 (red) 
and regulatory T 
lymphocytes with FoxP3 
(green) (Pt IT 11, wk 10). 
The cell counting feature 
of the Image J Analysis 
software was used to 
count the numbers of the 
representative cells. In 
this figure, the red dot 
represents a FoxP3 
positively stained cell 
and the blue dot 
represents a CD4 
positive cell. 
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2.2.7 IMMUNOFLUORESCENCE – SLIDE ANALYSIS AND CELL 
COUNTING 
 
2.2.7.1 SLIDE ANALYSIS 
 
Slide analysis was manually performed on a microscope attached to a 
computerised digital camera. The 40x objective was selected and the section 
to be analysed examined to gain an impression of the geography of the 
section. An area of the section representative of immune infiltrating cells was 
initially chosen and the image captured using the digital camera. For each of 
the visualised section, by shifting the correct filter into position on the 
microscope, it was possible to visualise the different stains individually. Nuclei 
were consistently stained blue with DAPI. The primary antibodies of CD4, 
CD8 and FoxP3CD4 were either stained green or red as shown in the figures 
6 to 9.   
  
After obtaining all the relevant images for one particular section, another field 
of the section was chosen. Moving to another field of the section was carried 
out in a systematic fashion in a stepwise manner. In total, tumour-infiltrating 
lymphocytes from five representative fields of image were counted for each 
section. In fact, in most cases this almost represented the entire section, as 
the punch biopsies were small in size.  Overall, five images for every section 
and for every antibody were captured. The images were saved on the 
computer attached to the digital camera in TIFF format. These images were 
then electronically transferred to a secure computer and saved using adobe 
photo shop 6.0. Images on the computer were saved with the study number, 
antibodies tested and the date to allow future verification of counts.  
 
2.2.7.2 CELL COUNTING 
 
Subsequently, using adobe photo shop software 6.0, the individual images of 
the differently stained antibodies, obtained from each field of the section 
visualised on the microscope, were composited to obtain a single hybrid 
image of either FoxP3CD4, CD4 and DAPI or FoxP3CD4, CD8 and DAPI, or 
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CD4, CD8 and DAPI as shown in the figure 7.   This made it possible to 
visualise and distinguish the different lymphocytes present in one particular 
filed of the section simultaneously in a snap shot. The composited images 
were saved in the TIFF format.  
 
Following image composition, by means of the ’ Image J analysis software’ 
version 1.36b (http://rsb.info.nih.gov/ij/) specking the differently stained nuclei 
and cell membranes was straightforward as shown in the figures 10 and 
11.The cell counting feature of the software enables easy calculation of the 
differently coloured cells on the image. In this process the cursor is moved 
over each cell to be counted and a mouse-click places a coloured dot over 
them. One is expected to opt for a different coloured dot for different cell types 
but maintain uniformity for the same cell type as shown in the figures 10 and 
11. Once all the cells of interest were dotted, total counts for the different 
coloured dots were displayed, which were documented both by hand and also 
on a computer data record sheet. The image now complete with the overlying 
dots was also saved in a TIFF format. Five sets of images were available for 
each of the antibodies tested. An average count was then obtained for each 
cell type. 
 
An independent observer (TS) reviewed a range of slides to verify the counts 
and the counts differed by no more than 5%. Results were reported as density 
per unit area of CD4, CD8 and double stained FoxP3CD4+ CD4+ Treg cells.   
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2.2.8 PERIPHERAL IMMUNE RESPONSES 
2.2.8.1 LYMPHOCYTE PROLIFERATION ASSAY  
 
Full functionality of CD4+ T helper lymphocytes can be measured by 
assessing their proliferation. PBMC isolated from heparinised blood by density 
gradient centrifugation are cultured in vitro with mitogens and specific 
antigens for 3–6 days, after which cells are pulsed with 3H-thymidine and 8–
16 hours later harvested onto glass fibre filter mats. Proliferation as measured 
by incorporation of a radiolabelled nucleotide (3H-thymidine) into the DNA of 
dividing cells is evaluated by liquid scintillation spectroscopy with a beta-plate 
counter. The total amount of radiolabel/activity measured represents DNA 
synthesis by the whole cultured PBMC population, which may include both 
CD4, and CD8 T lymphocytes. Results are expressed as the mean counts per 
minute (cpm) (usually for triplicate cultures) with an error of the mean, and / or 
as a stimulation index (SI). The SI is the ratio of the experimental cpm divided 
by cpm of the negative / background control (cells with tissue culture medium 
alone).  
 
2.2.8.2 LYMPHO PROLIFERATION ASSAYS – METHOD 
Peripheral immune response to HPV antigens was assessed by lympho 
proliferation assays. Proliferative T lymphocyte responses to HPV16 peptides 
E61, E6II, E6III, E6IV, E7I, E7II and the HPV 16 proteins TA-CIN (fusion 
protein of HPV 16 E6, E7, L2), HPV 16 L2, GST-E6, GST-E7 and TA-GW 
(HPV 6 L2E7) for negative control and PHA for positive control were 
measured by tritiated thymidine incorporation following a five day incubation of 
the patient PBMC with the respective peptides / antigens. PBMC collected 
from the three time-points of week 0 (pre-treatment), week 10 (post 
imiquimod) and week 20 (post vaccination) were available for eighteen 
women. For one patient (IT9) week 10 blood sample was not available due to 
inadvertent collection of the sample into an incorrect tube.  
PBMC were seeded in the wells of a 96-well round-bottomed microtiter plate 
(Alpha Laboratories Ltd.) in quadruples at the concentration of 2 x 105 cells / 
well in RPMI 1640 medium supplemented with 10% human AB serum (Quest 
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Biomedical), 100 µg/ml streptomycin, 100 IU/ml penicillin (Life Technologies, 
Inc.) and glutamine. PBMCs alone (medium control) or PBMCs with 25 µg/ml 
each of recombinant HPV-16 L2E6E7 protein (TA-CIN), HPV-16 L2, GST-E6, 
GST-E7, TA-GW and pools of E61, E6II, E6III, E6IV, E7I peptides at 20µg/ml 
and E7II peptide at the concentration of 25 µg/ml were seeded. In addition, 
PHA at two different concentrations of 2 µg/well and 5µg/well were incubated 
for five days at 37°C. 
 
During the final eighteen hours of the culture, 1 µCi/well of [3H] thymidine 
(NEN Life Science Products) was added. The cells were harvested using a 
Packard 96-well vacuum cell harvester onto Unifilter plates (Packard 
Biosciences) and were left to dry overnight. 30 µl/well of Microscint 20 
scintillation fluid (Packard) was then added. [3H] Thymidine incorporation was 
measured using a Top count scintillation counter (Packard). Replicates were 
usually within 10%. Replicates outside the 10% range were not considered for 
analysis. Results are presented as stimulation index (SI) = the mean number 
of counts incorporated by antigen-stimulated PBMCs divided by the mean 
number of counts for PBMCs in the medium alone (negative control); A pre-
existing proliferative T lymphocyte response was defined as SI 2. A post 
vaccination proliferative T-cell response was defined as a two-fold increase in 
the SI compared with the pre vaccination value. 
 
2.2.8.3 REAGENTS USED FOR LYMPHOPROLIFERATION ASSAYS 
 
The reagents and methods used in this study were previously optimised in this 
and the affiliated units for other studies [Davidson et al., 2003a;Davidson et 
al., 2004;de Jong et al., 2002;Smyth et al., 2004;Winters et al., 2008].  
 
2.2.8.4 PEPTIDE POOLS 
 
The configuration and concentration of the peptide pools utilised in the 
proliferation assay were previously optimised. The peptides spanned the HPV 
16 E6 and E7 protein and consisted of fifteen E6 and nine E7 overlapping 22-
mer peptides. Each peptide was identified by their first and last amino acid in 
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the protein. Four to five peptides were grouped into a pool at a concentration 
of 5  l / per peptide. The following pools were made. 
Peptide pool Peptide Identity Amino acids in the protein 
E6 I 1-22 mhqkrtamfq dpqerprklp ql 
 11-32 dpqerprklp qlctelqtti hd 
 21-42 qlctelqtti diilecvyc kq 
 31-52 hdiilecvyc kqqllrrevy df 
E6II 41-62 kqqllrrevy dfafrdlciv yr 
 51-72 dfafrdlciv yrdgnpyavc dk 
 61-82 yrdgnpyavc dkclkfyski se 
 71-92 dkclkfyski seyrhycysv yg 
E6III 81-102 seyrhycysv ygttleqqyn kp 
 91-112 ygttleqqyn kplcdllirc in 
 101-122 kplcdllirc incqkplcpe ek 
 111-132 incqkplcpe ekqrhldkkq rf 
E6 IV 111-132 incqkplcpe ekqrhldkkq rf 
 121-142 ekqrhldkkq rfhnirgrwt gr 
 131-152 rfhnirgrwt grcmsccrss rt 
 137-158 grwtgrcmsc crssrtrret ql 
   
E7I 1-22 mhgdtptlhe ymldlqpett dl 
 11-32 ymldlqpett dlycyeqlnd ss 
 21-42 dlycyeqlnd sseeedeidg pa 
 31-52 sseeedeidg pagqaepdra hy 
E7II 41-62 pagqaepdra hynivtfcck cd 
 51-72 hynivtfcck cdstlrlcvq st 
 61-82 cdstlrlcvq sthvdirtle dl 
 71-92 sthvdirtle dllmgtlgiv cp 
 77-98 rtledllmgt lgivcpicsq kp 
 
Table 4 Peptide pools for the Lymphoproliferation Assay – the peptides 
spanned the HPV 16 E6 and E7 protein and consisted of 15 E6 and 9E7 
overlapping 22-mer peptides 
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The following peptide pools, available in fine particle form were made into a 
suspension in DMSO at a stock concentration of 50 mg/ml  
 
2.2.8.4.1 GST TAGS 
The HPV E6 and E7 proteins were available as GST Tag proteins. Epitope 
tags such as glutathione-S-transferase (GST) are often used as tags for 
proteins for expression and purification applications. Glutathione transferases 
are abundant enzymes involved in cellular defence against electrophilic 
chemical compounds, which bind glutathione with high affinity and specificity. 
The strength and selectivity of this interaction enables glutathione-based 
affinity resins to effectively purify GST-tagged proteins. The glutathione resin 
selectively binds the GST-tagged protein under normal conditions, allowing 
the specific protein of interest to be separated from whole cell extracts rapidly 
and efficiently allowing a high degree of purification.   
GST is a 35-kDa protein that can be assayed biochemically as well as 
immunologically. This characteristic sets it apart from many epitope tags that 
are simply short peptides. However, the large size of GST results in a higher 
potential for degradation by proteases than other smaller tags. Therefore, 
performing GST-protein purification as quickly as possible under non-
degrading conditions is necessary in order to minimize sample loss.  
2.2.8.4.2 TA-GW 
TAGW is a recombinant HPV6 L2E7 protein and also a therapeutic vaccine 
for the treatment of genital warts. The function of this protein in the assays 
was as a negative control to HPV 16 proteins. This protein was kindly supplied 
by the Xenova Research Ltd. 
 
2.2.8.4.3 TA-CIN 
The HPV 16 E6, E7, L2 vaccine is produced in Escherechia Coli and purified 
using a proprietary downstream GMP-compatible process. TA-CIN is 
formulated in 5mM glycine buffer containing 0.9mM cysteine. TA-CIN is 
provided in 1 ml ampoules containing 0.6 ml HPV 16 E6E7L2 fusion protein in 
a total volume of 0.5ml. The ampoules were stored at -20C and allowed to 
 141
thaw for up to thirty minutes at room temperature. TA-CIN was alos supplied 
by Xenova Research Ltd. 
 
HPV 16 GST E6 & HPV 16 GST E7 were kindly donated by Pawlita et al 
[Smyth et al., 2004].  
 
HPV 16 L2 protein (full length HPV16L2 tagged with 6His at N-terminus) was 
a donation from Roden et al [Karanam et al., 2009].  
 
2.2.8.5 NEUTRALISATION ANTIBODIES 
 
Neutralising antibodies to HPV 16 pseudovirions were tested as by the SEAP 
pseudo virus neutralisation based assay at the virology research laboratories, 
John Hopkins University, Baltimore USA by Dr Roden and his team [Karanam 
et al., 2009]. The serum obtained from the blood samples of the trial 
participants, at weeks 0, 10 and 20 were aliquoted and shipped to USA for the 
SEAP (secreted alkaline phosphatase) pseudo virus neutralisation based 
assay.  
  
 
2.2.9 STATISTICAL ANALYSIS 
Analyses were performed using ‘Stats Direct Statistical Software’. Differences 
between responder and non-responder categories (baseline disease duration; 
HPV 16 positivity; smoking; symptom response at week 52 compared to 
baseline) were analysed using Fisher’s exact test. The non-parametric Mann-
Whitney U test was used to test for differences between lesion associated T 
lymphocyte densities, proliferation assays and neutralising antibodies 
between groups (histological responder and non-responder). The non-
parametric Wilcoxon’s signed rank test was used to analyse the differences in 
the lesion associated T lymphocyte densities, proliferation assays and 
neutralising antibodies within groups at different time-points. All reported P 
values are two-sided and have not been adjusted for multiple comparisons. A 
P value of <0.05 was considered to be statistically significant. 
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CHAPTER 3  
CLINICAL RESULTS 
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3 CLINICAL RESULTS 
 
This chapter describes the clinical results of this phase II study of sequential 
imiquimod and therapeutic HPV vaccination (TA-CIN) for high grade VIN. This 
study represents an attempt to develop an alternative non-surgical treatment 
option for VIN that would enable preserving the vulval anatomy and 
architecture. The objective of this study was to develop an effective treatment 
for VIN, which results in a sustainable response. We believe that a short 
course of imiquimod in addition to having a direct effect on VIN by stimulating 
a local immune response would also provide an immunological platform for 
the therapeutic HPV vaccination to achieve an enhanced response rate than 
that achieved in solo imiquimod or vaccination trials.  
 
The following variables were assessed to characterise any response to 
treatment. The size of the lesion, histopathological analysis of the punch 
biopsy of the lesion, symptoms and presence or absence of HPV-16 DNA was 
evaluated before any treatment and after imiquimod and vaccination 
treatments.  
 
3.1STUDY POPULATION  
3.1.1 TRIAL PARTICIPATION 
 
Twenty-five women with biopsy confirmed high-grade VIN were initially willing 
to participate in the study.  Five women defaulted after the initial screening 
visit, who when contacted by telephone said they had changed their minds 
regarding participation in the trial for the following reasons:  uncertainty as 
regards the efficacy of the trial treatment, inconvenience connected with 
frequent clinic visits and also lack of belief in any treatment for VIN as they 
have had developed recurrences on many occasions in the past.  
 
Twenty women commenced imiquimod treatment. One woman (IT22) was 
withdrawn four weeks into imiquimod treatment. This participant was twenty-
two years of age and was diagnosed with symptomatic high-grade VIN barely 
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few months prior to the trial enrolment. She did not undergo any treatment 
previously for VIN. This woman noted a new symptomatic white patch on her 
vulva four weeks into imiquimod treatment, which warranted an unscheduled 
visit to the hospital. On examination, a new VIN lesion with suspicious 
features was detected, which on biopsy was confirmed to be high-grade VIN 
with a focus (1mm) of micro invasive SCC of the vulva. At this stage she was 
withdrawn form the trial and underwent surgical excision of the lesion. 
 
3.1.2 TREATMENT SCHEDULE & COMPLETION OF TREATMENT 
 
This left a study population of nineteen women (table 5). All the nineteen 
women complied with the treatment schedule and follow-up appointments. 
One woman (IT22) received only two doses of the TA-CIN vaccination instead 
of the routine three, at weeks 10, 14 and missed her third vaccination 
scheduled for week 18. This was because the vaccine expired few days prior 
to her scheduled appointment and protein stability tests to check further 
validity of the vaccine were not carried out at this stage by the manufacturers.  
The rest eighteen women received all three doses of the TA-CIN vaccination 
as per protocol.  
 
3.1.3 DEMOGRAPHICS  
 
Age: The study cohort mainly comprised young and middle aged women as 
shown in figure 12.  The mean age of women in the trial was 45yr (range: 22-
66 yr). 25% were less than 39 years of age (22, 27, 28, 34 and 35yr 
respectively), 65% were aged between 40 and 59 years 
(40,40,43,43,45,47,48, 51, 51 51,55 56, 58yr respectively) and 10% were 60 
years or more (65, 66yr respectively).  
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Figure 12 - Age distribution of the patients - The youngest pt was 22 yr 
and the oldest 66 yr, with the mean age of 45 yr 
 
3.1.4 CIGARETTE SMOKING & PREVIOUS TREATMENT FOR VIN 
 
 As shown in the table 5, thirteen women (65%) were current smokers, three 
(15%) were ex-smokers and four (20%) never smoked. The study population 
was heavily pre-treated with thirteen women (65%) having had previous 
treatment for VIN. Seven women (35%) had not undergone any previous 
treatment for VIN. The variety of previous treatments included wide local 
excision, partial vulvectomy, vulvectomy, laser ablation, topical imiquimod 
treatment or diathermy to the vulva as shown in figure 13 and 14. On the 
whole, 60% of women underwent previous surgical treatment. Six women had 
undergone two or more modalities of treatment; three of who aged 35, 40 and 
66 yr in fact underwent treatment on ten, seven and nine previous occasions. 
In the majority of the women who underwent previous vulvectomy and in three 
women who underwent five or more previous surgical excisions, vulval 
anatomy was severely disfigured and compromised. Two women already had 
experience-using imiquimod for VIN prescribed by their local gynaecologist, 
which resulted in a partial clinical response and significant symptom response. 
At the time of recruitment, VIN had recurred in these women.  
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Figure 13 – Method and number of previous treatments – Method and 
number of previous treatment (s) undergone by the trial participants prior to 
recruitment. 13 women had undergone 2 vulvectomies, 27 surgical excisions, 
18 laser ablations, 2 courses of imiquimod and I diathermy session in total. 
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Figure 14 - Mode(s) of previous treatment for individual trial participant - 
prior to their recruitment to the trial. For example, IT1 had undergone 
vulvectomy, laser ablation and imiquimod treatment on separate occasions 
whereas IT9 had undergone vulvectomy and three surgical excisions on 
separate occasions. 
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3.1.5 PREVIOUS CERVICAL DISEASE 
 
Given that VIN often co-exists with CIN, we looked at the incidence of CIN in 
this cohort. Three of the participants underwent total hysterectomy, which left 
seventeen evaluable women, of who ten (59%) had a previous diagnosis of 
CIN as shown in the figure 15.None had active CIN at recruitment.  
 
3.1.6 DISEASE DURATION 
 
In thirteen women (65%), VIN at recruitment was of recurrent type with mean 
disease duration of seven years (range 1-20 yr). In the remaining 35%, VIN 
was either newly diagnosed or was diagnosed for a while but kept under 
clinical observation without undergoing any treatment. In twelve women 
(60%), the disease was diagnosed in the last five years, in two women (10%), 
disease was known to be present for the last ten years and in six women 
(30%) disease was diagnosed more than ten years back as shown in the 
figure 16. 
 
3.1.7 Focality 
 
 VIN was multifocal in seventeen women (85%) and unifocal in three women 
(15%) as shown in figure 16. 

 149
SMOKING & VIN
65%
15%
20%
Smokers Ex-smokers Non-smokers
History of CIN
59%
41%
h/o CIN no h/o CIN
 
 
Figure 15 – Incidence of smoking and CIN - 65% actively smoked; 59% gave a positive h/o CIN in the past 
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DURATION OF VIN
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Figure 16 – Duration of VIN and disease focality - 60% of the participants were given a diagnosis of VIN less than 5 yr ago, 10% 
between 5-10 years and 30% more than 10 yr ago; 85% of women had multifocal VIN and 15% had unifocal VIN 
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 AGE MULTI/ 
UNIFOCAL 
SMOKING H/O CIN PREV 
TREATMENT 
DISAESE 
DURATION 
IT1 51 Multifocal No Yes Laser, Vulvectomy, Imiquimod 4 yr 
IT2 43 Multifocal Yes-
20/day 
Yes Laser x 4 9 yr 
IT3 45 Multifocal Ex-smoker Yes Excision 3yr 
IT4 40 Multifocal Yes-
20/day 
Yes Excision x 3 10 yr 
IT5 40 Multifocal Yes-
20/day 
No Excision x 7 20yr 
IT8 65 Multifocal Ex-smoker No None 4yr 
IT9 58 Multifocal Yes-8/day Yes Excision x 3, Vulvectomy 15yr 
IT10 27 Multifocal Yes-6/day Yes None 1yr 
IT11 51 Multifocal Ex-smoker TAH Diathermy 1yr 
IT13 55 Multifocal Yes-
20/day 
Yes Excision 6 yr 
IT14 51 Unifocal Yes-
20/day 
No Laser x 2 16yr 
IT15 47 Unifocal No Yes None 1yr 
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IT16 56 Multifocal Yes-
12/day 
Yes None 2yr 
IT17 43 Multifocal No TAH Laser x 2, Excision  4yr 
IT18 48 Unifocal No No None 1yr 
IT19 34 Multifocal Yes-
20/day 
No Laser, Imiquimod 3yr 
IT20 22 Multifocal Yes-
20/day 
No None 1yr 
IT21 28 Multifocal Yes-
10/day 
No None 1yr 
IT22 66 Multifocal Yes-
20/day 
TAH Excision x 5, Laser x 4 16yr 
IT23 35 Multifocal Yes-
15/day 
Yes Excision x 6 Laser x 4 10yr 
Table 5 – Patient demographics -This table shows the age of the participant, if VIN was unifocal or multifocal, smoking 
status, whether there was a history of CIN in the past, previous treatment for VIN and the duration of years since the 
diagnosis of VIN was made along with the patient’s trial identification number.
 153
 
3.2 RESPONSE TO THE IMIQUIMOD TREATMENT AT WEEK 10 
  
The preliminary assessment of any response to the treatment was made at 
week 10, two weeks after completion of the eight-week course of the 
imiquimod treatment. Week 10 also marked the beginning of the TA-CIN 
vaccination schedule. 
 
 
3.2.1 CLINICAL RESPONSE  (POST IMIQUIMOD) 
 
At week 10, fourteen out of the nineteen participants (74%) made a clinical 
response (defined as 50% or more reduction in the overall size of the lesions). 
This included three complete (16%) (total clearance of VIN on vulvoscopy) 
and eleven partial (58%) clinical responders (reduction in the size of the 
lesion(s) equivalent to or greater than 50% but less than 100%). The 
remaining five women maintained stable disease status (less than 50% 
reduction in the size of the lesion(s) or less than 25% progression in the size 
of the lesion(s)). In fact, no disease progression was noted at week 10. 
 
3.2.2 HISTOLOGICAL RESPONSE  
 
Six women (32%) had completely cleared VIN on the punch biopsy of the 
index lesion at week 10. Complete regression of high grade VIN (VIN 2 or 3) 
to no VIN on the histopathology of the punch biopsy of the index lesion was 
defined as histological response. This was rather unpredicted as three of 
the four women who demonstrated histological response in fact were classed 
as partial responders on vulvoscopy.   
 
3.2.3 SYMPTOM RESPONSE  
 
Upon questioning at week 10, seven out of nineteen women (37%) happened 
to perceive a change for the better in their symptoms. Symptom response was 
defined as regression of symptoms from the ‘moderate’ or ‘severe’ category to 
the ‘mild ‘ or ‘none’ categories.  Although these women were experiencing 
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severe side effects linked with the application of the imiquimod cream, 
generally they were able to make a distinction between the symptoms 
associated with VIN and the side effects of the imiquimod cream.  
 
3.2.4 HPV RESPONSE  
 
At week 10, eleven women were HPV 16 negative on the biopsy. Six of these 
eleven women were positive for HPV 16 on the previous pre-treatment biopsy 
taken at the baseline and thus were considered to have made a HPV 
response (43%), defined as clearance of HPV 16 from the biopsy site in 
somebody who was previously positive for the presence of HPV 16.  Eight 
women who were previously positive for HPV 16 on the baseline biopsy 
continued to remain so.  
 
Correlating the HPV response with VIN resolution, of the six women who 
happened to clear HPV16 from their biopsy site, one woman made a complete 
clinical response and the remaining five women made a partial clinical 
response. Interestingly, four of the six women (67%) who cleared HPV 16 also 
established VIN clearance on histopathology of the index lesion. All the 
responses at week 10 are shown in figure 17. 
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Figure 17 – Responses at week 10 - This figure summarises the responses 
at week 10. 74% clinical response (50% reduction in the size of the lesions); 
32% biopsy proven resolution of high grade VIN; 37% reduction in symptoms 
from moderate/severe category to mild/none category and 43% biopsy proven 
HPV 16 negativity in women who were previously positive  
 
 
3.3 RESPONSES TO THE TA-CIN VACCINATION AT WEEK 20  
 
Two weeks following the third and final dose of the TA-CIN vaccination and 
twelve weeks following the completion of the imiquimod treatment, a 
comprehensive assessment took place when all the parameters were re-
evaluated.  
 
3.3.1 CLINICAL RESPONSE  
 
At week 20, sixteen women (84%) showed a clinical response (50% or more 
reduction in the size of the lesions). Six women (32%) demonstrated a 
complete clinical response (total clearance of VIN on vulvoscopy) and ten 
women (52%) a partial clinical response (reduction in the size of the lesion(s) 
equivalent to or greater than 50% but less than 100%). Three women (16%) 
had stable disease (less than 50% reduction in the size of the lesion(s) or 
less than 25% progression in the size of the lesion(s)). No disease 
progression was observed. 
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3.3.2 HISTOLOGICAL RESPONSE 
 
Eleven women (58%) were negative for VIN on histopathological analysis of a 
punch biopsy at week 20. On vulvoscopy however, again only six of the 
histological responders were located in the complete clinical response 
category and the remaining five women were in the partial clinical response 
group.  
 
3.3.3 SYMPTOM RESPONSE  
 
At recruitment, fifteen women reported moderate to severe symptoms 
whereas at week 20, only five of these women continued to experience 
moderate to severe symptoms. A 67% symptom response (resolution of 
symptoms from moderate to severe category to mild or none category) was 
thus observed at week 20.  
 
Overall, at week 20, fourteen women accounted for none or mild symptoms 
(74%) and five women (26%) for moderate to severe symptoms.  
 
3.3.4 HPV RESPONSE  
  
Twelve women were HPV 16 positive at baseline, eight of who continued to 
demonstrate HPV 16 positivity at week 20 on the punch biopsy. A 33% HPV 
response (clearance of HPV 16 from the biopsy site in somebody who was 
previously positive for the presence of HPV 16) was observed at week 20.  
 
Correlating HPV 16 clearance with disease resolution, of the four women who 
cleared HPV in their lesions, two women made a complete clinical response, 
the other two women made a partial clinical response; and in all the four 
women histological regression of VIN was also established. Additionally, three 
of the four women who cleared HPV were also symptom free at week 20. All 
the responses at week 20 are shown below in the figure 18. 
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Figure 18 – Responses at week 20- This figure summarises the responses 
at week 20, two weeks after completion of the vaccination schedule. 84% 
clinical response (50% reduction in the size of the lesions); 58% biopsy 
proven resolution of high grade VIN to no VIN on histopathology; 67% 
reduction in symptoms from moderate/severe category to mild/none category 
and 33% biopsy proven HPV 16 negativity in women who were previously 
positive is shown in this column chart. 
 
 
3.4 RESPONSES AT THE PRIMARY END-POINT OF WEEK 52 
 
At the study primary end-point of week 52, in addition to a thorough clinical 
assessment, histological analysis and HPV typing also took place.   
 
 
3.4.1 CLINICAL RESPONSE  
 
On the whole, fifteen women (79%) showed a clinical response. Ten women 
(53%) made a complete clinical response with no detectable lesion(s) on 
vulvoscopy. Partial clinical response (reduction in the size of the lesion(s) 
equivalent to or greater than 50% but less than 100%) was detected in five 
women (26%).  In four women (21%) the disease was considered to be 
‘stable’ (less than 50% reduction in the size of the lesion(s) or less than 25% 
progression in the size of the lesion(s)).  One woman (IT9) by this stage 
developed a microinvasive focus that was completely excised on a punch 
biopsy. No further invasion was diagnosed at this stage. 
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3.4.2 HISTOLOGICAL RESPONSE   
 
Twelve women (63%) were negative for VIN on histopathological analysis of 
the punch biopsy. On vulvoscopy, no VIN was visible in nine out of these 
twelve women and some residual VIN measuring about 3-4 mm was visible in 
three women, although the representative punch biopsy was negative for VIN 
on histopathology.   
 
3.4.3 SYMPTOM RESPONSE   
 
At the study finishing point, fifteen women agreed they were either 
asymptomatic or had only mild symptoms.  Of these fifteen women, twelve of 
them reported moderate to severe symptoms at recruitment. An 80% 
symptom response (resolution of symptoms from moderate to severe category 
to mild or none category) was thus observed.  
 
Overall, fifteen women had none or mild symptoms (79%) and four women  
(21%) reported moderate to severe symptoms.  
 
3.4.4 HPV RESPONSE   
 
Nine women were HPV 16 negative in the punch biopsy at week 52. Six of 
these women were previously positive for HPV 16. Ten women were HPV 16 
positive even at week 52. Overall, out of fifteen women who were previously 
HPV 16 positive at any given time point, six of them were HPV 16 negative at 
week 52, resulting in a response rate of 40%.  
 
Correlating HPV 16 clearance with treatment response, five of the six women 
who demonstrated HPV 16 negativity at week 52 also concurrently proved to 
have fulfilled clinical, histological and symptom response criterion too. All the 
responses at week 52 are shown below in figure 19. 
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Figure 19 – Responses at week 52- This figure summarises the responses 
at week 52, the primary end-point of the study. 79% clinical response (50% 
reduction in the size of the lesions); 63% biopsy proven resolution of high 
grade VIN to no VIN on histopathology; 80% reduction in symptoms from 
moderate/severe category to mild/none category and 40% biopsy proven HPV 
16 negativity in women who were previously positive is shown in this column 
chart. 
 
3.5 TRENDS IN THE RESPONSE OVER 52 WEEKS 
 
3.5.1 TREND IN THE CLINICAL RESPONSES  
 
 
As shown in figure 20, the majority of the clinical response was already 
established by week 10 (74%). This rate of clinical response marginally 
improved to 84% by week 20 with a slight drop to 79% by week 52. Clinical 
response includes complete and partial response. Complete clinical response 
improved from 16% at week 10 to 32% at week 20. This further improved to 
53% at week 52. On the other hand, the rate of partial clinical response went 
down from 58% at week 10 to 52% at week 20 and 26% at week 52. The 
reduction in the partial response rate compensates the increase in the 
complete response rate. The increase in the rate of complete response, after 
completion of imiquimod and TA-CIN treatment, from 32% to 53% between 
the weeks 20 and 52 is noticeable. 
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Figure 20 – Trend in the clinical response Complete (CR) and partial (PR) 
clinical response rates as observed at weeks 10, 20 and 52. 16% CR and 
58% PR at week 10; 32% CR and 52% PR at week 20; and 53% CR and 26% 
PR at week 52 was observed 
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3.5.2 TREND IN THE HISTOLOGICAL RESPONSES 
 
A gradual increase in histological response was noticed until week 20, as of 
21% at week 10 to 58% at week 20 with a further slight rise to 63% at week 
52 as shown below in figure 19. Unlike the clinical response majority of which 
was obvious by week 10, only 21% of women were proved to be negative for 
VIN on histopathology of the punch biopsy from the lesion site. This however 
improved to 58% by week 20 as shown in figure 21.  
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Figure 21 – Trend in the histological response - An improvement in 
histological response was observed from 32% at week 10 to 58% at week 20 
and 63% at week 52. 
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3.5.3 CLINICAL RESPONSE VS.  HISTOLOGICAL RESPONSE 
 
There was a discrepancy between clinical response rates determined on 
vulvoscopy and histological response rates determined following the 
histological analysis of the punch biopsy.  In comparison to the complete 
clinical response rates of 16%, 32% and 53% at weeks 10, 20 and 52, the 
histological response rates were 32%, 58% and 63% as shown in figure 22 
and tables 6 and 7. 
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Figure 22 – Discrepancy between clinical and histological response- 
Comparison of complete (CR) and partial (PR) clinical response rates with 
histological response rates at different time points. At week 10, histological, 
CR, PR rates were 32%, 58% and 21%; at week 20 - 58%, 32%, and 52% 
and at week 52 – 63%, 53%, 26% respectively. 
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                  CLINICAL RESPONSE                   HISTOLOGICAL RESPONSE 
 
Post 
imiquimod 
Post 
vaccination 
Week 
52 
Post 
imiquimod 
Post 
vaccination 
Week 
52 
IT1 PR PR PR No No No 
IT2 SD SD SD No No No 
IT3 SD PR PR No No No 
IT4 SD SD SD No No No 
IT5 PR CR CR Yes Yes Yes 
IT8 PR PR CR Yes Yes Yes 
IT9 PR PR CR Yes Yes Yes 
IT10 PR PR PR No No Yes 
IT11 PR PR PR No No No 
IT13 PR CR CR No Yes Yes 
IT14 CR CR CR Yes Yes Yes 
IT15 CR CR CR No Yes Yes 
IT16 SD PR CR No Yes Yes 
IT17 PR PR CR No Yes Yes 
IT18 PR CR CR Yes Yes Yes 
IT19 SD SD SD No No No 
IT20 PR PR CR No Yes Yes 
IT21 SD SD SD No No No 
IT23 CR CR CR Yes Yes Yes 
Table 6 – Clinical Response vs. Histological Response - This table 
illustrates the unexpected inconsistency between complete, partial clinical 
response and histological response assessed from the representative punch 
biopsy. Partial clinical responders who actually made a histological response 
are highlighted in grey; complete clinical responders who did not make a 
histological response are highlighted in blue. CR – complete clinical response; 
PR – partial clinical response; SD – stable disease; No – no histological 
response; Yes – histological response 
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          SIZE OF THE LESION in mm                       HISTOLOGY 
 Wk 0 Wk 10 Wk 20 Wk 52 Wk 0 Wk 10 Wk 20 Wk 52 
IT1 80 35 30 40 VIN1/2/3 VIN1/2/3 VIN2/3 VIN2/3 
IT2 75 60 70 70 VIN3 VIN1/2/3 VIN2/3 VIN2/3 
IT3 90 65 40 30 VIN2/3 VIN2/3 VIN2/3 VIN1/2 
IT4 50 40 30 45 VIN2/3 VIN2/3 VIN2/3 VIN2/3 
IT5 60 10 0 0 VIN1/2/3 no VIN no VIN no VIN 
IT8 65 25 5 0 VIN2/3 no VIN no VIN no VIN 
IT9 100 50 50 0 VIN3 no VIN no VIN no VIN 
IT10 60 25 25 25 VIN2/3 VIN2/3 VIN2 no VIN 
IT11 >100 25 20 10 VIN3 VIN2/3 VIN2/3 VIN2/3 
IT13 25 10 0 0 VIN2/3 VIN1/2/3 no VIN no VIN 
IT14 25 0 0 0 VIN3 no VIN no VIN no VIN 
IT15 20 0 0 0 VIN3 VIN1/2 no VIN no VIN 
IT16 50 40 20 0 VIN3 VIN1/2 no VIN no VIN 
IT17 90 15 15 0 VIN2/3 VIN1/2 no VIN no VIN 
IT18 25 3 0 0 VIN3 no VIN no VIN no VIN 
IT19 45 20 30 40 VIN2/3 VIN2/3 VIN2/3 VIN2/3 
IT20 40 3 4 0 VIN2 VIN1/2 no VIN no VIN 
IT21 30 20 10 20 VIN2/3 VIN2/3 VIN2/3 VIN2/3 
IT23 >100 0 0 0 VIN2/3 no VIN no VIN no VIN 
 
Table 7- Clinical Response vs. Histological Response - Lesion size in 
mm at weeks 0, 10, 20 and 52 vs. histological analysis of the 
representative biopsy at weeks 0, 10, 20 and 52. This table shows the 
overall size of the lesions decided on vulvoscopy at different time points and 
the respective histology of the representative biopsy of the lesions. Women 
who were positive for VIN on vulvoscopy but negative on histology are 
highlighted in grey; women who were negative for VIN on vulvoscopy but 
positive on histology for VIN are highlighted in blue. 
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In one case (IT15), clinical examination was indicative of complete clinical 
response with no detectable lesion, biopsy however revealed VIN 1 and 2 on 
histological analysis. Rather similarly, on ten occasions, clinical examination 
was indicative of partial clinical response with some residual VIN, but the 
comprehensive histological analysis of the representational biopsy indicated 
resolution of VIN, as shown in (tables 6 and 7).  
 
3.5.4 TREND IN THE SYMPTOM RESPONSES 
 
At baseline, fifteen women (79%) were experiencing moderate to severe 
symptoms, in comparison to eleven women (58%) at week 10, five women 
(26%) at week 20 and four women (21%) at week 52 as shown in table 8. The 
fall in the number of women who were experiencing severe symptoms was 
statistically significant between weeks 0 and 52 (P=0.01, Fisher’s exact test).  
Consequently, an improvement in symptoms from the moderate or severe 
category to the none or mild category (symptom response) was observed in 
37% at week 10, 67% at week 20 and 80% at week 52 as shown in figures 23 
and 24.  
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Figure 23 – Trend in the Symptom Response- An increase in symptom 
response from 37% at week 10 to 67% at week 20 and 80% at week 52 was 
evident. 
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Figure 24-None/Mild symptoms vs. Moderate/Severe symptoms -This 
figure shows an increase in the percentage of ‘none/mild’ symptom category 
from 21% at recruitment (baseline) to 42% at week 10, 74% at week 20 and 
79% at week 52 and a corresponding fall in the ‘moderate/severe’ category of 
symptoms from 79% at baseline to 58% at week 10, 26% at week 20 and 21% 
at week 52 (P=0.01 at week 52).  
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                                      INDIVIDUAL SYMPTOM RESPONSE 
 
Recruitment 
After 
imiquimod 
After 
vaccine 
Week 52 
IT1 Mild Moderate Mild Moderate 
IT2 Severe Moderate Moderate Severe 
IT3 Moderate Severe Mild Mild 
IT4 Severe Moderate Mild Mild 
IT5 Mild Moderate None None 
IT8 Severe Mild None None 
IT9 Severe Mild Mild Mild 
IT10 Severe Severe Severe Severe 
IT11 Severe Moderate Mild Mild 
IT13 Severe None None Mild 
IT14 Moderate Moderate None None 
IT15 Moderate Moderate None None 
IT16 None Mild None None 
IT17 Moderate None Moderate Mild 
IT18 Severe None None None 
IT19 Severe Severe Severe Severe 
IT20 Moderate Moderate Moderate Mild 
IT21 Mild Mild Mild Mild 
IT23 Severe Mild Mild None 
Table 8 – Individual Symptom Response – this table shows the different 
categories of symptoms experienced by women at different time points.  - 
women who did not make a histological response at week 52;  - women who 
made a histological response 
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3.5.5 TREND IN THE HPV RESPONSES 
 
3.5.5.1 PRESENCE OF HPV 16 GENOTYPE 
 
At weeks 0, 10, 20 and 52 - 14, 8, 9 and 10 of the nineteen women were 
HPV16 positive respectively.  
 
3.5.5.2 PRESENCE OF OTHER HIGH-RISK HPV GENOTYPES 
One woman (IT9) was also HPV 33 and 84 positive in addition to HPV16. This 
participant although made a complete clinical, histological and symptom 
response at week 52 was found to have developed a focus of early stromal 
invasion at the site of the previous punch biopsy between weeks 26 and 52. A 
4 mm punch biopsy of the suspicious area was taken which served as both 
diagnostic and therapeutic in this case and no further treatment was 
warranted.  
 
One other participant (IT20) on HPV genotyping was also positive for types 
33,42,53,61 in addition to HPV16. This woman was subsequently withdrawn 
from the trial at week 4, half way through the imiquimod treatment, for having 
developed a new suspicious lesion which on biopsy was confirmed to be an 
early stromal invasion, warranting close clinical follow-up.   
 
3.5.5.3 ABSENCE OF HPV 16 GENOTYPE 
Four women (IT1, 13, 14, 15) were negative for any HPV type at baseline. 
This did not disqualify them from participating in the trial, as HPV16 positivity 
at baseline was not an essential criterion for trial enrolment. In fact, on 
subsequent biopsies at different time-points, three of these participants were 
HPV 16 (IT1, IT15), HPV 84 (IT14) and HPV 33 (IT15) positive. One woman 
(IT3) was only HPV 42 positive. One woman (IT13) was exclusively and 
consistently negative for any of the HPV genotypes at all the time points. This 
participant demonstrated a complete clinical, histological and symptom 
response at both weeks 20 and 52 respectively.  
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3.5.6 HPV CLEARANCE VS. CLINICAL, HISTOLOGICAL & SYMPTOM 
RESPONSE 
 
As shown in figure 25 and table 9, at week 10, six women appeared to have 
cleared HPV 16 from the biopsy site.  Of these six women, one woman 
demonstrated a complete clinical response and five women, partial clinical 
response. In addition, in four of the six women histological response was also 
confirmed. 
 
At week 20, the outcome of HPV typing was not evaluable in two women due 
to technical difficulties with the test method. Four women who were previously 
HPV 16 positive were now HPV 16 negative on the biopsy. Complete clinical 
response was observed in two of these women and partial clinical response in 
the remaining two. All four women demonstrated a histological response. 
Symptom response was observed in three participants.  
At week 52, nine women were HPV 16 negative. Six of these participants 
were previously HPV 16 positive. Of these six participants who showed HPV 
16 clearance from the biopsy site, five women demonstrated clinical, 
histological and symptom responses and one woman did not.    
 
Also at week 52, five out of ten (50%) histological responders and one out of 
six (17%) histological non-responders who were initially HPV 16 positive 
cleared HPV. This however did not reach statistical significance. Additionally 
there were no differences between women who made a histological response 
and who did not with respect to HPV detection at baseline (P=0.66, Fisher’s 
exact test). 
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Figure 25 – Trend in the HPV Response - This figure shows the HPV 16 
response rates at weeks 10, 20 and 52. 43% who were previously HPV 16 
positive were clear of HPV 16 on the biopsy at week 10, compared to 33% at 
week 20(only 17 evaluable patients compared to 19 at weeks 0, 10 and 20) 
and 40% at week 52. No statistical significant differences were observed at 
any of the time points. 
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                                                HPV RESPONSE 
 
Recruitment 
Post 
imiquimod 
Post 
vaccination 
Primary end-
point week 
52 
IT1 Neg Neg 16 16 
IT2 16 16 16 16 
IT3 42 neg neg neg 
IT4 16 16 16 neg 
IT5 16 neg neg neg 
IT8 16 16 neg 16,53 
IT9 16,33,84 neg n/e 33 
IT10 16 16,33,81 n/e 16 
IT11 16 16 16 16 
IT13 neg neg neg neg 
IT14 neg neg 84 84 
IT15 neg 33 neg 16,33 
IT16 16 16 16 16 
IT17 16 neg neg neg 
IT18 16 neg 16 neg 
IT19 16 16 16 16 
IT20 16 neg 16 16 
IT21 16 16 16 16 
IT23 16 neg 6 6 
 
Table 9 – Individual HPV Response - this table shows the different HPV 
genotypes detected on the biopsy at different time points.  - women who did 
not make a histological response at week 52;  - women who made a 
histological response, n/e, non evaluable;  
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Figure 26 – Clinical, histological, symptom and HPV responses at weeks 10, 20 and 52- This figure compares the response 
rates between different time points of week 10 – post imiquimod, wk 20 – post vaccination and wk 52 – primary end-point for the 
clinical, histological, symptom and HPV response categories. At weeks 10, 20 and 52, clinical response was 74%, 84% and 79%; 
histological response was 32%, 58% and 63%; symptom response was 37%, 67% and 80%; HPV response was 43%, 33% and 
40%respectively.
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3.5.7 SAFETY, TOXICITY & TOLERABILITY OF THE TREATMENT 
REGIME 
 
One of the secondary study objectives was to evaluate the safety, toxicity and 
tolerability of the treatment regime. Overall the treatment schedule was safe.  
Only one adverse event was detected, which was not serious. No serious 
adverse-events were observed.  Tolerance to imiquimod, however, was an 
issue. This section details the tolerability to imiquimod treatment. 
 
3.5.7.1 TOLERABILITY TO IMIQUIMOD TREATMENT  
 
3.5.7.1.1 IMIQUIMOD COMPLIANCE, DOSE REDUCTIONS, AND 
TREATMENT BREAKS 
 
In this study, imiquimod application schedule was for eight weeks, in a dose 
escalating manner, building up to three applications each week for the final six 
weeks. Seventeen women (90%) completed the prescribed eight-week course 
of the imiquimod treatment. One participant (IT3) did not comply with the 
treatment schedule and one other participant (IT21) was unexpectedly 
advised to discontinue imiquimod treatment due to an adverse event.  Of the 
remaining seventeen women who completed the course of imiquimod 
treatment, sixteen women required a break from the treatment due to the side 
effects.  ‘Treatment break’ was defined as a ‘interruption from the treatment 
schedule for duration of few days but never more than a period of one week’, 
the purpose of which was to allow the side effects to calm down and improve 
treatment compliance.   Women were advised not to have more than two 
‘treatment breaks’ in total. Nine out of seventeen women (50%) completed the 
full course of the imiquimod treatment but with ‘treatment breaks’. The 
remaining eight women (50%) who completed the full eight-week schedule of 
the imiquimod treatment required ‘dose reduction’. ‘Dose reduction’ was 
defined as ‘reduction in the imiquimod dosing frequency from three 
applications per week to no less than two applications per week’. As shown in 
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figure 27, dose reduction varied from one dose to up to a maximum of four 
imiquimod doses.  
 
Only one woman (IT18) could tolerate the imiquimod treatment regime entirely 
without any treatment breaks or dose reductions. At the time of recruitment, 
this woman was diagnosed with a unifocal lesion on the lateral aspect of the 
left labia majora.  
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Figure 27 – Imiquimod dose per participant - this figure shows the number 
of imiquimod doses used by the individual trial participants. 9 out of 19 women 
completed the full-prescribed 21-dose imiquimod regime. All women except 
IT18 required a break from the treatment schedule.  
 
 
3.5.7.1.2 SIDE EFFECTS ASSOCIATED WITH THE IMIQUIMOD 
TREATMENT 
 
Every one of trial participants reported side effects associated with the 
imiquimod treatment. The most common side effects experienced were 
localised burning, soreness, aching, smarting during micturition and lumpiness 
or swelling. Skin peeling at the site of imiquimod application and ulceration 
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was also apparent in some women on examination. In fact two women 
necessitated oral antibiotics for the treatment of superimposed bacterial 
infection of the ulcerated areas. This was further confirmed as excessive 
growth of mixed skin flora on swabs taken for bacterial culture and sensitivity.  
Additionally, majority of the women also mentioned flu like symptoms i.e. 
symptoms of fatigue, myalgia, arthralgia, headaches, apathy and weariness 
associated with the imiquimod application.  Side effects were first evident in 
the majority of women at week three with gradual build up in severity with 
continuing use of the imiquimod cream application.   
 
Clearly as shown in the table 10, the side effects although varied in intensity 
from person to person, were extreme and categorised as ’severe’ (severely 
interfering with lifestyle) in 79% and ‘moderate’ (moderately interfering with 
lifestyle) in intensity in the remaining 24% of women.   
 
Upon further close questioning, the problems women faced with the 
application of imiquimod cream on the labia majora, labia minora, introitus, 
peri-urethra and peri-anal areas were relatively site-specific. In addition to 
finding it difficult to sit down or walk without experiencing discomfort, women 
with periurethral lesions found micturition extremely painful, whereas women 
with peri-anal lesions found defecating, wiping and keeping the area clean just 
as agonizing. Also, using sanitary protection at the time of menstrual periods 
was pointed out to be incredibly cumbersome by some of the participants.   
 
Figures 28 a and b elicit the vulval inflammation and excoriation commonly 
observed with imiquimod treatment. 
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Figures 28 a and b– Vulval inflammation and excoriation associated with 
imiquimod treatment 
 
 
 
3.5.7.1.3 PATIENT DRIVEN APPROACH TO COPE WITH THE IMIQUIMOD 
TREATMENT 
 
Most women believed they obtained relief from cold-water baths. Some 
women altered the timing of imiquimod application to daytime, when they were 
more likely to be distracted from the treatment related side effects as opposed 
to the suggested night time applications, when their sleep was disturbed due 
to the treatment related side effects. During the final weeks of the imiquimod 
treatment, some of the participants who were fairly sore and inflamed on the 
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vulva took help in applying the imiquimod cream from either close family 
members or their family doctor. 
 
3.5.7.1.4 CLINICAL STRATEGIES TO IMPROVE COMPLIANCE WITH 
IMIQUIMOD TREATMENT 
 
Women were advised to take oral analgesia as and when required and 
prescriptions were provided. A small proportion of women required potent oral 
opiod analgesia. Five women (26%) required a prescription for anxiolytics, 
sedatives and/or antihistamines to help them sleep better and to relieve vulval 
itching.  A regularly supply of Vaseline coasted dressings (gelonet) to create a 
non-adhesive barrier between the raw surfaces on the vulva and patient’s 
clothing was also made available. With the participant’s consent, their general 
practitioner was informed. Upon request, a brief letter to the participant’s 
employer explaining the clinical situation at that point of time was presented. 
Topical local anaesthetic cream or gel (Emla cream, istillagel pre-filled 
syringes) for application on the skin or mucosal surfaces was also offered 
having received positive feedback from the initial few participants who found it 
beneficial.  Mostly women needed regular encouragement over phone.  
 
3.5.7.1.5 ADVERSE EVENT ASSOCIATED WITH IMIQUIMOD TREATMENT 
 
One out of the nineteen women (IT21) experienced unusual side effects with 
the imiquimod treatment.  She initially remarked on severe headache and 
dizziness through the fourth week of the imiquimod treatment. There was 
uncertainty as regards the cause, warranting a thorough clinical examination, 
urinalysis and blood tests. No abnormality was detected and the woman felt 
better within few days of taking a break from the imiquimod treatment. Two 
weeks later imiquimod treatment was resumed. No further headaches or 
dizziness occurred except during week six of imiquimod treatment, she 
developed flu like illness with myalgia, arthralgia and generalised unwell 
feeling. She also complained of a rash. She was on a holiday when this 
happened and noticed the rash to be photosensitive. Steven-Johnson 
syndrome was suspected. Examination revealed a generalised papular rash, 
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more severe on the dorsal aspects of her upper limbs. Although the 
conjunctiva and oral mucosa appeared inflamed, no obvious ulcerations were 
visible. All the standard tests were within normal limits. She was commenced 
on a low dose steroid cream and was advised to stop using the imiquimod 
cream and felt normal within two weeks.  This adverse event did not exceed 
grade two of the ‘Common Terminology Criteria for Adverse Events of the 
National Cancer Institute’ and therefore no further action related to reporting 
the adverse event to higher authorities was taken. 
 
 
3.5.7.1.6 THE EFFECT OF IMIQUIMOD TREATMENT ON THE SKIN 
During the course of the imiquimod treatment, three women observed a 
dramatic remission in facial acne. An improvement in their generalised skin 
condition with smoother skin and fewer spots was also obvious.  While 
assessing the effect of imiquimod on the skin was not one of the trial 
objectives, it was nevertheless interesting and worthy of note.  
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 Side 
effects 
Adverse 
Effects 
Treatment 
Breaks 
Dose 
Reductions 
Number 
Symptom 
Improvement 
IT1 Severe No Yes Yes-4 No 
IT2 Severe No Yes Yes-3 Yes 
IT3 Severe No Yes Yes-8 No 
IT4 Severe No Yes Yes-4 Yes 
IT5 Severe No Yes Yes-2 No 
IT8 Severe No Yes Yes-2 No 
IT9 Moderate No Yes No Yes 
IT10 Severe No Yes No No, Acne 
improved 
IT11 Severe No Yes Yes-3 Yes 
IT13 Moderate No Yes No No 
IT14 Moderate No Yes No No 
IT15 Severe No Yes No No, Acne 
improved 
IT16 Severe No Yes No No 
IT17 Severe No Yes Yes-1 Yes, Acne 
improved 
IT18 Moderate No No No Yes 
IT19 Severe No Yes No No 
IT20 Severe No Yes Yes-2 No 
IT21 Severe Yes Yes Yes-3 No 
IT23 Severe No Yes No Yes 
 
Table 10 - Tolerability of imiquimod treatment - Details of side effects, 
treatment breaks, dose reductions and symptom improvement  
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3.5.7.2 TOLERABILITY TO TA-CIN VACCINATION 
 
 
Eighteen out of nineteen women received all the three doses of the TA-CIN 
vaccination.  One woman (IT21) received only two doses of the vaccination 
and missed out the third dose due to the vaccine expiration.  TA-CIN 
vaccination was well tolerated with no evident side effects or adverse events. 
The only side effect experienced by all the women was a sharp and smarting 
sensation followed by a dull ache or discomfort lasting for few hours at the 
injection site.  
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Figure 29 Complete clinical response in patient 8 (a) pre-treatment (b) 
post imiquimod wk 10 (c) post vaccination wk 20 (d) week 52 
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Figure 30 Partial clinical response in patient 11 (a) pre-treatment (b) post 
imiquimod wk 10 (c) post vaccination wk 20 (d) week 52 
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CHAPTER 4  
IMMUNOLOGICAL RESULTS 
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4 IMMUNOLOGICAL RESULTS 
 
In addition to evaluating the clinical responses, representative tissue biopsies 
from the VIN lesions and the blood samples from the nineteen women who 
participated in the trial were also considered to improve our understanding of 
the immunological phenomena, both within the lesions and systemically, in 
response to the treatment at various stages. It is already established that VIN 
lesions contain increased number of helper (CD4) and cytotoxic (CD8) T 
lymphocytes when compared to the normal vulval epithelium [Abdel-Hady et 
al., 2001;Davidson et al., 2003c;Gul et al., 2004]. Effect of treatment on the 
local immune environment is likely to determine and influence the clinical 
outcome of treatment [Davidson et al., 2003c]. Imiquimod acts at least partly 
through inducing a local inflammatory response whilst TA-CIN induces virus 
specific T lymphocyte responses. In this context, the local immunological 
monitoring of the lesion was carried out using immunofluorescence with 
emphasis on T regulatory cells on sections of frozen tissue samples collected 
from women who participated in the trial. The emphasis on examining the 
local immune environment was to decide whether the numbers of infiltrating 
lymphocytes altered in response to the treatment with imiquimod and TA-CIN.   
 
HPV 16 specific systemic responses were determined using proliferation 
assays to the different HPV antigens. In addition, neutralising antibody assays 
were also carried out. 
 
4.1 DEFINITION OF TREATMENT RESPONDERS AND TREATMENT NON-
RESPONDERS 
 
In the clinical results chapter, discrepancy in the results between clinical 
responses, complete clinical responses and histological responses was 
shown. Considering histological response to any treatment is traditionally 
considered to be the gold standard, we defined ‘complete clearance of VIN on 
histology of the punch biopsy at week 52, the study primary end-point ’ as 
‘treatment response’ and ‘failure to clear VIN on histology of the punch biopsy 
at week 52’ as ‘treatment non-response’. Women who made a treatment 
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response were called ‘responders’(R) and women who did not make a 
treatment response were called ‘non-responders’ (NR).  
 
All the results from this section onwards are compared between treatment 
responders (R) and treatment non-responders (NR). As shown in the table 11, 
twelve treatment responders (IT5, 8,9,10,13,14,15,16,17,18,20,23) and seven 
treatment non-responders (IT1, 2,3,4,11,19,21) were identified.  
 
 Histology at Wk 52 Response Category 
IT1 VIN2/3 NR 
IT2 VIN2/3 NR 
IT3 VIN1/2 NR 
IT4 VIN2/3 NR 
IT5 no VIN R 
IT8 no VIN R 
IT9 no VIN R 
IT10 no VIN R 
IT11 VIN2/3 NR 
IT13 no VIN R 
IT14 no VIN R 
IT15 no VIN R 
IT16 no VIN R 
IT17 no VIN R 
IT18 no VIN R 
IT19 VIN2/3 NR 
IT20 no VIN R 
IT21 VIN2/3 NR 
IT23 no VIN R 
 
Table 11 – Assignment of treatment response category- this table shows 
the individual histology results of the punch biopsy of the index lesion or the 
residual VIN on vulvoscopy at week 52 (study primary end-point) and the 
corresponding treatment response status. R – treatment responder; NR – 
treatment non-responder. 12 treatment responders and 7 treatment non-
responders were identified. 
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4.2 TUMOUR INFILTRATING LYMPHOCYTES  
 
Cryostat sectioning of the punch biopsies was planned and the slides were 
laid out and labelled in way to facilitate serial sections to be placed 
consecutively on the slides. When studying the proportion of different types of 
the T lymphocytes in the biopsy specimen, serially laying out the sections to 
some extent maintained the continuity of the tissue architecture.  
 
The densities per unit area of CD4, CD8 and T regulatory (Tregs) 
lymphocytes (FoxP3CD4) were assessed. For the detection of Tregs and the 
ratio of CD4 and CD8 lymphocytes within a tissue section, double 
immunofluorescence labelling was carried out. This enabled simultaneous 
detection of FoxP3CD4 and CD4+ lymphocytes on one spot of the tissue 
section, and similarly FoxP3CD4 and CD8 + lymphocytes on one other spot 
and CD4 and CD8 T lymphocytes on one other spot (two slides with two spots 
each were used for the detection of the above mentioned lymphocytes. The 
fourth spot was used for control antibodies). This approach was more practical 
in overcoming any inter section variability in the densities of the T lymphocyte 
infiltration, more so when the aim was to assess the proportions of different 
types of lymphocytes in each of the tissue sections.   
 
Tissue samples from the three clinically relevant time-points of week 0 (pre-
treatment) post imiquimod but pre TA-CIN vaccination treatment (week 10) 
and post TA-CIN treatment (week 20) were available for all the nineteen 
women.  
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 4.2.1 TUMOUR INFILTRATING LYMPHOCYTES  
 
At recruitment the majority of the lymphocytes infiltrating the VIN lesions were 
CD4 expressing lymphocytes (median 104; range 63 to 188) with a smaller 
proportion of CD8 expressing lymphocytes (median 38; range 26 to 68). 
FoxP3CD4 expressing cells could also be detected in much smaller numbers 
(median 14; range 6 to 33). At recruitment, the median density per unit area of 
CD4 expressing cells in the responder group was 80 (range 58-130) 
compared to a median of 109 (range 82-190) in the non-responder group; The 
median density of CD8 expressing lymphocytes was 40 (range 27-67) in the 
responder group compared to a median of 37(range 22-97) in the non-
responder group. The median density of FoxP3CD4 expressing T regulatory 
lymphocytes in the responder group was 11 (range 2-14) in comparison to a 
median of 25 (range 18-35) in the non-responder group as shown in table 12.  
 
The trends in the median density of CD4, CD8 and FoxP3 lymphocytes 
following imiquimod and vaccination treatment in both the responder and non-
responder patient groups are shown in figure 31. In the treatment responders, 
a significant increase in the CD4 cell count was noticed at week 20 compared 
to pre-treatment levels (P=0.03). A similar significant increase in the CD8 
lymphocyte count was observed in the responder group, however, both at 
weeks 10 and 20 (P=0.05, 0.03 respectively). In contrast, a significant 
increase in FoxP3CD4 positive cells was only observed in the non-responder 
group, at week 20 (P=0.05) as shown in table 13.  
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 Group (n=19) Responders (n=12) Non-Responders (n=7) 
Recruitment    
CD4  104 (63-188)  80 (58-130) 109 (82-190) 
CD8  38 (26-68)  40 (27-67) 37 (22-97) 
FoxP3CD4  14 (6-33)  11 (2-14) 25 (18-35) 
    
Week 10    
CD4 103 (65-155) 93 (67-130) 139 (48-160) 
CD8 61 (30-111) 51 (24-110) 66 (50-145) 
FoxP3CD4 25 (8-37) 26 (8-39) 22 (6-31) 
    
Week 20    
CD4 170 (76-301) 124 (65-214) 215 (76-350) 
CD8 89 (30-142)  72 (20-106) 152 (37-170) 
FoxP3CD4 19 (5-50) 8 (4-37) 43 (19-95) 
 
Table 12 - Lesion associated immune cells in the group, responders, 
non-responders at recruitment, following Imiquimod (week 10) and TA-
CIN (week 20). Median number +/- upper and lower quartiles of lesion 
associated immune cells in the brackets in patient biopsies.  
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Figure 31 – Lesion associated 
immune cells in the 
Responders (R) and Non-
Responders (NR) groups pre-
treatment (Wk 0), post-
imiquimod (Wk 10), post-
vaccination (Wk 20). Median 
number +/- upper and lower 
quartiles per unit area of the 
biopsy are shown in box-
feather plots. Wilcoxon signed 
rank test was used to 
determine the significance of 
within group differences pre 
and post-treatment.  denotes 
a statistically significant value.  
P value of <0.05 was 
considered statistically 
significant. 
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4.2.2 TUMOUR INFILTRATING LYMPHOCYTES AT RECRUITMENT 
RESPONDERS VS. NON-RESPONDERS 
  
Upon comparing the differences between tumour infiltrating CD4, CD8 and 
FoxP3CD4 cell densities between the responder and the non-responder 
groups at recruitment as shown in table 12, with the Mann-Whitney U test, the 
difference for CD4 and CD8 lymphocytes was not statistically significant 
(P=0.2; 0.5 respectively) but non-responders had significantly higher 
infiltration of FoxP3CD4 positive lymphocytes in comparison to the responders 
(P=0.05) as shown in table 13.  
 
4.2.3 TUMOUR INFILTRATING LYMPHOCYTES AT WEEK 10 (post 
imiquimod) and at WEEK 20 (post vaccination) - RESPONDERS VS. 
NON-RESPONDERS 
 
As shown in table 13 at recruitment, the median density per unit area of CD4 
expressing cells in the responder group was 93 (range 67-130) compared to a 
median of 139 (range 48-160) in the non-responder group; The median 
density of CD8 expressing lymphocytes was 51 (range 24-110) in the 
responder group compared to a median of 66(range 50-145) in the non-
responder group. The median density of FoxP3CD4 expressing T regulatory 
lymphocytes in the responder group was 26 (range 8-39) in comparison to a 
median of 22 (range 6-31) in the non-responder group.  
 
Upon comparing the differences between tumour infiltrating CD4, CD8 and 
FoxP3CD4 cell densities between the responder and the non-responder 
groups at week 10 with the Mann-Whitney U test, the difference in the density 
of infiltration for CD4, CD8 and FoxP3CD4 lymphocytes was again not 
statistically significant (P=0.2; 0.2, 0.2 respectively).  
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Table 13 Lesion associated immune cells in whole group, responders, 
non-responders pre-treatment, following Imiquimod (week 10) and TA-
CIN (week 20) with statistical significance. Median number +/- upper and 
lower quartiles of lesion associated immune cells in patient biopsies. The 
Wilcoxon’s signed ranks test was used to determine the significance of within 
group differences pre and post treatment.  
 
4.2.4 TUMOUR INFILTRATING LYMPHOCYTES AT WEEK 20 (post 
vaccination) - RESPONDERS VS. NON-RESPONDERS 
 
As shown in table 13, at week 20, the median density per unit area of CD4 
expressing cells in the responder group was 124 (range 65-214) compared to 
a median of 215 (range 76-350) in the non-responder group; The median 
density of CD8 expressing lymphocytes was 72 (range 20-106) in the 
responder group compared to a median of 152(range 37-170) in the non-
responder group. The median density of FoxP3CD4 expressing T regulatory 
Group (n=19) CD4 CD8 FoxP3CD4 
Wk0  104 (63-188) 38 (26-68) 14 (6-33) 
Wk10 103 (65-155)  61 (30-111) 8 25 (8-37) 
Wk20 170 (76-301)  89 (30-142) 6 19 (6-50) 
Wk0 vs. wk10 P=0.7 P=0.04 P=0.2 
Wk0 vs. wk20 P=0.03 P=0.01 P=0.04 
    
Responders (n=12)    
Wk0 80 (58-130) 40 (27-67) 11 (2-14) 
Wk10 93 (67-130) 51 (24-110) 26 (8-39) 
Wk20 124 (65-214) 72 (20-106) 8 (4-37) 
Wk0 vs. wk10 P=0.5 P=0.05 P=0.2 
Wk0 vs. wk20 P=0.03 P=0.03 P=0.2 
    
    
Non-Responders(n=7)    
Wk0 109 (82-190) 37 (22-97) 25 (18-35) 
Wk10 139 (48-160) 66 (50-145)  22 (6-31) 
Wk20 215 (76-350) 152 (37-170) 43 (19-95) 
Wk0 vs. wk10 P=0.6 P=0.2 P=0.5 
Wk0 vs. wk20 P=0.2 P=0.1 P=0.05 
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lymphocytes in the responder group was 8 (range 4-37) in comparison to a 
median of 43 (range 19-95) in the non-responder group.  
 
Upon comparing the differences between tumour infiltrating CD4, CD8 and 
FoxP3CD4 cell densities between the responder and the non-responder 
groups at week 20 with the Mann-Whitney U test, the difference for CD4 and 
CD8 lymphocytes was again not statistically significant (P=0.1; 0.07 
respectively) but similar to the findings on the pre-treatment biopsy at 
recruitment where the potential non-responders demonstrated higher 
infiltration of FoxP3CD4 cells and in contrast to the findings at week 10, at 
week 20,  non-responders showed significantly higher infiltration of FoxP3CD4 
positive lymphocytes in comparison to the responders and this was 
statistically significant (P=0.01). 
 
4.3 THE CYTOTOXIC VS. HELPER T LYMPHOCYTE RATIO PRE-
TREATMENT, WEEK 10 AND WEEK 20 
In the vulval epidermis, CD8 T lymphocytes are shown to be more prevalent 
with equal distribution of CD4 and CD8 T lymphocytes in the vulval dermis 
[Abbas and Janeway, Jr., 2000]. We were interested in assessing the 
CD8:CD4 ratios following treatment and compare the results with pre-
treatment values, expecting an enhancement in the CD8 T lymphocyte 
infiltration [Gul et al., 2004;Piersma et al., 2008;Curiel et al., 2004;Wolf et al., 
2005a]. Table 14 shows the individual ratios of CD8 and CD4 density in the 
tumour at different time-points. 
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  CD8: CD4  
 Week 0 
CD8: CD4  
Week 10 
CD8: CD4  
Week 20 
IT1α 0.19 0.57 0.37 
IT2 α 0.85 0.64 0.51 
IT3 α 0.17 0.25 0.43 
IT4 α 0.52 0.28 0.25 
IT5β 0.10 0.37 0.28 
IT8 β 0.21 0.28 0.61 
IT9 β 0.38 0.26 0.48 
IT10 β 0.41 0.42 0.73 
IT11 α 0.27 0.17 0.28 
IT13 β 0.11 0.72 0.23 
IT14 β 0.49 0.82 0.20 
IT15 β 0.19 0.43 0.62 
IT16 β 0.14 0.33 0.48 
IT17 β 0.25 0.87 0.36 
IT18 β 0.29 0.27 0.95 
IT19 α  0.54 1.18 0.26 
IT20 β 0.14 0.21 0.32 
IT21 α 0.29 0.68 0.36 
IT23 β 0.22 0.53 0.83 
 
Table 14 Ratio of CD8:CD4 density in the individual participants at 
weeks 0, 10 and 20.  This table shows the trend in the ratio of CD8:CD4 
double immunofluorescence labelled lymphocytes pre-treatment (Wk0), post 
imiquimod (Wk10) and post vaccination (Wk 20).  represents- women who 
did not make a histological response at week 52;  represents - women who 
made a histological response 
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When CD8:CD4 ratios are compared as shown in table 15, the CD8:CD4 ratio 
increased to 0.4 from 0.3 at both weeks 10 and 20, in the group as a whole 
and this increase was statistically significant (P=0.006 at week 10) and 
(P=0.03 at week 20) at both the time-points.  
 
However, when the group was stratified into treatment responders and non-
responders, the increase in CD8:CD4 ratio was significant only in the 
responder group at both weeks 10 and 20 (P=0.02 at week 10 and P=0.05 at 
week 20). A significant increase in the ratio of CD8:CD4 was evident in the 
non-responders at week 10, following imiquimod, but this enhancement was 
not significant any more at week 20.  
 
Group (n=19) CD8:CD4 Ratio 
Wk0 0.25 (0.1-0.4) 
Wk10 0.42 (0.1-0.7) 
Wk20 0.37 (0.1-0.7) 
Wk0 vs. wk10 P=0.006 
Wk0 vs. wk20 P=0.03 
  
Responders (n=12)  
Wk0 0.22 (0.1-0.5) 
Wk10 0.40 (0.1-0.7) 
Wk20 0.48 (0.1-0.8) 
Wk0 vs. wk10 P=0.02 
Wk0 vs. wk20 P=0.03 
  
  
Non-Responders (n=7)  
Wk0  0.29 (0.1-0.7) 
Wk10  0.59 (0.1-0.5) 
Wk20  0.36 (0.1-0.5) 
Wk0 vs. wk10 P=0.02 
Wk0 vs. wk20 P=0.2 
 
Table 15 Comparison in the ratio of CD8:CD4 between wk 0 and 10; wk 0 
and 20 in the group, responders and non-responders. The Wilcoxon’s 
signed ranks test was used to determine the significance of within group 
differences pre and post treatment.  
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4.4 SUMMARISING THE OVERALL INTRALESIONAL LYMPHOCYTE 
RESPONSES 
In the group as a whole, significant increases in the number of CD4, CD8 and 
FoxP3CD4 positive T lymphocytes were evident by week 20 compared to pre-
treatment levels (P=0.03, P=0.01, P= 0.04 respectively); a significant increase 
after imiquimod treatment was only apparent for CD8 lymphocytes in the 
group (P=0.04) and treatment responders (P=0.05). Further stratification of 
the group into responders and non-responders led us to believe that the 
significant increase in CD4 and CD8 cells witnessed in the group was only 
significant in the treatment responders (p=0.03, 0.03 respectively). Conversely 
the significant increase in FoxP3CD4 cells noted in the group was actually 
only significant in the treatment non-responders (p=0.05). Although the non-
responders at week 20 did demonstrate a trend towards denser infiltration of 
CD4 and CD8 lymphocytes, this did not reach statistical significance 
(p=0.2,0.1respectively).  
 
There were no significant pre-treatment differences in the density of CD4 or 
CD8 T cells in the treatment responder and non-responders (P=0.2, P=0.5 
respectively) but intralesional FoxP3CD4 density was significantly higher in 
non-responders compared to responders (P=0.05).  By week 20, a significant 
reduction in FoxP3CD4 T cell population density was apparent in the 
treatment responders, which was significantly different from non-responder 
densities (P=0.01).  
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4.5 SYSTEMIC IMMUNE RESPONSES 
 
4.5.1 LYMPHOCYTE PROLIFERATIVE RESPONSES TO HPV 16 
ANTIGENS 
 
Lymphoproliferation to HPV antigens was used to analyse patient systemic 
cellular immunity to HPV 16 before and after the imiquimod and vaccination 
steps in the protocol.   PBMC alone or PBMC with HPV antigens:  HPV16 
E6E7L2 protein - TA-CIN (Xenova Research Ltd.), HPV16 GST E6, HPV16 
GST E7[Smyth et al., 2004], HPV16L2 (full length HPV16L2 tagged with 6His 
at N-terminus), TA-GW (HPV 6 L2E7; Xenova Research Ltd. For negative 
control) and PHA (for positive control) were performed. 
 
A pre-existing proliferative T lymphocyte response was defined as a 
stimulation index (SI) of two or greater than two. A post treatment proliferative 
response was defined as two fold increase in the SI compared with the pre 
treatment value.  This section of this chapter described the lymphoproliferative 
responses of the trial participants at different time points, pre treatment, 
following imiquimod treatment and post TA-CIN vaccination. An attempt was 
also made to compare the lymphoproliferative responses between the 
responders (women who managed to clear VIN from the biopsy site taken at 
week 52) and the non-responders (women who failed to clear VIN on 
histology) pre and post imiquimod and vaccination treatment. 
 
4.5.2 PRE-EXISTING PROLIFERATIVE RESPONSE TO TA-CIN, 
CORRELATION WITH TREATMENT RESPONSE 
 
As illustrated in the table 16, sixteen of the nineteen women (84%) 
demonstrated a pre-existing proliferative response to the TA-CIN protein. Of 
these sixteen women, eleven women (61%) subsequently made a histological 
response to the treatment and five women (59%) failed to demonstrate a 
histological response. Of the remaining three women who did not show a pre-
existing response to the TA-CIN antigen, one woman subsequently was a 
responder and the remaining two were non-responders.  
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The difference in the magnitude of the lymphoproliferative response (SI) 
between the responder and the non-responder groups was not statistically 
significant (P=0.4, Fisher’s exact test).  
 
 
 
Pre-existing 
response 
(SI) 
Pre-existing 
response 
Treatment 
Response 
IT1 7.2 Yes No 
IT2 1.0 No No 
IT3 7.0 Yes No 
IT4 1.9 No No 
IT5 4.4 Yes Yes 
IT8 2.9 Yes Yes 
IT9 0.9 No Yes 
IT10 26.6 Yes Yes 
IT11 5.1 Yes No 
IT13 3.0 Yes No 
IT14 10.9 Yes Yes 
IT15 3.5 Yes Yes 
IT16 3.3 Yes Yes 
IT17 5.6 Yes Yes 
IT18 2.5 Yes Yes 
IT19 7.4 Yes No 
IT20 27.8 Yes No 
IT21 6.3 Yes No 
IT23 6.0 Yes No 
Table 16 Pre-existing response (SI) and the final treatment response – no 
statistical significant difference between pre-existing response was noted 
between the subsequent treatment responders and non-responders (P=0.4 
Fisher exact test).  
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4.5.3 PRE-EXISTING PROLIFERATIVE RESPONSE TO TA-CIN, 
CORRELATION WITH HPV POSITIVITY  
 
Women who previously received any HPV vaccination were not eligible to 
participate in this study. Any demonstrated pre-existing lympho proliferative 
response to HPV 16 proteins ought to have resulted from the immunological 
memory associated with previous HPV infection. As shown in the table 17 of 
the sixteen women who demonstrated a pre-existing response to TA-CIN 
protein, fourteen women were HPV 16 positive in the biopsy specimen at any 
given time-point during the study period. Two women were positive for the 
other oncogenic HPV types (HPV 42 and 84, respectively). One woman who 
indeed expressed a pre-existing response to TA-CIN (IT15, SI – 3.5) at week 
0 was actually negative for any HPV genotype in the biopsy at all the time-
points. All the three women who failed to mount a pre-existing response to the 
TA-CIN fusion protein were all proved to be HPV 16 positive on the biopsy 
sample. 
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Pre-existing 
Response 
(SI) 
Pre-existing 
response 
HPV 
genotypes 
IT1 7.2 Yes 16 
IT2 1.0 No 16 
IT3 7.0 Yes 42 
IT4 1.9 No 16 
IT5 4.4 Yes 16 
IT8 2.9 Yes 16 
IT9 0.9 No 16 
IT10 26.6 Yes 16 
IT11 5.1 Yes 16, 53 
IT13 3.0 Yes 16, 33, 84 
IT14 10.9 Yes 16, 33, 81 
IT15 3.5 Yes Neg 
IT16 3.3 Yes 84 
IT17 5.6 Yes 16, 33 
IT18 2.5 Yes 16 
IT19 7.4 Yes 16 
IT20 27.8 Yes 16 
IT21 6.3 Yes 16 
IT23 6.0 Yes 6, 16 
Table 17 Pre-existing response (SI) and the presence of HPV oncogene 
type – three women who were negative for HPV 16 at any given time point 
demonstrated a pre-existing response 
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4.6 LYMPHOPROLIFERATIVE RESPONSE TO TA-CIN  
 
Treatment with imiquimod cream although was expected to encourage local 
immune infiltration, HPV antigen specific immune response was unpredicted. 
Accordingly, a two-fold increase in the SI following imiquimod treatment was 
only evident in two women from the ‘responder’ group and none from the ‘non-
responder’ group. The difference in the magnitude of the SI pre-treatment and 
post imiquimod treatment in the group, responders or non-responders was not 
significant, P= 0.5, 0.8 and 0.2 respectively. The difference in the magnitude 
of proliferative response between pre-treatment and post vaccination 
treatment was significantly different in the group as a whole and in the 
responders, P=0.0002, 0.0002 respectively, but not in the non-responders, 
P=0.3.  
 
Upon comparison of the magnitude of the stimulation index (SI) between the 
responder and non-responders groups, statistical significant difference in SI 
was observed at both week 10, following imiquimod treatment (P=0.05) and at 
week 20, following vaccination treatment (P=0.003) but not at recruitment 
(P=0.4). The above data is shown in tables 18, 19 and 20. 
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Proliferative Responses to TA-CIN 
Responders Pre-treatment 
Post imiquimod 
(Wk 10) 
Post vaccination 
(Wk 20) 
IT5 4.4 6.3 9.4 
IT8 2.9 4.7 32.9 
IT9 0.9 N/A 12.3 
IT10 26.6 18.5 84.2 
IT13 3.0 3.1 3.8 
IT14 10.9 10.0 31.6 
IT15 3.5 6.4 10.9 
IT16 3.3 8.4 15.6 
IT17 5.6 4.0 11.6 
IT18 2.5 1.4 5.4 
IT20 27.8 1.3 13.8 
IT23 6.0 1.0 17.4 
Non-responders    
IT1 7.2 5.7 25.0 
IT2 1.0 1.2 2.5 
IT3 7.0 7.2 2.2 
IT4 1.9 2.0 5.5 
IT11 5.1 1.6 1.1 
IT19 7.4 2.2 3.6 
IT21 6.3 1.1 1.2 
Table 18 Proliferative Responses to TA-CIN in the responders and non-
responders at weeks 0, 10, 20 Two fold change in the stimulation index (SI) 
was considered as a response, highlighted in grey, N/A – not available 
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Wk 
0 
Wk 
10 
Wk 
20 
Wk 0 vs. Wk 10 
(P, WSR) 
Wk 0 vs. Wk 20 
(P, WSR) 
Group (n=19) 5.1 3.6 10.9 P=0.5 P=0.0002 
Responders 
(n=12) 
4.0 4.7 13.1 P=0.8 P=0.0002 
Non-Responders 
(n=7) 
6.3 2.0 2.5 P=0.2 P=0.3 
 
Table 19 Change in the lymphoproliferative responses to TA-CIN in the 
group, responders, non-responders between weeks 0, 10, 20. A 
significant difference in the magnitude of response (median Stimulation Index 
SI) was observed in the group and responders following vaccination 
treatment; Wilcoxon signed rank test (WSR) 
 
 
 
 
 
 
Responders vs. Non-Responders 
(P, MWU) 
Wk 0 P=0.4 
Wk 10 P=0.05 
Wk 20 P=0.003 
 
Table 20 Statistical significance of the difference in the 
lymphoproliferative response to TA-CIN between responders and 
nonresponders at weeks 0, 10 and 20, calculated using Mann-Whitney U 
test. 
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4.7 LYMPHOPROLIFERATIVE RESPONSE TO HPV 16 L2 PROTEIN 
 
A significant difference in the magnitude of lympho-proliferative response to 
HPV 16 L2 protein was observed in the group as a whole and in the 
responders, P=0.01 and 0.05 respectively, but not in the non-responders, 
P=0.5 as shown in the tables 21 and 22.  No significant difference in the 
magnitude of response was observed between the responders and non-
responders at any give time-point as shown in the table 23.  
 
LYMPHOPROLIFERATIVE RESPONSE TO HPV 16 L2 PROTEIN 
Proliferative Responses to HPV 16 L2 
Responders Pre-treatment 
Post imiquimod 
(Wk 10) 
Post vaccination 
(Wk 20) 
IT5 2.8 6.4 5.2 
IT8 0.7 6.2 14.7 
IT9 1.6 N/A 7.5 
IT10 3.0 8.2 21.0 
IT13 0.8 0.7 0.8 
IT14 1.6 2.1 2.1 
IT15 2.0 5.0 3.0 
IT16 2.9 7.8 7.6 
IT17 3.1 5.7 7.9 
IT18 2.8 1.7 2.9 
IT20 17.0 2.0 9.0 
IT23 1.0 1.3 3.7 
Non-responders    
IT4 3.2 3.7 3.0 
IT11 3.3 1.6 4.7 
IT19 2.0 2.0 9.4 
IT21 17.0 2.0 9.0 
Table 21Proliferative Responses to HPV 16L2 in the responders and 
non-responders at weeks 0, 10, 20 Two fold change in the stimulation index 
(SI) was considered as a response, highlighted in grey, N/A – not available 
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 Wk 
0 
Wk 
10 
Wk 
20 
Wk 0 vs. Wk 10 
(P, WSR) 
Wk 0 vs. Wk 20 
(P, WSR) 
Group (n=16) 2.8 2.1 6.4 P=0.4 P=0.01 
Responders 
(n=12) 
2.4 5.0 6.4 P=0.07 P=0.05 
Non-Responders 
(n=4) 
3.3 2.0 6.8 P=0.7 P=0.5 
Table 22Change in the lymphoproliferative responses in the group, 
responders, non-responders between weeks 0, 10, 20. A significant 
difference in the magnitude of response (median Stimulation Index SI) was 
observed in the group and responders following vaccination treatment; 
Wilcoxon signed rank test (WSR) 
 
 
 
 
 
Responders vs. Non-Responders 
(P, MWU) 
Wk 0 P=0.09 
Wk 10 P=0.5 
Wk 20 P=0.9 
 
Table 23 Statistical significance of the difference in the 
lymphoproliferative response to HPV16-L2 between responders and 
nonresponders at weeks 0, 10 and 20, calculated using Mann-Whitney U 
test. 
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4.8 LYMPHOPROLIFERATIVE RESPONSE TO GST E6 PROTEIN 
 
4.8.1 RESPONSE TO GST-E6 PROTEIN 
 
At week 10, four responders and one non-responder patient showed a 
response greater than two fold when compared to week 0. At week 20, eight 
responders and two non-responders showed a greater than two fold change in 
the SI when compared to baseline. In the whole group, the differences in the 
SI’s (stimulation indices) between week 0 and week 10 was not significant; 
however, there was a significant difference between week 0 and 20 
(P=0.002), as shown in tables 24 and 25. When the findings were assessed 
for both the responder and non-responder groups separately, in the responder 
group, the increase in the SI between weeks 0 and 20 was statistically 
significant (P=0.005). However, in the non-responder group, no significant 
difference in the SI’s at any time-point was noted. When the responder group 
was compared to the non-responder group, there was a significant difference 
in the fold change both at week 10 (post imiquimod) and week 20 (post 
vaccination) between responders and non-responders (p=0.05) as shown in 
table 26. 
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Proliferative Responses to GST-E6 
Responders Pre-treatment 
Post imiquimod 
(Wk 10) 
Post vaccination 
(Wk 20) 
IT5 5.1 11.8 11.9 
IT8 0.6 1.3 8.3 
IT9 1.3 N/A 9.1 
IT10 6.6 5.7 16.3 
IT13 1.1 0.8 0.9 
IT14 5.1 5.1 3.0 
IT15 1.9 5.4 5.5 
IT16 3.4 7.7 10.4 
IT17 6.7 9.2 11.2 
IT18 2.8 3.9 7.1 
IT20 27.2 3.5 9.7 
IT23 5.6 1.3 11.4 
Non-responders    
IT1 1.8 1.0 2.4 
IT2 0.6 0.3 1.3 
IT3 0.9 1.7 1.3 
IT4 3.1 1.9 11.3 
IT11 7.1 7.6 5.0 
IT19 7.6 2.0 3.0 
IT21 7.4 2.6 11.0 
Table 24 Proliferative Responses to GST E6 in the responders and non-
responders at weeks 0, 10, 20 Two fold change in the stimulation index (SI) 
was considered as a response, highlighted in grey, N/A – not available 
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Wk 
0 
Wk 
10 
Wk 
20 
Wk 0 vs. Wk 10 
(P, WSR) 
Wk 0 vs. Wk 20 
(P, WSR) 
Group (n=19) 3.4 2.6 7.7 P=0.8 P=0.002 
Responders 
(n=12) 
4.3 5.1 9.4 P=0.5 P=0.005 
Non-Responders 
(n=7) 
3.1 1.9 3.0 P=0.2 P=0.2 
Table 25 Change in the lymphoproliferative responses to GST-E6 in the 
group, responders, non-responders between weeks 0, 10, 20. A 
significant difference in the magnitude of response (median Stimulation Index 
SI) was observed in the group and responders following vaccination 
treatment; Wilcoxon signed rank test (WSR) 
 
 
Responders vs. Non-Responders 
(P, MWU) 
Wk 0 P=0.9 
Wk 10 P=0.05 
Wk 20 P=0.05 
  
Table 26 Statistical significance of the difference in the 
lymphoproliferative response to GST-E6 between responders and 
nonresponders at weeks 0, 10 and 20, calculated using Mann-Whitney U 
test. 
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4.9 LYMPHOPROLIFERATIVE RESPONSE TO GST E7 PROTEIN 
 
As shown in the tables 27 and 28, post imiquimod, at week 10, three women 
demonstrated a greater than two fold change in the SI when compared to 
week 0. All of these women were responders. At week 20, eight women 
showed a greater than two fold change in the SI when compared to week 0. In 
the group as a whole, there is no significant increase in response between 
weeks 0 and 10(P=0.8). However, there is a significant increase in 
proliferative response between weeks 0 and 20 (P=0.006). In the responder 
group, there is no significant difference between weeks 0 and 10 (P=0.7); 
however, there is a significant difference between weeks 0 and 20 (P=0.02). 
 
In the non-responder group, unlike with the other HPV proteins, a significant 
increase in proliferative response between weeks 0 and 20 was noticed 
(P=0.03). When the responder group was compared to the non-responder 
group, a significant difference in the level of responses was seen both at 
weeks 10 (P=0.05) at week 20 (P=0.008), with greater significance at week 20 
as shown in table 29. 
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LYMPHOPROLIFERATIVE RESPONSE TO GST E7 PROTEIN  
 
 
Proliferative Responses to GST-E7 
Responders Pre-treatment 
Post imiquimod 
(Wk 10) 
Post vaccination 
(Wk 20) 
IT5 4.3 9.0 14.1 
IT8 0.8 1.2 5.7 
IT9 0.8 N/A 4.7 
IT10 6.2 6.0 20.4 
IT13 0.8 0.3 0.6 
IT14 4.4 7.3 3.9 
IT15 1.1 3.1 4.7 
IT16 0.7 3.6 2.0 
IT17 1.3 5.0 5.1 
IT18 1.3 1.2 1.6 
IT20 13.8 1.1 3.7 
IT23 5.9 1.1 13.1 
Non-responders    
IT1 1.8 1.3 2.6 
IT2 0.7 0.7 0.9 
IT3 1.5 1.0 1.3 
IT4 1.7 2.5 3.2 
IT11 3.0 4.0 3.6 
IT19 3.2 0.7 1.6 
IT21 2.4 0.8 1.4 
 Table 27 Proliferative Responses to GST E7 in the responders and non-
responders at weeks 0, 10, 20 Two fold change in the stimulation index (SI) 
was considered as a response, highlighted in grey, N/A – not available 
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Wk 
0 
Wk 
10 
Wk 
20 
Wk 0 vs. Wk 10 
(P, WSR) 
Wk 0 vs. Wk 20 
(P, WSR) 
Group (n=19) 1.6 1.3 3.3 P=0.8 P=0.006 
Responders 
(n=12) 
1.3 3.3 4.7 P=0.7 P=0.02 
Non-Responders 
(n=7) 
1.8 1.0 1.6 P=0.5 P=0.03 
 
Table 28 Change in the lymphoproliferative responses to GST-E7 in the 
group, responders, non-responders between weeks 0, 10, 20. A 
significant difference in the magnitude of response (median Stimulation Index 
SI) was observed following vaccination treatment; Wilcoxon signed rank test 
(WSR) 
 
 
 
Responders vs. Non-Responders 
(P, MWU) 
Wk 0 P=0.9 
Wk 10 P=0.05 
Wk 20 P=0.008 
 
Table 29 Statistical significance of the difference in the 
lymphoproliferative response to GST-E7 between responders and 
nonresponders at weeks 0, 10 and 20, calculated using Mann-Whitney U 
test. 
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4.10 LYMPHOPROLIFERATIVE RESPONSE TO E6 & E7  PEPTIDES 
No significant lymphoproliferative responses were observed for all the E6 
peptides. A significant lymphoproliferative response to E7I peptide was 
demonstrated in the responder group at both weeks 10 and 20, however the 
significance of the change in response was greater at week 20.  Stimulation 
indices with fold change for individual E6 and E7 peptides are shown in the 
appendix 4.   
 
4.11 LYMPHOPROLIFERATIVE RESPONSE TO TA-GW PROTEIN 
TA-GW protein was used as a negative control to the HPV 16 proteins. 
Although proliferative response to TA-GW protein was demonstrated, there 
was no significance in relation to treatment response or type of treatment as 
shown in tables 30 - 32. 
 
Proliferative Responses to TA-GW 
Responders Pre-treatment 
Post imiquimod 
(Wk 10) 
Post vaccination 
(Wk 20) 
IT8 0.5 0.9 1.5 
IT9 2.0 N/A 5.1 
IT10 10.8 7.3 21.4 
IT13 0.6 1.5 1.9 
IT15 1.2 5.3 3.6 
IT16 1.1 4.2 5.2 
IT17 2.3 3.5 1.6 
IT18 3.6 1.1 1.4 
IT23 4.2 1.2 2.1 
Non-responders    
IT11 1.0 2.2 1.2 
IT19 16.0  7.5 
IT21 1.9 0.5  
Table 30 Proliferative Responses to TA-GW protein in the responders 
and non-responders at weeks 0, 10, 20 Two fold change in the stimulation 
index (SI) was considered as a response, highlighted in grey, N/A – not 
available 
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Wk 
0 
Wk 
10 
Wk 
20 
Wk 0 vs. Wk 10 
(P, WSR) 
Wk 0 vs. Wk 20 
(P, WSR) 
Group (n=12) 2.0 2.2 2.1 P=0.2 P=0.4 
Responders (n=9) 2.3 3.5 2.1 P=0.1 P=0.4 
Non-Responders 
(n=3) 
1.9 1.4 4.4 P=0.4 P=0.9 
Table 31 Change in the lymphoproliferative responses to TA-GW protein 
in the group, responders, non-responders between weeks 0, 10, 20. No 
significant difference in the magnitude of response (median Stimulation Index 
SI) was observed following vaccination treatment; Wilcoxon signed rank test 
(WSR) 
 
 
 
 
 
 
 
 
Responders vs. Non-Responders 
(P, MWU) 
Wk 0 P=0.9 
Wk 10 P=0.5 
Wk 20 P=0.9 
Table 32 Statistical significance of the difference in the 
lymphoproliferative response to TA-GW protein between responders and 
nonresponders at weeks 0, 10 and 20, calculated using Mann-Whitney U 
test 
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4.12 LYMPHOPROLIFERATIVE RESPONSE TO PHA 
All women demonstrated a proliferative response to PHA. There was no 
difference in the responsiveness to PHA at different time-points or between 
patient groups as shown in tables 33-35. 
 
Proliferative Responses to PHA 
Responders Pre-treatment 
Post imiquimod 
(Wk 10) 
Post vaccination 
(Wk 20) 
IT5 4.4 32.6 22.3 
IT8 12.1 90.0 35.0 
IT9 6.6 N/A 19.0 
IT10 23.3 33.7 6.7 
IT13 7.8 10.1 2.6 
IT14 62.9 88.9 83.4 
IT15 22.9 21.6 4.0 
IT16 33.6 10.3 8.2 
IT17 11.2 2.9 18.3 
IT18 13.6 6.1 23.7 
IT20 19.3 2.9 8.2 
IT23 12.0 6.5 105.2 
Non-responders    
IT1 11.2 17.9 7.5 
IT2 9.7 16.0 16.9 
IT3 6.1 10.5 4.6 
IT4 5.1 40.4 20.2 
IT11 16.6 10.1 2.3 
IT19 8.7 4.8 14.2 
IT21 12.6 10.6 98.7 
Table 33 Proliferative Responses to PHA in the responders and non-
responders at weeks 0, 10, 20 Two fold change in the stimulation index (SI) 
was considered as a response, highlighted in grey, N/A – not available 
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Wk 
0 
Wk 
10 
Wk 
20 
Wk 0 vs. Wk 10 
(P, WSR) 
Wk 0 vs. Wk 20 
(P, WSR) 
Group (n=19) 12.0 10.6 16.9 P=0.4 P=0.2 
Responders 
(n=12) 
12.9 10.3 18.6 P=0.7 P=0.5 
Non-Responders 
(n=7) 
9.7 10.6 14.2 P=0.3 P=.0.3 
Table 34 Change in the lymphoproliferative responses to PHA in the 
group, responders, non-responders between weeks 0, 10, 20. No 
significant difference in the magnitude of response (median Stimulation Index 
SI) was observed following vaccination treatment; Wilcoxon signed rank test 
(WSR) 
 
 
Responders vs. Non-Responders 
(P, MWU) 
Wk 0 P=0.6 
Wk 10 P=0.08 
Wk 20 P=0.2 
 
Table 35 Statistical significance of the difference in the 
lymphoproliferative response to PHA between responders and 
nonresponders at weeks 0, 10 and 20, calculated using Mann-Whitney U 
test. 
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In summary, sixteen women (84%) demonstrated pre-existing 
lymphoproliferative response to TA-CIN (SI ≥ 2), of whom 14 were HPV16 
positive on vulval biopsy on at least one occasion. Of these, 11 were lesion 
responders and 5 non-responders with no significant difference in magnitude 
of pre-existing response (P=0.4). Following vaccination, 10/12 lesion 
responders compared to 3/7 non-responders showed ≥ 2-fold SI change 
compared with baseline.    Strong PHA responses were demonstrated by all 
the women with median SIs of 12, 10.6, 16.9 at week 0, 10 and 20 
respectively; these responses were not significantly different after imiquimod 
or vaccination (P=0.4, 0.2 in the group) or when patients were stratified by 
lesion response (P=0.7, 0.5 in responders and P=0.3, 0.3 in non-responders). 
By contrast, a significant increase in proliferation to TA-CIN was seen in the 
patients after vaccination compared to pre-treatment (P=0.01) and this was 
associated with lesion responders (P=0.008) but not the non-responders 
(P=0.7) Similar significant patient proliferative responses to each of the 
individual HPV16L2, E6 and E7 antigens after vaccination were seen (P=0.02, 
0.01, 0.02 respectively), with this increased proliferation associated with lesion 
responders (P=0.01,0.03,0.03) and not non-responders (P=0.5,0.5,0.2).  
Specificity of the HPV 16 responses was supported by the absence of any 
significant increase in patient lymphoproliferation post-vaccination to TA-GW 
(HPV6 L2E7), nor in the responder (P=0.4) or non-responder (P=0.9) groups. 
No significant increase in proliferation to any of the antigens was noted post-
imiquimod in any of the patient groups. A significant difference in the 
magnitude of proliferation response was evident between the responder and 
the non-responders groups following imiquimod treatment for some of the 
HPV 16 proteins, which enhanced following vaccination. Post-vaccination 
proliferative response to TA-CIN and its components appears to correlate with 
the clearance of VIN on histology.  
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Figures 32 Lymphoproliferation Responses to HPV 16 proteins in 
treatment responders. Patient 5 demonstrated a response to TA-CIN, GST-
E6 and GST-E7. Patient 10 demonstrated a response to TA-CIN, HPV 16L2, 
GST-E6 and GST-E7;  
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Figures 33 Lymphoproliferation Responses to HPV 16 proteins in 
treatment non-responders. Patient 11 and patient 19 demonstrated 
lymphoproliferative response to TA-CIN, HPV 16-L2, GST-E6 and GST-E7 in 
a non-specific manner with no relation to treatment 
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4.13 NEUTRALISING ANTIBODIES 
 
Pre-existing HPV 16 antibodies correlated with documented HPV 16 exposure 
in twelve out of fifteen women (80%) as shown in table 36. Overall patient pre-
existing neutralizing antibody levels did not differ or alter significantly after 
imiquimod or vaccination in either the responders who cleared VIN on 
histological analysis or in the histological non-responders who failed to clear 
VIN. 
 
Individual patient neutralisation antibody titres are shown in the table 37 and 
no significant stimulation in the titres with treatment was observed, 
irrespective of the patient’s response to the treatment (P=0.2 in the 
responders and P=0.5 in the non-responders). 
 
Trend in the neutralisation antibody titres with treatment is compared with the 
magnitude of the SI on lymphoproliferation assays to HPV 16 proteins and the 
negative control TA-GW and the positive control PHA is shown in the table 38. 
Again, no stimulation with treatment was observed in contrast to the 
responses seen to HPV 16 proteins on the lymphoproliferation assay. 
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 HPV positivity          NA titres 
 0, 10, 20, 52 wk 0 10 20 
1 - - + + 6400 6400 6400 
2 + + ++ 0 200 200 
3 - -  - - 100 200 200 
4 + + + - 3200 800 800 
11 + + + + 12800 12800 12800 
19 + + + + nt nt nt 
22 + + + + 200 400 400 
     
5 + - - - nt nt nt 
8 + + - + 100 200 6400 
9 + - ne + 12800 3200 3200 
10 + + - + 400 1600 1600 
13 - - - - 100 0 0 
14 - - - - 1600 1600 1600 
15 - - + + 0 0 200 
16 + + + + 1600 1600 1600 
17 + - - - nt nt nt 
18 + - + - 400 200 200 
21 + - + + nt nt nt 
23 + - - - 800 1600 1600 
 
Table 36 Relation between HPV positivity and the neutralisation antibody 
titres  - correlation between pre-existing antibodies and HPV positivity was 
seen in twelve women. NA-neutralisation antibody; nt – not tested; + HPV 
positive; - HPV negative; ne – not evaluable 
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HPV 16 Neutralization Assay
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Table 37 Neutralization Assay Titres for individual patients at wk0 (pre treatment), wk10 (post imiquimod) and wk 20 (post 
vaccination) No significant difference in the titres was evident with treatment and no significant difference in the titres was obvious 
between treatment responders and non-responders. 
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                                                                     NEUTRALISING ANTIBODIES TABLE 
Pt                    NA         TA-CIN             E6              E7              L2          TAGW              PHA 
 0 10 20 0 10 20 0 10 20 0 10 20 0 10 20 0 10 20 0 10 20 
1 6400 6400 6400 7.2 5.7 25.0 1.8 1.0 2.4 1.8 1.3 2.6 nt nt nt 1.1 1.4 2.1 11.2 17.9 7.5 
2 0 200 200 1.0 1.2 2.5 0.6 0.3 1.3 0.7 0.7 0.9 nt nt nt 1 1.2 2.1 9.7 16.0 16.9 
3 100 200 200 7.0 7.2 2.2 0.9 1.7 1.3 1.5 1.0 1.3 nt nt nt 3.4 1.2 1.6 6.1 10.5 4.6 
4 3200 800 800 1.9 2.0 5.5 3.1 1.9 11.3 1.7 2.5 3.2 2.0 2.0 9.4 1.8 1.6 3.6 5.1 40.4 20.2 
11 12800 12800  12800 5.1 1.6 1.1 7.1 7.6 5.0 3.0 4.0 3.6 3.2 3.7 3.0 1.0 2.2 1.2 16.6 10.1 2.3 
19 nt nt nt 7.4 2.2 3.6 7.6 2.0 3.0 3.2 0.7 1.6 17.0 2.0 9.0 16.0 8.0 7.5 8.7 4.8 14.2 
21 200 400 400 6.3 1.1 1.2 7.4 2.6 11.0 2.4 0.8 1.4 3.3 1.6 4.7 4.2 1.2 2.1 12.6 10.6 98.7 
                      
5 nt nt nt 4.4 6.3 9.4 5.1 11.8 11.9 4.3 9.0 14.1 2.8 6.4 5.2 1.8 2.1 4.2 4.4 32.6 22.3 
8 100 200 6400 2.9 4.7 32.9 0.6 1.3 8.3 0.8 1.2 5.7 0.7 6.2 14.7 0.5 0.9 1.5 12.1 90.0 35.0 
9 12800 3200 3200 0.9 nt 11.0 1.3 nt 9.1 0.8 nt 3.7 1.6 nt 7.5 2.0 nt 2.5 6.6   19.0 
10 400 1600 1600 26.6 18.5 84.2 6.6 5.7 16.3 6.2 6.0 20.4 3.0 8.2 21.0 10.8 7.3 21.4 23.3 33.7 6.7 
13 100 0 0 3.0 3.1 3.8 1.1 0.8 0.9 0.8 0.3 0.6 0.8 0.7 0.8 0.6 1.5 1.9 7.8 10.1 2.6 
14 1600 1600 1600 10.9 10.0 31.6 5.1 5.1 3.0 4.4 7.3 3.9 1.6 2.1 2.1 nt nt nt 62.9 88.9 83.4 
15 0 0 200 3.5 6.4 10.9 1.9 5.4 5.5 1.1 3.1 4.7 2.0 5.0 3.0 1.2 5.3 3.6 22.9 21.6 4.0 
16 1600 1600 1600 3.3 8.4 15.6 3.4 7.7 10.4 0.7 3.6 2.0 2.9 7.8 7.6 1.1 4.2 5.2 33.6 10.3 8.2 
17 nt nt nt 5.6 4.0 11.6 6.7 9.2 11.2 1.3 5.0 5.1 3.1 5.7 7.9 2.3 3.5 1.6 11.2 2.9 18.3 
18 400 200 200 2.5 1.4 5.4 2.8 3.9 7.1 1.3 1.2 1.6 2.8 1.7 2.9 3.6 1.1 1.4 13.6 6.1 23.7 
20 nt nt nt 27.8 1.3 13.8 27.2 3.5 9.7 13.8 1.1 3.7 17.0 2.0 9.0 1.9 0.5 1.1 19.3 2.9 8.2 
23 800 1600 1600 6.0 1.0 17.4 5.6 1.3 11.4 5.9 1.1 13.1 1.0 1.3 3.7 2.3 3.5 4.5 12.0 6.5 105.2 
Table 38 Comparison of neutralising antibody titres with proliferative responses to HPV 16 proteins, negative control and 
positive control in treatment responder and non-responder patients – this table shows the levels of response observed for 
each of the patients at different time-points from the neutralising antibody assay and the lymphoproliferation assays. In contrast to 
treatment linked lymphoproliferation response to HPV 16 proteins (TA-CIN, E6, E7, L2) in the treatment responders, no similar 
trend was observed with the positive control (PHA), negative control (TA-GW) or for the neutralising antibodies (NA). 
Nt – not tested; Pt – patients 1,2,3,4,11,19, 21 – treatment non-responders; patients – 5,8,9,10,13,14,15,16,17,18, 20, 23 – 
treatment responders 
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4.14 RESULTS OF EXTENDED CLINICAL FOLLOW-UP 
 
All the trial participants were followed up for an average of fifteen months past 
the primary endpoint of week 52.  Extended follow-up of these women showed 
that 84% of women who previously achieved a greater than 50% reduction in 
the size of their lesions continued to stay in remission as shown in figure 34. 
Unfortunately, biopsy of any index lesion after week 52 was not performed 
unless clinically indicated. Overall, one woman developed microinvasive 
disease on two occasions, two women developed new lesions during the 
study period and one woman developed recurrence on two occasions six 
months following the primary end-point of week 52. Four women underwent 
additional treatment for symptom control.  
 
  
4.14.1 NEW LESIONS DETECTED PRIOR TO STUDY COMPLETION 
 
Two women (IT10, IT20) aged 27 and 22, smokers and HPV 16 positive in the 
biopsy, developed new lesions that were clearly absent at recruitment 
between weeks 26 and 52 of the study period. Both the women made clinical 
and histological response to the study treatment.  
 
4.14.2 FURTHER TREATMENT AFTER TRIAL COMPLETION 
 
Patients 2,4 and 19, who did not demonstrate clinical or histological response 
during the study period, underwent laser treatment for symptom control. 
Patient 11 who made a partial clinical response and no histological response 
underwent laser treatment for completion of treatment.  
 
4.14.3 DISEASE RECURRENCE AT FOLLOW-UP 
 
Patient 17, forty-three years of age, non-smoker, who made a complete 
clinical and histological response to treatment, developed recurrences on two 
occasions six months following the study primary end-point.    
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4.14.4 DISEASE PROGRESSION 
 
Patient 9, at week 30 complained of a non-healing symptomatic raw area on 
the vulva, which was the site of her previous punch biopsy. A diagnostic 
punch biopsy was taken, which confirmed a completely y excised focus of 
early stromal invasion. Following the study primary end-point, this woman 
developed a recurrent malignancy, which was treated by surgical excision.   
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Figure 34 Reduction in Lesion Size at follow-up. Reduction in lesion size 
by 100%, >50% but less than 100% and <50% at baseline (Wk0), post-
imiquimod (Wk10), post-vaccination (Wk20), primary end-point (Wk52) and 
follow-up (62 wk after primary end-point) in the group (n=19). 
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5. DISCUSSION 
5.1 MANAGEMENT OF VIN 
 
Management of VIN is led by two main aims: symptom resolution and cancer 
prevention. Increasing incidence, especially in younger women [Akerman et 
al., 2007b], compounded by the characteristic features of distressing 
symptoms, persistent disease and recurrence following treatment  begs for an 
irrefutable need to discover conservative management options for VIN. The 
existing treatment modalities such as surgery where the lesion is physically 
removed and laser ablation, often effective for short term can both be 
effective, however, do not address the issue of underlying HPV infection and 
are also limited by significant procedure related morbidity, psychosexual 
morbidity, high rates of incomplete treatment in turn resulting in high rates of 
recurrence [Likes et al., 2007;Shylasree et al., 2008].  
 
HPV suppresses the expression of several proinflammatory proteins that are 
crucial in clearing infection and activating the cytotoxic T lymphocytes 
involved in killing virus-infected cells. Despite HPV’s ability to inhibit host 
defences, a successful immune response to genital HPV infections is 
established in most cases as demonstrated by a certain proportion of HPV 
related intraepithelial neoplasia that undergo immune-mediated regression. As 
immunosuppression has been shown to be a risk factor for increased 
incidence and progression of HPV associated lower genital tract neoplasias 
[Bouwes Bavinck and Berkhout, 1997;Palefsky and Holly, 2003], there is a 
significant role for the development of immunotherapeutic modalities as 
treatment options for HPV associated intraepithelial neoplasia. The aim of 
immunotherapy is to enhance the natural immune response against HPV and 
to induce an immune environment that stimulates immature tolerising dendritic 
cells to become activated dendritic cells in combination with enhanced 
cytotoxic T lymphocyte responses against HPV proteins, thereby providing a 
superior approach to treating established HPV infection.  
 
Majority of the non-surgical treatments for VIN such as topical 5-FU, cidofovir, 
IFN  have resulted in variable outcomes with response rates varying from 
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40% to 67% [Sillman et al., 1985;Tristram and Fiander, 2005]. Although the 
results from these small studies appear promising, the efficacy cannot be 
determined until large, preferably placebo controlled studies are conducted. At 
the time of imiquimod / PDT trial conducted in this unit [Winters et al., 2008] 
and when the current imiquimod / TA-CIN trial was envisaged, the only data 
available for imiquimod in the management of VIN was that from case-reports 
and small observational studies demonstrating some response to treatment 
(table 1). Since, two randomised trials of imiquimod alone treatment for VIN 
have been published quoting response rates of 60 to 90% [Mathiesen et al., 
2007;van Seters et al., 2008b]. Information gained from the solo PDT [Martin-
Hirsch et al., 1998] or therapeutic HPV vaccination trials [Davidson et al., 
2004] also conducted  in this unit led us to believe that a short course of 
imiquimod would encourage non-specific inflammation locally, which in 
addition to having a direct effect on the condition, would also create an 
enhanced immunological milieu for the PDT or TA-CIN treatment to take 
effect. Imiquimod in combination with PDT when used sequentially, the 
observed overall clinical response rate was 60% at week 52 [Winters et al., 
2008]. As the majority of women with VIN have long-standing disease 
intractable to numerous previous treatments, in this study it was felt 
unreasonable to subject these women to placebo treatment. The study design 
was therefore prospective (uncontrolled) and observational. The objective of 
this study was thus to develop an effective treatment option for VIN, with the 
novel combination of the two relatively new modalities of treatment, imiquimod 
to induce non-specific inflammation and therapeutic HPV vaccination (TA-
CIN) to induce HPV specific immunity. The emphasis was on accomplishment 
of sustainable and durable treatment response.  
 
Although in the evaluation of response to treatment, an array of responses 
such as lesion size, histological grade of VIN, symptoms, and presence or 
absence of HPV-16 DNA was studied, resolution of VIN on histology was 
considered to be the gold standard against which the intralesional and 
systemic immune responses were compared. Histological diagnosis is 
objective, reproducible with a high sensitivity and specificity in contrast to 
clinical assessment. 
 232
5.2 STUDY COMPLETION 
 
Twenty women were recruited and nineteen women completed the study. The 
mean age of the trial participants was forty-five at recruitment, with more than 
two-thirds going through a recurrent phase of VIN, with average disease 
duration of seven years. The cohort was also heavily pre-treated for VIN with 
more than two-thirds having undergone previous treatment(s) unsuccessfully. 
80% of women gave a history of smoking cigarettes and 65% were actively 
smoking during the study period. No significant change in the smoking habits 
was noticed during the study period, despite education regarding the strong 
association between smoking and the risk of acquiring high-risk HPV 
infections [Madsen et al., 2008] and encouragement to quit. It has therefore 
not been possible to ascertain the effect of smoking on clinical response or 
disease recurrence at follow-up. Although women with a history of 
immunosuppression were excluded from the study, the diagnosis of 
immunosuppression was only established by taking a detailed medical history 
but not by any extra blood tests other than the routine FBC and serum 
biochemistry. One participant aged 22 years was withdrawn early in the 
imiquimod treatment phase of the trial for having developed a new lesion of 
VIN with a focus of micro-invasive carcinoma. This woman was subsequently 
(twelve months later) diagnosed with myelodysplastic syndrome, a 
haematological and immunological condition resulting in bone marrow failure. 
In retrospect, background immunosuppressive environment, which was not 
picked up on the routine blood tests, could have contributed to her very 
‘unstable’ vulva.  
 
5.3 CLINICAL RESULTS 
 
5.3.1 TOLERABILITY OF IMIQUIMOD TREATMENT 
 
In considering the imiquimod treatment, tolerability is a significant issue since 
the majority of women experience local and systemic side effects lasting for 
the duration of imiquimod treatment, which may impact on daily activities. In 
fact, in one of the first studies of imiquimod for VIN by Todd et al, it was 
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observed that the side effects with imiquimod treatment limited the frequency 
of application and that only twelve out of twenty women tolerated the regime 
that was intended with no dose reductions or treatment breaks [Todd et al., 
2002]. Since, tolerance to imiquimod treatment has been a recurring theme in 
all the published studies of imiquimod for VIN (table 1). 
 
Majority of the recent studies of imiquimod for VIN [Le et al., 2007;Mathiesen 
et al., 2007;van Seters et al., 2008b] recommend  two or three applications 
per week for sixteen weeks, the strategy adopted from studies of  imiquimod 
treatment for genital warts [Beutner and Ferenczy, 1997;Edwards et al., 
1998]. In this study, women were advised to use imiquimod cream for only 
eight weeks, a significantly shorter duration, furthermore in a dose escalating 
fashion. Numerous supportive measures were in place and women were 
strongly encouraged from all fronts (study investigators, nurses, and general 
practitioners) to improve compliance to imiquimod treatment in this study. 
Completing the prescribed course of imiquimod however was a difficult task 
for the group as a whole. In this study, with significant hand holding, 84% of 
the participants applied imiquimod cream for the suggested eight weeks, with 
the all the participants reporting either moderate or severe degree of side 
effects. Also, in the imiquimod / PDT study, 20% of women reported 
intolerance to imiquimod treatment and discontinued the treatment [Winters et 
al., 2008]. Interestingly, when the response to imiquimod treatment was 
evaluated two weeks after completing the scheduled eight-week course of the 
imiquimod treatment, 74% of women in this study showed a clinical response 
and 32% demonstrated histological response in contrast to 50 % clinical 
response and 25% histological response in the imiquimod/PDT study[Winters 
et al., 2008]. The enhanced response in this study compared to the latter 
study is more than likely to be due to improved treatment compliance, as all 
the variables in both these studies were otherwise common and comparable. 
Two other recent studies by van Seters et al and Mathiesen et al of solo 
imiquimod treatment for VIN also reported intolerance to topical imiquimod 
treatment in 15% and 23% of cases respectively [Mathiesen et al., 2007;van 
Seters et al., 2008b].  
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Topical imiquimod treatment is expected to cause inflammation at the site of 
application and it has also been suggested that the degree of local 
inflammation matches the subsequent clinical response in most cases [Le et 
al., 2007;van Seters et al., 2008b]. The degree of local inflammation and the 
subsequent clinical response corresponded in most cases. Providing an 
obvious inflammatory response is evident in fact it might not even be 
necessary to strictly apply imiquimod cream as often as three times a week. 
This belief led to allowance of treatment free periods of no more than few 
days at a time to allow side effects to subside and thereby improve 
compliance to treatment.  
 
5.3.2 TOLERABILITY OF TA-CIN 
 
TA-CIN was well tolerated by all the study participants in this study, similar to 
the other previous TA-CIN vaccination studies [Davidson et al., 2004;de Jong 
et al., 2002;Karanam et al., 2009;Smyth et al., 2004].  
 
Overall, our treatment regimen was feasible but as expected, was associated 
with considerable imiquimod induced discomfort necessitating breaks in 
treatment. Women with refractory VIN are, however, highly motivated to 
comply with the treatment protocol, and in the event, 85% persevered with 
treatment and finished the full course of imiquimod. 
 
 
5.4 CLINICAL, HISTOLOGICAL, SYMPTOM & HPV RESPONSE TO 
TREATMENT 
 
This study demonstrated that topical imiquimod followed by TA-CIN 
vaccination resulted in a 50% or more reduction in the overall size of the 
lesions (clinical response) in the majority of the participants from week 10 
onwards. In fact, by week 10, clinical response was detected in 74% of 
women, in who the response was sustained and improved to some extent to 
84% and 79% on successive assessments at weeks 20, 52 and to 84% at 
follow-up. Majority of the participants were diagnosed with multifocal disease 
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at recruitment and no significant difference in the response rates was 
observed between the unifocal and the multifocal disease groups. It is 
believed that the local immunologic up regulation with imiquimod treatment is 
not just restricted to the area in direct contact with the cream but is 
widespread into the adjacent skin as well [Todd et al., 2002]. 
 
Other studies of imiquimod for VIN report varying response rates to imiquimod 
treatment (table 1) and differences in the treatment schedule, treatment 
duration and the demographics of the study participants makes it difficult to 
draw direct comparisons. Mathiesen et al in a randomised double-blinded 
study of imiquimod for VIN in twenty-one women who received active 
treatment with imiquimod for sixteen weeks observed clinical response in 
more than 90% of women who received the active treatment in comparison to 
none, who received placebo treatment [Mathiesen et al., 2007]. Le T et al in 
their study of imiquimod for VIN in thirty-three patients observed a 77% 
response rate by the intention to treat principle [Le et al., 2007]. van Seters et 
al in their randomised study of imiquimod for VIN scheduled twenty-six women 
to receive topical imiquimod treatment, twice weekly for sixteen weeks. This 
trial is an advance over the previous studies in the randomised trial design 
and reduction in the approved frequency of dosage to twice weekly 
applications. The primary study outcome was a reduction of more than 25% in 
the lesion size at week 20, which was in effect observed in 81% in the 
imiquimod arm and none in the placebo arm [van Seters et al., 2008b]. 
Response rates of such degree are clinically relevant and imiquimod 
treatment although not well tolerated is feasible. Our study differs from the 
above-mentioned studies by advocating imiquimod treatment for only eight 
weeks in contrast to the sixteen-week regime. Side effects with imiquimod 
treatment build up with time and appear to be most bothersome from week 4 
onwards. In the solo imiquimod study by Le et al the need for dose reductions 
and treatment breaks in fact was most desperate at about week 9 (median) 
[Le et al., 2007]. In our study, in spite of halving the imiquimod treatment 
duration from the routine sixteen weeks to eight weeks, the response to 
treatment observed in this trial is comparable to other solo imiquimod studies, 
making a proposition for reducing the duration of imiquimod treatment for VIN. 
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The TA-CIN component of the study treatment has previously been tested as 
either the prime vaccine or in the form of a boost vaccine following priming 
with TA-HPV vaccine [Davidson et al., 2004;Fiander et al., 2006;Smyth et al., 
2004] with minimal improvement in the clinical response rates. Davidson et al. 
in their study of ten women with high-grade VIN who received three booster 
vaccinations with TA-CIN observed objective clinical response in two women 
[Davidson et al., 2004]. Fiander et al in their prime boost vaccination trial with 
TA-CIN for ano-genital intraepithelial neoplasia followed by a booster with TA-
HPV noted one complete and five partial clinical responses out of twenty-nine 
women [Fiander et al., 2006]. Overall, in the vaccination trials with TA-HPV 
and TA-CIN, the clinical response rates appeared to be around 20%.  
 
In our study, with the sequential combination regime, it is difficult to distinguish 
the contribution of the individual components of the treatment regimen. The 
contribution of the different treatment components could be additive or 
synergistic. Although some of the response noted at week 52 was evident 
from week 10 (post-imiquimod) onwards, response enhanced with time. 
 
In addition to the clinical response, histological response (clearance of VIN 
on histology at week 52, primary end-point) enhanced steadily with time from 
21% immediately following imiquimod treatment at week 10, to 58% at week 
20 and 63% at week 52. Histological diagnosis is however considered to be 
the gold standard, because it is objective, reliable, and reproducible. In 
contrast to the clinical response that was immediately evident following 
imiquimod treatment, attainment of histological response was slow in 
comparison. It is however reasonable to argue that an immunologically 
challenged chronic condition which takes time to establish will equally take 
time to regress, explaining the continuing response noted long after treatment 
completion. 
 
Histological responses were persistently lower than the combined clinical 
response rates (complete and partial) but higher than complete clinical 
response rates. This observation is worthy of note. In one case histological 
diagnosis of VIN1/2 was in disagreement with a clinical diagnosis of complete 
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clinical response. In some other cases, histological diagnosis confirmed 
absence of VIN within the biopsy, when in fact; partial clinical response was 
diagnosed on vulvoscopy. Discrepancy in the clinical and histological 
response rates could be due to the difficulty in the accurate assessment of the 
extent of the true lesion. Imiquimod treatment can result in a background of 
inflammation and pigmentation, confounding the true assessment of any 
lesion and thus emphasises the need for histological definition of VIN. One 
other likely reason for the discrepancy between clinical and histologic 
response rates is the possibility of the biopsy not been representative of the 
true clinical lesion, although every effort was made to overcome this risk.  
 
The histologic response rates in this study compare well with other similar 
studies. In the other studies as well, the trend of clinical response rates 
subjugating the histologic response rates continued. In the imiquimod/PDT 
study, 25% showed evidence of complete histologic regression at both weeks 
10 and 20 and 35% at week 52 compared to histologic response rates of 32%, 
58% and 63% in this study at weeks 10, 20 and 52 [Winters et al., 2008]. In 
the other solo imiquimod studies for VIN, where imiquimod was used for 
sixteen weeks, Mathisien et al reported outstanding histologic response rates, 
81% complete histologic regression to no VIN and 10% partial regression from 
VIN2/3 to VIN1 in twenty-one women who had a biopsy taken two months 
after completion of imiquimod treatment [Mathiesen et al., 2007]. Le et al 
stated that a histologic response was seen in 64% of women and biopsies in 
this study were taken soon after completion of imiquimod treatment [Le et al., 
2007]. van Seters et al quoted 69% histologic regression from biopsies taken 
2 months after treatment completion [van Seters et al., 2008b]. The 
histological response rate of 63% noted in the current study was based on 
histopathology of the biopsy taken at week 52 emphasising the longevity of 
response achieved with imiquimod and TA-CIN treatment.  
 
Achievement of clinical and histological response is an important element to 
any successful treatment fro VIN; however, the drive to undergo treatment, for 
many women diagnosed with VIN is to achieve symptom control. In a recent 
small prospective study, eight women with newly diagnosed VIN consented to 
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be observed at six monthly intervals for a two-year period rather than undergo 
any active treatment. Surgery would be on offer only to exclude disease 
progression or for uncontrollable symptoms. Nevertheless, six out of eight 
volunteers required immediate surgical treatment and of the remaining two 
who were been carefully observed for evidence of any malignancy, one 
required surgical treatment before the study completion period. Majority of the 
treatments were carried out for symptom control, clearly demonstrating that 
wait and watch policy is not particularly feasible for women with VIN as the 
majority appear to require treatment for symptom control [McFadden et al., 
2009]. 
 
In the current study, 79% reported moderate or severe symptoms at 
recruitment compared to 58% at week 10, 26% at week 20 and 21% at week 
52. Akin to clinical and histologic response, majority of the symptom 
response (regression of symptoms from moderate or severe category to none 
or mild category) was achieved by week 20. Of the four women who continued 
to experience symptoms of moderate or severe intensity at week 52, three 
women were non-responders to the trial treatment. Strangely, one woman, 
who in spite of making a clinical and histological response to treatment did not 
recover from the severe symptoms, was subsequently at follow-up diagnosed 
with a new lesion of VIN. It is plausible that symptoms precede the clinical 
manifestation of lesions.  
 
Impressive symptom response rates were detected in other similar studies. In 
the imiquimod/PDT study, at recruitment 70% of the women declared 
moderate or severe symptoms in comparison to 25% at week 52 [Winters et 
al., 2008]. In the current and the imiquimod/PDT studies, symptom 
improvement was not necessarily associated with clinical or histological 
response. This could be due to the local effect of imiquimod or PDT on 
perineal sensory nerve fibres. A similar phenomenon was seen in the solo 
vaccination trials, where in, a higher degree of symptom response was 
evident compared to histological response [Baldwin et al., 2003;Davidson et 
al., 2003a], which is more difficult to explain. One could argue that symptom 
response could be due to placebo effect and this cannot be clarified when the 
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study is not randomised and placebo controlled. van Seters et al in their 
double-blind placebo controlled randomised study of imiquimod for VIN 
described a significant reduction in pain and pruritus both at week 20 and at 
twelve months in the treated group when compared to the placebo group [van 
Seters et al., 2008b]. Improvement in symptomatology for this group of 
women is an important outcome, and it cannot be easily explained other than 
as a response to treatment. 
 
Unexpectedly, three out of nineteen women observed an improvement in their 
general skin condition and also acne remission, possibly due to the pro-
inflammatory properties of imiquimod treatment. This overall improvement on 
the general condition of skin has thus far not been mentioned in the literature. 
 
A weak HPV response (clearance of HPV 16 from the biopsy site in 
somebody who was previously positive for HPV 16) of 43% at week 10, 33% 
at week 20 and 40% at week 52 in this study in comparison with other 
variables such as clinical, histologic or symptom response is disappointing as 
this might be a prelude to persistent or recurrent disease. Three women who 
were negative for HPV 16 from the biopsy site did demonstrate a pre-
treatment systemic immune response to HPV16. Such systemic antibody 
response in the absence of HPV16 on biopsy probably reflects latency of the 
virus rather than paucity of the HPV detection methodology, as this was the 
case in only a minority. At week 52, concomitant loss of HPV16 from the 
biopsy site was noted in five out of six histological responders and one out of 
six histological non-responders. Similarly, in the imiquimod/PDT study, 53% 
were HPV16 negative at week 10 compared to 16% at recruitment. Fourteen 
women were HPV typed at week 52, eight of who were HPV negative [Winters 
et al., 2008]. Although this did not reach statistical significance in either of the 
studies, a trend towards loss of HPV and clinical response was evident.  
 
van Seters et al in the randomised imiquimod study for VIN reported just 
about 50% HPV clearance rate. 96% were HPV positive at recruitment 
compared to 42% and 92% HPV positivity in the imiquimod and placebo 
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treatment groups, four weeks after completing imiquimod treatment, 
respectively.  
 
Wieland et al stated that imiquimod treatment for AIN lead to significant 
reduction in the levels of high-risk HPV DNA loads and also to a fall in the 
number of HPV types at the end of therapy [Wieland et al., 2006]. Kreuter et al 
conducted a follow-up study of these patients and observed that high-risk 
HPV-DNA loads continued to remain at low-levels at the end of the follow-up 
period (average 30.3months) and high-risk HPV-DNA loads continued to be 
significantly lower than pre-treatment levels [Kreuter et al., 2008]. These 
findings are not substantiated by any other studies of imiquimod for VIN. 
 
Smyth et al in the TA-HPV vaccination study demonstrated a reduction in viral 
load after vaccination in twelve out of eighteen women with one women 
showing complete viral clearance who also happened to make a complete 
clinical response. This group of women who demonstrated a reduction in the 
viral load included six of eight women who made a clinical response [Smyth et 
al., 2004]. Although local HPV clearance with imiquimod or therapeutic HPV 
vaccination has not reached statistical significance in most of the studies for 
VIN, correlation with clinical response is apparent. 
 
5.5 IMMUNOLOGICAL RESPONSES TO TREATMENT 
 
5.5.1 LOCAL IMMUNOLOGICAL RESPONSES 
 
In this study, following imiquimod and TA-CIN treatment, enhancement in the 
local infiltration of helper, cytotoxic and regulatory T lymphocytes was obvious 
in the majority. Upon stratification of the group into treatment responders and 
non-responders, the rise in helper and cytotoxic T lymphocytes was significant 
only in the responder group. Conversely, the rise in regulatory T lymphocytes 
was significant only in the non-responder group. It therefore appears that in 
some women with high-grade VIN, despite stimulation of an immune rich local 
environment, the activity of T regulatory cells appears to be dominant, 
suppressing the T helper 1 defence responses, subsequently resulting in 
failure to elicit a response to treatment.   
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Earlier studies suggested that the inability to reject a tumour by the host may 
be due to insufficient generation of tumour specific helper T-cells [Greenberg, 
1991]. It has also been suggested that when aiming to target pre-invasive 
disease with immunotherapy, helper T-cell response should be an important 
consideration [Steele et al., 2005]. Similar to the findings in this study, 
imiquimod treatment resulted in significant increase in cytotoxic T 
lymphocytes in the imiquimod/PDT study and another randomised study of 
imiquimod for VIN [van Seters et al., 2008a;Winters et al., 2008]. Imiquimod 
treatment has been shown to polarise the immune responses towards T 
helper 1 pattern by Smyth et al. who reported an increased local cytotoxic T 
lymphocyte activity when imiquimod was used in patients with anal cell 
carcinoma [Smith et al., 2004]. Studies of naturally regressing genital warts 
and HPV infections have shown a T-helper 1 or cell-mediated immune 
response to be necessary and effective in the spontaneous regression of 
these viral conditions [Coleman et al., 1994;Sheu et al., 2001].  
 
Gul et al have postulated that an increase in the cytotoxic/helper (CD8/CD4) 
T-cell density could re-establish local immune control which is lost or 
suppressed as VIN progresses [Gul et al., 2004]. Likewise, in this study, we 
noted a significant rise in CD8:CD4 ratio post treatment, at week 10 and 20, 
only in the responder group. The increase in helper and cytotoxic T 
lymphocyte density evident post treatment at week 20, but significant only in 
the responder group, may well be a useful prognostic biomarker. 
 
5.5.2 INTRALESIONAL T REGULATORY LYMPHOCYTES 
 
Of the many factors that play a role in dictating the final outcome of any 
treatment, one such factor that may impact negatively on the immune system 
is the T-regulatory lymphocyte activity. There is compelling evidence to show 
that cancers and pre-invasive cancers induce or recruit T regulatory cells to 
inhibit the immune system [Knutson et al., 2007]. Studies on CIN and cervical 
cancer have shown a large number of T-regulatory cells in HPV derived 
lesions suggesting their pivotal role in counteracting the host immune 
 242
response [Loddenkemper et al., 2009]. In cancer patients, an increased 
number of T-regulatory cells have been shown both locally within the tumour 
and also in the blood [Baecher-Allan and Anderson, 2006]. 
 
In this study, pre-treatment, women who subsequently did not make clinical or 
histologic response to treatment were found to be harbouring significantly 
more number of regulatory T lymphocytes when compared with women who 
later, following treatment, demonstrated a clinical and histologic response. 
However, following imiquimod treatment, by week 10, there was no apparent 
difference in the levels of T-regulatory cells between responders and non-
responders, probably due to an increase in the density of both the helper and 
regulatory T lymphocytes. By week 20 however, a marked fall in the density of 
T-regulatory cells was apparent in the responder group and in sharp contrast, 
a remarkable spike in the infiltration of regulatory T lymphocytes in the non-
responder group was obvious. Basically in treatment non-responders, there 
appears to be a higher intralesional density of T regulatory lymphocytes pre 
and post treatment. Although Foxp3 expressing T regulatory lymphocytes and 
their inhibitory role in the immune system has previously been described in 
studies of CIN [Kobayashi et al., 2004] and cervical cancer [Fattorossi et al., 
2004], they were first studied in the context of VIN in the imiquimod/PDT 
study, in which treatment non-responders were found to harbour significantly 
higher number of T regulatory lymphocytes [Winters et al., 2008] and these 
findings were later confirmed in other imiquimod studies for VIN [van Seters et 
al., 2008a]. 
 
These observations reflect the balance of useful CD4 and CD8 effector T 
lymphocytes against T regulatory activity and the clinical impact of the 
resulting immune control. Thus, increasing the CD8/CD4 T lymphocyte 
density may be able to re-establish local immune control which is lost or 
suppressed in chronic VIN [Gul et al., 2004], where the T regulatory cells 
dominate the local immunological milieu and can continue to suppress the 
HPV antigen-specific cytotoxic T lymphocyte response facilitating persistent 
VIN [Kobayashi et al., 2004;Stanley, 2008a]. 
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5.6 SYSTEMIC IMMUNOLOGICAL RESULTS 
 
Therapeutic HPV vaccines are designed to generate cell-mediated immunity 
against HPV infected cells that express the early viral proteins E6, E7 which 
act as oncogenes and also tumour specific antigens. The TA-CIN vaccination 
component of the protocol was aimed at expanding E6 and E7 specific T 
lymphocyte effectors with the possibility that immediately following topical 
imiquimod treatment, their entry, and activity in the VIN lesions would not be 
limited by local immunosuppressive factors. 
 
5.6.1 PERIPHERAL CHANGES IN HELPER AND CYTOTOXIC T 
LYMPHOCYTES 
 
Studies have shown that HPV specific T lymphocyte responses are weak or 
lacking in patients with VIN [Baldwin et al., 2003;Davidson et al., 2003a;Smyth 
et al., 2004;Van Poelgeest et al., 2005]. Kenter et al in the long-peptide 
vaccination study for VIN noted a strong and significant correlation between 
post-treatment complete regression of the lesions and a high number of HPV 
specific CD4+ T lymphocytes producing large amounts of IFN [Kenter et al., 
2009]. A definite direct link between enriched helper and cytotoxic T 
lymphocyte environment, both local and systemic, and treatment response 
thus exists. 
 
5.6.2 PRE-EXISTING PROLIFERATION RESPONSE TO TA-CIN 
 
Sixteen out of nineteen women in this study revealed pre-existing proliferative 
response to TA-CIN (fusion protein of HPV16 E6, E7, and L2). Of these 
sixteen women, fourteen women were HPV16 positive from the biopsy site 
and three women who were HPV 16 negative from the biopsy site 
demonstrated a pre-existing immune response to HPV 16. Carter et al. 
studied five hundred and eighty eight young women with incidental HPV 
infection women and demonstrated that seroconversion for HPV-16 infections 
occurred most frequently between six and twelve months after DNA detection 
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but the levels eventually diminish. Some women with persistent HPV DNA 
however, were found to never seroconvert [Carter et al., 2000]. Negative 
serology thus does not rule out previous infection or the possibility of the 
subject possessing HPV specific memory T lymphocytes.  
 
A significant correlation between the presence of circulating, pre-existing 
HPV-16 specific, interferon-gamma-producing T lymphocytes and regression 
of HPV-16-positive lesions was suggested by Van Poelgeest et al in their 
study of imiquimod for VIN and Winters et al in the imiquimod/PDT study for 
VIN [Van Poelgeest et al., 2005;Winters et al., 2008]. In this study, a trend 
towards higher pre-existing responses to HPV16 early antigens in the lesion 
responder group was noted, which was significantly stimulated by the TA-CIN 
vaccination. By contrast, the lesion non-responders showed little pre-existing 
response and this was not boosted by the TA-CIN vaccine.   
 
5.6.3 PROLIFERATION ASSAY RESPONSES TO HPV 16 
 
It has long been predicted that therapeutic HPV vaccination might overcome 
the inertia of the immune system in patients with VIN, in whom the levels of 
IFN- producing virus specific CD4+ and CD8+ T lymphocytes directed 
against HPV16 E6 and E7 proteins are not detectable or present in low 
numbers [Baldwin et al., 2003;Davidson et al., 2003a;Smyth et al., 2004;Van 
Poelgeest et al., 2005]. 
 
In this study lymphoproliferation assay showed striking and significant 
lymphoproliferative response, but only in the in the histological responder 
group to the TA-CIN and the individual HPV 16 E6, E7and L2 proteins, only 
following vaccination at week 20 but not before treatment or after imiquimod 
treatment at week 10 are suggestive of a vaccine response. The outstanding 
lymphoproliferative response in the responder group is probably related to TA-
CIN vaccine induced HPV-16 specific T lymphocyte responses. It was 
however not possible to elicit similar lymphoproliferative responses for the 
respective peptides of the individual E6 and E7 oncoproteins in any of the 
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patients, irrespective of their treatment response category. This probably 
reflects an error in the methodology of preparing the peptides rather than a 
lack of lymphoproliferative response.  Interestingly, although the response to 
HPV 16 proteins was not significant following imiquimod treatment in any of 
the patient categories, the magnitude of response between treatment 
responders and treatment non-responders was significant for some of the 
HPV 16 proteins. This further enhanced to significant proportion in the 
majority of the treatment responders. Either this is an indication that 
imiquimod treatment in fact does stimulate HPV 16 specific systemic immune 
response or that imiquimod stimulate a generalised immune activation which 
when reaches higher levels results in disease clearance.  
 
The results of the lymphoproliferative assays clearly show that in addition to 
the differences in systemic immune response to HPV 16 between responder 
and non-responder patients, the proliferative responses vary for individual 
HPV 16 oncoproteins. In this study, the TA-CIN protein, followed by E6, HPV 
16 L2 and the E7 oncoproteins, stimulated the best lymphoproliferative 
response. In other TA-CIN vaccination studies, vaccine induced T-cell 
responses were predominantly directed against HPV-16 oncoprotein E6. 
Smyth et al in the heterologous prime-boost HPV oncogene vaccination study 
similar to this study detected strong proliferative TA-CIN specific responses in 
patients with AGIN, and a higher level of proliferation was noted with respect 
to E6 oncoprotein than with the E7 oncoprotein [Smyth et al., 2004]. This 
finding is consistent with the association between spontaneous clearance of 
HPV infection and detection of CD8+T lymphocyte responses that are specific 
for HPV-16 oncoprotein E6 [Nakagawa et al., 1997;Nakagawa et al., 
2000;Nimako et al., 1997].  
 
In the imiquimod/PDT study, lymphoproliferative responses to TA-CIN were 
not significant post imiquimod or PDT treatment, clearly demonstrating that 
neither imiquimod not PDT treatment are able to induce HPV specific 
immunity or delivery HPV specific immunotherapy [Winters et al., 2008]. 
Davidson et al in the TA-CIN booster vaccination study for VIN observed that 
the measured HPV specific immune responses were detectable only 
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transiently in the peripheral blood, peaking at four to eight weeks, and falling 
to their baseline levels by twelve weeks post vaccination [Davidson et al., 
2004]. In a recent HPV-16 E6E7 ISCOMATRIX therapeutic HPV vaccine 
study for men with AIN, vaccination treatment induced strong and durable 
antibody and IFN- levels that fell to pre-vaccination levels by week 24 
[Anderson et al., 2009]. In contrast, the synthetic long-peptide vaccination 
study in women with VIN demonstrated strong HPV 16 specific proliferative 
responses which were detectable even one to two years after the last 
vaccination in twelve out of fourteen patients [Kenter et al., 2009].  
 
In this study, systemic immune responses were checked only once, two 
weeks following the triple dose vaccination schedule. Although sustained 
clinical responses at follow-up are indicative of disease control, it would be 
interesting to find out if the systemic immune responses were sustained after 
completion of treatment. 
 
Thus following the imiquimod and TA-CIN vaccination schedule, while the 
responder patients have higher pre-existing responses to HPV 16 early 
antigens which can be significantly stimulated by vaccination, the non-
responders show little pre existing responses which are not stimulated by the 
vaccine.   
 
5.6.4 NEUTRALISATION ASSAYS 
 
There is an element of sequence homology between related HPV types, 
which prompted us to perform neutralisation antibody assays to detect cross-
reactive responses to other genital HPV infections. Studies on HPV VLP 
vaccines have shown that although cross- reactive cross-neutralising 
antibodies are generated, the titres are reduced compared to vaccine-specific 
types and the titres required to protect against non-vaccine types are not yet 
known [Pastrana et al., 2004].  
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HPV 16 L2 protein has the ability to elicit cross-neutralizing antibodies and 
thereby its role as a component of the TA-CIN vaccine. In this study, however, 
the overall patient pre-existing neutralizing antibody levels did not differ or 
alter significantly after imiquimod or TA-CIN vaccination treatment in either the 
responders or non-responders. 
 
 
5.7 EXTENDED CLINICAL FOLLOW-UP 
 
Most VIN studies report short-term response rates when in fact the objective 
should be to achieve long-term disease control. For this study, data is 
available for an extended average follow-up period of fifteen-month following 
the completion of the study (week 52), when a continuing however enhanced 
clinical response (50% or more reduction in the size of the lesions) rate of 
84% was detected implying continuing control of VIN. Response achieved due 
to any other treatment offered outside the trial did not influence the clinical 
response outcome. The quoted clinical response rate of 84% was purely 
owing to the trial treatment. Unfortunately, biopsy of any index lesion after 
week 52 was not performed unless clinically indicated. Containment of 
response for such length of time in a heavily pre-treated cohort of women with 
long standing disease is remarkable.  
 
Similarly, in the imiquimod/PDT study, follow-up data is available for an 
average of thirty-four months past week 52, the study primary end-point, when 
65% clinical response rate was observed (60% at week 52) [Winters et al., 
2008]. van Seters et al in the randomised imiquimod study for VIN have 
follow-up data for an average of twelve months following study completion at 
week20. They found at follow-up all the complete and partial clinical 
responders to be in remission [van Seters et al., 2008a]. Similarly, Kenter et 
al. in the long-peptide vaccine study of VIN described a 25% complete clinical 
and histological response and 35% partial clinical response three months 
following the vaccination schedule. Nevertheless, at twelve months of follow-
up, the complete and partial clinical response rates increased spontaneously 
 248
to 47 and 32% respectively. At twenty-four month follow-up period, the 
complete clinical response was still maintained [Kenter et al., 2009].  
 
This phenomenon of demonstrating a late response was also recognised in 
other vaccination studies and in fact Palefsky et al who studied therapeutic 
HPV vaccination in men with AIN upon detecting some late response to 
treatment suggested that longer follow-up in future vaccination studies is 
necessary to capture the late responses [Palefsky and Holly, 2003]. For 
chronic lesions that have been present for many years, the precise time 
course of immune responses relevant to HPV lesion clearance are completely 
unknown. There is thus no particular reason why immunotherapy would 
achieve its full potential at the arbitrary study endpoint, which explains the 
response observed long after completion of treatment. 
 
In this study, treatment response in some women has been dramatic. For e.g. 
Patient 5 (40 yr of age at recruitment, VIN for twenty years, seven previous 
surgical excisions) and patient 23 (35yr of age at recruitment, multifocal VIN 
for ten years, ten previous surgical treatments) who have both achieved 
complete clinical and histological response to treatment and continue to be in 
remission, three years following the completion of the trial (unpublished data) 
illustrate particularly impactful treatment responses achieved by week 52 in 
this study but which have been maintained for a further three years thus far. In 
both these cases, intralesional pre-treatment T regulatory cell density was 
low, with no enhancement following treatment contrary to increased density of 
CD4 and CD8 T lymphocytes. Both these women also demonstrated a pre-
existing proliferative response to HPV16 with significant increase in 
proliferation response post-vaccination.  
 
5.8 RECURRENCES, MALIGNANT POTENTIAL AND NEW DISEASE 
In this study, during the average fifteen-month follow-up period, one (IT17) out 
of nineteen participants, who demonstrated a complete clinical response and 
histological response to treatment, developed recurrence on two occasions. In 
the imiquimod/PDT study, one out of twenty participants, a clinical responder 
developed recurrence at week 52 [Winters et al., 2008]. Le et al observed 
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20.5% rate of disease recurrence following imiquimod alone treatment for VIN 
at a median follow-up of sixteen months, and found all the women with 
recurrence disease to be heavy smokers [Le et al., 2007]. van Seters et al 
reported enlargement of lesions in two out of twelve women, during the twelve 
month follow-up period following imiquimod treatment [van Seters et al., 
2008a]. In a retrospective study by Hillemanns et al of ninety-three women 
with VIN who were followed up for a mean period of fifty-three months, the 
relapse rate was 40% following laser treatment, 48% following photodynamic 
therapy, 42% following local excision and 0% following vulvectomy 
[Hillemanns et al., 2006]. The recurrence rate observed in this trial (5%) and 
the other above-mentioned imiquimod trials appears to be lower than that 
following surgery or laser treatment. The possible rationale for recurrence of 
VIN could be compromised immune status, reinfection with new HPV types, 
reactivation of indolent HPV infection resulting in increase in HPV DNA loads 
or unknown host genomic mutations.  
 
Two women (IT9, IT22) in this study developed microinvasive disease. Patient 
22 was withdrawn from the trial early at week 4, whereas patient 9 developed 
microinvasive disease ten weeks following completion of the vaccination 
treatment and a recurrent malignant lesion at follow-up. No malignancy was 
reported in any of the participants in the imiquimod / PDT study [Winters et al., 
2008]. In the peptide vaccination study of VIN by Kenter et al out of twenty 
participants, by twenty-four months of follow-up, one woman developed 
microinvasive carcinoma and two had developed invasive carcinoma [Kenter 
et al., 2009]. van seters et al in the imiquimod alone study for VIN reported 6% 
progression to invasive disease within twelve months of follow-up. This 
included two out of twenty-six women who received placebo treatment and 
one out of twenty-six women who received imiquimod treatment. The 
available long-term follow up data suggests that only 9% of untreated VIN 
patients will progress to invasive disease [van Seters et al., 2008b]. This 
assumption has however retrospectively been questioned by Jones et al who 
reported invasive disease in seven out of eight untreated VIN cases in their 
observation study of hundred and thirteen women diagnosed with VIN [Jones 
and Rowan, 1994]. Reassuringly, with long term follow up data available for 
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some of the investigational studies of VIN; the rate of disease progression 
appears to match that following the conventional treatment modalities.  
 
New lesions were detected in two out of nineteen women (IT10, IT22) in this 
study, within the trial period, between weeks 26 and 52. Both the women were 
active smokers, aged 22, and 29 at recruitment. Both of them underwent laser 
treatment to the new lesions, and both coincidentally developed recurrences 
within six months of the initial laser treatment. On the contrary, four women in 
this study who failed to achieve a complete clinical response and underwent 
surgical excision or laser ablation for treatment completion did not develop 
disease recurrence at follow-up. A similar observable fact occurred following 
imiquimod /PDT treatment, when seven women who failed to achieve a 
complete treatment response, underwent additional surgical excision or laser 
ablation following imiquimod / PDT treatment for completion of treatment. No 
recurrences were noted during follow-up in this group either [Winters et al., 
2008]. Similarly Le et al in the solo imiquimod study noted a trend towards 
lower local recurrence rate in women who required further surgical ablative 
treatment after finishing the study protocol compared to historical surgically 
treated patients [Le et al., 2007]. This observation has major clinical 
implications for women, who make partial clinical response to immunotherapy, 
as minimal surgery or laser ablation following immunotherapy might offer them 
a durable, recurrence free completion treatment. In fact, following an 
incomplete response to immunotherapy, surgery or laser could be offered as 
maintenance therapy.  
 
In the treatment of VIN, duration of efficacy and prevention of recurrences is 
crucial. Immunotherapeutic approaches with imiquimod alone or in 
combination with PDT or therapeutic HPV vaccination appear promising. In 
those women who fail to achieve a complete response, immunotherapy 
followed by completion surgical excision and laser ablation appears more 
promising. 
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5.9 CONVENTIONAL AND EMERGING TREATMENT OPTIONS FOR 
VIN 
 
Surgery and LASER remain the mainstay of treatment for VIN. Surgical 
excision can be both diagnostic and therapeutic. This is an advantage over 
laser or medical management options, as undetected foci of minimally 
invasive squamous cell carcinoma of the vulva remain a concern with VIN. 
The aim of surgical treatment is to obtain disease free biopsy margins. 
Removal of multi-focal disease might involve surgical removal of more or less 
the entire external female genitalia. It is equally important to avoid over 
treatment and permanent disfigurement of the vulva. With large surgical 
excisions, rotational skin flap procedures are increasingly used. For VIN 
involving the clitoris, organ sparing surgery in the form of skinning vulvectomy 
has also been described [Terlou et al., 2009]. In a recent study where hundred 
and eighty six patients with VIN were treated surgically with wide local 
excision or skinning vulvectomy, presence of multifocal VIN was the only 
factor that was associated with significant incomplete resection in univariate 
and multivariate analyses [Polterauer et al., 2009]. Fong et al reported only 
3% patient dissatisfaction rate following surgical treatment for VIN [Fong et al., 
2008]. Modified minimally invasive surgical procedures may have an important 
role in the surgical management of VIN. Surgery although remains the most 
common treatment modality for VIN, thus far, no systematic reviews or 
randomised controlled trials comparing surgery with other modalities of 
treatment are available.  
 
LASER is one suitable treatment option for multiple superficial lesions in the 
non-hair bearing areas on the vulva. With LASER ablation, histological 
assessment of the entire specimen is not possible and unrecognised 
malignancy may be missed. There is always a risk of under diagnosis and 
missing occult cancers with pre-treatment diagnostic biopsies. A study of 
hundred and eighty six VIN patients who were treated with excisional surgery 
or skinning vulvectomy underwent preoperative biopsy to assess the accuracy 
by evaluating the rates of correct diagnosis, under diagnosis and occult 
cancer. A significant number of pre-operative biopsies were under diagnosed 
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when compared with excisional biopsies [Polterauer et al., 2009]. The risk of 
persistent or recurrent disease is also higher with ablative treatment 
compared with surgical treatment.  Laser treatment is however, cosmetically 
more appealing.  
 
TLR 7 and 8 agonists are emerging treatment options for VIN, now that 
TLR7 and 8 expressions on human langerhan cells (LC) are well established. 
TLR 7and 8 agonists in the form of imiquimod and resiquimod, non-HPV 
specific immunomodulators, are expected to activate LC exposed to HPV16 
leading to the induction of an HPV16 specific cell mediated immune response. 
Fahey et al compared the levels of immune responses induced on HPV16 
infected cervical cells when treated with imiquimod (TLR7 agonist), 3 M-002 
(TLR8 agonist), and resiquimod (TLR8/7 agonist). Unexpectedly, both 
phenotypic and functional hallmarks of immune activation were not observed 
when treated with imiquimod (TLR7 agonist) in contrast to treatment with 
resiquimod (TLR8/7 agonist) or 3M-002(TLR8 agonist), where high up-
regulation of surface activation markers, proinflammatory cytokines and 
initiation of HPV-16-specific CD8+ T lymphocyte response was evident. This 
data strongly suggests that other Toll-like receptor agonists like resiquimod or 
TLR8 agonist (3M-002) might indeed be superior to imiquimod as therapeutic 
strategies for HPV infections and HPV induced intraepithelial neoplasia like 
VIN [Fahey et al., 2009].  
 
For any therapy to be effective against multifocal disease, it must also 
promote strong systemic antitumour response in addition to local response 
that targets satellite foci in addition to the primary tumour. Preliminary data 
has shown that antitumour responses delivered locally by the TLR7 agonists 
such as imiquimod can be harnessed systemically by combining the treatment 
with surrogates for CD4 T lymphocyte help for treating the multifocal disease 
or satellite lesions or even distal tumour. Pending the results of these initial 
studies, modified TLR agonistic therapy might play a major role in the 
management of multifocal VIN [Broomfield et al., 2009].  
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Association of pre-existing proliferative response to HPV16 proteins and 
treatment response with imiquimod has been detected in the imiquimod 
studies of VIN indicating that the success of imiquimod treatment may depend 
on IFN producing HPV-16-specific T lymphocytes. If this is true, imiquimod 
might in fact be more beneficial if used after therapeutic HPV vaccination and 
generate better clinical response rates. Additionally, there might be a role for 
using imiquimod as a maintenance therapy after surgery or laser to prevent or 
reduce recurrences [Van Poelgeest et al., 2005]. 
 
The advantage of PDT is short healing time and preservation of vulval 
anatomy with minimal disfigurement. In a recent study, photodynamic therapy 
using a novel bio adhesive type patch loaded with 5-ALA designed to conform 
to the unevenness of vulval skin were tested. Among twenty-three women 
who in total underwent forty-nine cycles of PDT treatment, 52% reported a 
symptom response and 38% demonstrated histologic response [Zawislak et 
al., 2009]. Although imiquimod in combination with PDT has been used 
successfully in the management of other dermatological conditions [Devirgiliis 
et al., 2008], to our knowledge, only one study thus far in the management of 
VIN has been reported where sequential imiquimod and photodynamic 
therapy was shown to result in better clinical response rates than solo PDT 
trials and the results were comparable to those achieved with sixteen weeks 
of imiquimod alone treatment. Additionally, longevity of treatment response 
was established in this trial [Winters et al., 2008]. The imiquimod / PDT 
treatment is now being offered to a selected group of women diagnosed with 
multifocal disease not suitable for surgical excision or as a maintenance 
therapy following incomplete treatment with surgical excision or laser ablation.  
 
Prophylactic HPV vaccination of young women against HPV 16 and 18 is 
anticipated to lessen the incidence of HPV16, 18 related diseases and with 
time may significantly avoid about 40% of vulval carcinoma and 75% of VIN 
[De Vuyst et al., 2009]. On the other hand, it is felt that the potential effect of 
HPV vaccines on vulval and vaginal cancers is unlikely to be as high as for 
cervical cancers [Smith et al., 2009]. Although therapeutic HPV vaccines 
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offer an alternative HPV specific immunotherapy, designing a successful 
therapeutic vaccine can be challenging due to the high genetic variability of 
the virus.  
 
A number of candidate therapeutic vaccines have been developed and in the 
trials thus far have proven to be effective, safe, tolerable, and feasible but with 
limited immunogenicity. DNA vaccines are a potential alternative and patients 
vaccinated with TA-CIN alone have shown to develop weak HPV neutralising 
antibodies and E6/E7 specific T lymphocyte responses [Karanam et al., 2009]. 
Welters et al proposed subversion of the immune system, sub optimal design 
of therapeutic vaccines, intrinsic property of cancer cells and the regulatory 
networks imposed by the growing tumours to be the reasons for the vaccine 
induced T-cell mediated immunotherapy to fail to improve therapeutic results 
[Welters et al., 2008]. Adjuvant enhances the immunity to vaccine and new 
approaches to adjuvanted therapeutic HPV vaccines are in motion. By 
developing a nontransforming HPV16 E7 based vaccine supported by co-
application of the adjuvanted gene containing DNA encoded cytokines and 
chemokines, an enhanced immune response was noted in women with 
cervical cancer [Ohlschlager et al., 2009].  
 
Several other therapeutic HPV vaccines have been generated which have 
generated significant antitumour effects. Combining DNA vaccines with 
immunostimulatory molecules like calreticulin and methylating agents to 
enhance the level of expression of the antigen encoded in the vaccine have 
been shown more promise in controlling HPV associated malignancies. Lu et 
al demonstrate combining CRT/E7 HPV DNA therapeutic vaccination with 5-
aza-2’-deoxycytidine (DCA), a demethylating agent, to be a potential 
promising approach in the management of HPV-associated neoplasia [Lu et 
al., 2009]. Another therapeutic HPV vaccine ISCOMARIX in randomised, 
placebo controlled, dose escalation study in HIV positive men for HPV 
infected AIN to determine the safety, tolerability, and immunogenicity revealed 
no dose limiting toxicities or serious adverse events. 96% of vaccine 
recipients had at least a four-fold increase in HPV16 antibody from pre-
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vaccination levels and 71% had at least three-fold increase in interferon-
gamma responses to E6E7 peptides [Anderson et al., 2009].  
 
On the other hand, DNA vaccines are shown to be less immunogenic than 
protein or peptide based vaccines. Vaccination with long peptides appears to 
induce potent T lymphocyte response and this has been ascribed to the 
efficiency of the vaccine to target dendritic cells, absence of antigenic 
competition from viral vectors and the high-doses of the specific antigen 
[Melief and van der Burg, 2008]. The study by Kenter et al is the first 
therapeutic HPV vaccination (mix of long-peptides from the HPV-16 viral 
oncoproteins E6 and E7 in incomplete Freund’s adjuvant) study in women 
with VIN with remarkable results of 79% overall clinical response rate 
comprising 47% complete clinical response at twelve months, which was also 
maintained at twenty four months of follow-up. Complete clinical responders 
mounted a significantly stronger HPV-16 specific immunity and also showed 
significantly stronger IFN associated proliferative CD4+ T lymphocyte 
responses and a broad response of CD8+ interferon- gamma T lymphocyte in 
comparison to women who failed to demonstrate a treatment response 
[Kenter et al., 2009].  
 
With the intention of improving the DNA vaccine efficiency, routes and 
methods of vaccine administration were also studied. Conventional 
intramuscular route of administration of a DNA vaccine was compared with 
electropolation mediated intramuscular delivery and epidermal gene gun-
mediated particle delivery in an HPV-16 E7 expressing tumour line. The 
highest number of E7 specific CD8+ cytotoxic T lymphocytes were generated 
following vaccination via the electropolation mediated intramuscular delivery. 
Again, improvised route of vaccine delivery shows promise in human trials of 
DNA vaccines [Best et al., 2009]. 
 
Another challenge to the immunogenicity of vaccines that are specific for 
tumour antigens is the immune-suppressive effect of the tumour 
microenvironment and the modulation of T cell expansion by the inhibitory 
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cells such as the regulatory T cells. The down regulation of T regulatory 
cells might therefore be beneficial for the enhancement of the vaccine 
immunogenicity. In fact, T regulatory depletion prior to imiquimod or 
therapeutic vaccination, particularly in women with higher proportion of 
systemic or intralesional T regulatory cells pre-treatment might enhance the 
stimulation and efficacy of the useful HPV specific effector T cells. Thus, 
blocking T regulatory function could improve human cancer immunotherapy.  
 
Indeed, there have been several attempts to improve the outcome of different 
vaccination regimes either by down regulating or blocking T regulatory cells 
with anti-CD25 antibodies. An anti-CD25 monoclonal antibody (PC61) when 
used prior to DNA vaccination which encoded E7 linked to heat shocked 
protein 70 (Hsp70), generated higher levels of E7-specific CD8+ T 
lymphocytes compared to the control antibody, leading to significantly 
improved therapeutic and long-term protective anti-tumour effects against E7- 
expressing tumour, TC-1[Chuang et al., 2009]. Elimination of T-regulatory 
cells using the recombinant IL-2 diphtheria toxin conjugate (DAB (389) IL-2) 
was studied in patients with metastatic renal cell carcinoma. In this study, 
DAB (389) IL-2-mediated elimination of T regulatory cells followed by 
vaccination with RNA-transfected dendritic cells significantly improved the 
stimulation of tumour-specific T lymphocyte responses in renal cell carcinoma 
patients when compared with vaccination alone, suggesting a role for T-
regulatory cell depletion strategy to achieve potent anti-tumour immunity 
[Dannull et al., 2005]. 
 
 
5.10 FUTURE DIRECTION & CONCLUSIONS 
 
VIN is not a common condition and research into this condition is limited. A 
number of treatment options have shown promise, but are yet to be proven in 
randomised controlled studies. Although progression of VIN to invasive 
carcinoma is assumed to be low, around 9% over a number of years of 
disease positivity, spontaneous regression is rare, around 1% [van Seters et 
al., 2005]. The rate of progression to invasive carcinoma has however been 
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questioned as majority of women diagnosed with VIN undergo treatment for 
one reason or the other [Jones et al., 2005;McFadden et al., 2009]. 
 
The treatment choice for VIN is based on several factors, including precise 
location of the lesions, the number of lesions and patient’s past medical, 
surgical and treatment history. Although the existing treatments of surgery and 
laser are effective, there are certain limitations, such as residual disease, high 
rates of recurrence and treatment associated physical and psychological 
morbidity causing an impact on the quality of life. Imiquimod and PDT, 
although associated with poor patient tolerability, show promise. Strategies 
are in place to improve the efficacy of therapeutic HPV vaccination. 
Monotherapies are unlikely to be effective and the way forward must be the 
combination of treatment that eliminate the lesion and prevent recurrences. 
Combination treatments of imiquimod with PDT or therapeutic HPV 
vaccination appear to deliver a greater response to treatment than PDT or 
vaccination alone.   
 
Saraiya et al emphasised the need for reporting and submitting high quality 
data on VIN3 and more research on the data in the cancer registers to enable 
further assessment and understanding of the impact of HPV on the disease 
[Saraiya et al., 2008]. Not many studies thus far have recruited large enough 
subject numbers or long-enough follow-up to enable robust conclusions. For 
conditions like VIN, which pose therapeutic challenges, there is a strong case 
for establishing research colloboratives. A multi-centre trial has the 
advantages of quicker recruitment of the necessary number of patients with 
quality assurance related to recruitment, treatment, and follow-up. Consensus 
needs to be reached on how outcomes are measured and response is 
defined. The acceptance of results will then be higher as the patient sample of 
multicentre trials is supposed to be a true representation.  
 
Developing means of pre-treatment identification of potential responders from 
the likely non-responders using local or systemic biomarkers will be valuable. 
Although immune correlates for a clinical response need determining, pre-
treatment assessment of dominant immunological cell types in the lesion 
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microenvironment and levels of systemic cytokines might help differentiate 
potential responders from non-responders. Identifying assays that are likely to 
correspond to measurable immunological variables after treatment, like 
proliferation assays, interferon gamma ELISPOT assay, interferon-gamma 
ELISA assays [Baldwin et al., 2003;Davidson et al., 2003a;Kenter et al., 
2009;Smyth et al., 2004;Van Poelgeest et al., 2005;Winters et al., 2008] are  
also likely to aid in the assessment of response to treatment. Smyth et al have 
suggested that pre-selection of VIN patients with HLA class-I positive lesions 
displaying intralesional T lymphocyte infiltration before vaccination may 
identify a group of subjects who benefit the most from vaccination [Smyth et 
al., 2004]. 
 
At face value looking at pre-existing immunity to HPV could provide the basis 
for selecting patients most likely to benefit from imiquimod with or without 
vaccination regimes [Van Poelgeest et al., 2005;Winters et al., 2008]. 
Advance in the methods of identifying HPV specific T lymphocyte responses 
could enable monitoring of immune T lymphocytes in HPV associated clinical 
lesions, and of the correlation of tissue and systemic immune responses to 
HPV proteins. Equally, studying the lesion microenvironment some time after 
treatment can provide further insight into how the immunotherapy might work 
for persistent infection. 
 
When attempting more than one form of medical treatment for VIN in a 
sequential fashion, similar to the current and previous studies from this unit 
[Winters et al., 2008], a crossover clinical trial design is more likely to 
distinguish the individual treatment contributions. In crossover trial design, 
there is a possibility of carrying over the benefit either through persistent 
action of the treatment or simply by an enhancement in immune response 
induced by the initial treatment. This might however make the second 
treatment in the crossover trial seem more effective than the first.  
 
The response rates noted in this trial support further innovative trial, in 
particular the addition of an adjuvant to therapeutic HPV vaccines or a 
different type of HPV therapeutic vaccine. 
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A multicentre randomised study comparing upfront surgical excision/laser 
ablation with solo toll-like receptor agonists or therapeutic HPV vaccination, 
and a combination of toll-like receptors with therapeutic HPV vaccination in a 
crossover study design will be valuable to understand the individual role of 
each of these modalities and also to detect any synergistic action when 
administered sequentially. 
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ABSTRACT 
BACKGROUND: Vulval intraepithelial neoplasia (VIN) is a premalignant condition, 
which is frequently associated with type HPV16 infection, and multifocal disease has 
high rates of surgical treatment failure.  
METHODS: We report a phase II clinical trial of the topical immunomodulator, 
imiquimod for 8 weeks, followed by 3 doses (weeks 10,14,18) of therapeutic HPV 
vaccination (TA-CIN, fusion protein HPV16 E6E7L2) in nineteen women with 
VIN2/3.  Histology and HPV testing of biopsies were performed at week 0, 10, 20 and 
52. Intralesional infiltration of T cell subsets and lymphocyte proliferation for HPV 
systemic immune responses were also assessed.  
RESULTS: Lesion response (complete regression of VIN on histology) was seen in 
32% (6/19) of women at week 10, increasing to 58% (11/19) at week 20 and 
63%(12/19) at week 52. At this time 36% (5/14) of lesions showed HPV 16 clearance 
and 79% (15/19) of women were symptom free. At week 20, after treatment with 
imiquimod and vaccination, there was significantly increased local infiltration of CD8 
and CD4 T cells in lesion responders; by contrast non-responders (persistent VIN by 
histology) showed an increased density of T regulatory cells. Following vaccination, 
only lesion responders had significantly increased lympho-proliferation to the HPV 
vaccine antigens.  
CONCLUSION: The therapeutic impact of treatment depends on the differential 
immune response of responders and non-responders impacting both locally and 
systemically.  
 
Keywords: Vulval intraepithelial neoplasia (VIN), imiquimod, therapeutic HPV 
vaccination, T regulatory cells 
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INTRODUCTION 
Vulval intraepithelial neoplasia (VIN) is increasing in incidence, more so in younger 
women. A greater than 400% increase in the incidence of VIN has been reported 
between 1973 to 2000, whilst the corresponding increase in incidence of vulval cancer 
has only been 20% [Akerman et al., 2007a]. This probably reflects an increasing 
incidence of human papillomavirus (HPV) high risk type genital tract infections, as 
the most common type of VIN (usual or undifferentiated) shows over 85% HPV 
positivity, with type16 DNA being detected in 75% of high grade VIN [De Vuyst et 
al., 2009]. HPV infection of the lower genital tract and its outcome are influenced by 
host immune response, virulence of the HPV, smoking and immunosuppression 
[Sherman et al., 2008;Duong and Flowers, 2007]. Successful adaptive immune 
responses which lead to clearance of genital HPV infection are believed to be 
mediated by local T cell mediated immunity [Farhat et al., 2009]. The virus life cycle 
and several immune evasion mechanisms limit virus-specific immunity facilitating 
persistent infection and the increased risk of carcinogenesis [Stern, 2005]. Indeed, it 
has been shown that patients with persistent HPV infection have depleted T cell 
responses against the viral early gene products E2 and E6 measured systemically [de 
Jong et al., 2004;Farhat et al., 2009]. In addition, T regulatory cells are negative 
regulators of otherwise useful anti-tumour T cell immunity and locally increased 
levels have been implicated in the persistence of both cervical and vulval HPV 
associated lesions [van der Burg et al., 2007;Winters et al., 2008]. 
 
VIN, which is often multifocal and extensive has been traditionally treated by surgical 
excision or laser ablation but such therapies are associated with high rates of 
recurrence [Jones et al., 2005]. Unfortunately, for patients with chronic VIN, younger 
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age and extent of surgery correlate directly with psychological morbidity and poorer 
sexual function [Likes et al., 2007;Shylasree et al., 2008;Thuesen et al., 1992]. The 
natural history of VIN can be viewed as a struggle between HPV driven premalignant 
intraepithelial neoplasia and immune control mechanisms.  With time, the selection of 
cells with a malignant phenotype and ability to escape the immune control can result 
in vulval cancer.  Non-surgical management of VIN with anti-viral and anti-neoplastic 
agents has had limited success [Tristram and Fiander, 2005;Vilmer et al., 1998] but a 
rational  therapeutic strategy for chronic VIN could aim to alter the local immune 
response in favour of persistently HPV infected cells.  
 
Several different clinical studies influencing local and/or systemic immunity to HPV 
using imiquimod, photodynamic therapy (PDT) and therapeutic HPV vaccination in 
the management of VIN have been reported. Imiquimod, an immune response 
modifier acting through a Toll like receptor (TLR), [Schon and Schon, 2007] can 
stimulate local innate immunity (non-specific) with potent anti-tumoral effects but 
also drives an adaptive immune response (e.g.  specific T cell effectors) in secondary 
lymphoid tissues by activating tissue antigen presenting cells.  In a recent randomised 
controlled trial, treatment of VIN with imiquimod twice weekly for 16 weeks resulted 
in a 25% or more lesion size reduction at 20 weeks in 81% of patients compared with 
none in the placebo group [van Seters et al., 2008b]. PDT uses a combination of light 
and photosensitiser drug to damage tumour tissue by modifying cellular functions, 
inducing cell death by necrosis or apoptosis, and encourages inflammation and anti-
tumour immunity [Castano et al., 2006]. Studies using PDT have shown good 
symptom and clinical response in patients with VIN [Fehr et al., 2001;Martin-Hirsch 
et al., 1998;Olejek et al., 2008].  A recent trial of combined treatment with imiquimod 
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followed by PDT [Winters et al., 2008] showed  an overall lesion response rate of 
55% with 30% showing complete lesion resolution at 52 weeks.  In this study, non-
responders showed a significantly higher level of T regulatory cells in the lesions after 
imiquimod treatment [Winters et al., 2008]. Such response rates are clinically 
relevant, and the treatment regimen was feasible for the majority. Non-responders to 
imiquimod seem to be relatively refractory, and this may derive from their 
unfavourable local immune environment, in particular, increased proportions of T 
regulatory cells, limiting the action and development of any HPV T cell immunity. 
Therapeutic HPV vaccines are designed to generate cell-mediated immunity against 
HPV infected cells that express the early viral proteins E6, E7 which act as oncogenes 
and also tumour specific antigens. Clinical trials using either PDT or therapeutic HPV 
vaccination have demonstrated an association between clinical responses and tumour 
infiltrating lymphocytes (TILs) [Abdel-Hady et al., 2001;Davidson et al., 2003a].  
 
Optimal therapeutic immunity results from the interaction of non-specific innate 
immunity and antigen specific adaptive immunity. Stimulation of the local innate 
immunity can have a direct controlling effect on virally infected cells as well as 
attracting local infiltration of TILs [Dermime et al., 2002b]. The challenge is to get 
the most useful balance of helper (CD4) and cytotoxic (CD8) T cell infiltration which 
are associated with positive prognosis and minimize the T regulatory cell infiltration 
which is known to be associated with poor outcome as shown in several studies of 
gynaecological cancer [Kondratiev et al., 2004;Sato et al., 2005;Wolf et al., 
2005b;van der Burg et al., 2007]. The rationale of this study was that an initial local 
imiquimod treatment, in addition to having a direct effect on VIN can also provide an 
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immunological platform for the therapeutic HPV vaccination to achieve an enhanced 
and durable response.  
 
In this phase II trial, we used a combination of imiquimod and vaccination with TA-
CIN which is a subunit vaccine comprising a HPV16 E6E7L2 fusion protein, proven 
safe and immunogenic in previous phase I and II trials [Davidson et al., 2004;de Jong 
et al., 2002;Smyth et al., 2004]. 
 
PATIENTS AND METHODS 
Women aged 18 - 70 years with biopsy proven VIN grades 2 and 3, were recruited 
between March 2006 and May 2007. Exclusion criteria were pregnancy, invasive 
disease, immunosuppression, history of severe allergy and previous HPV vaccination. 
Imiquimod 5% cream was self administered for 8 weeks escalating from one 
application in week 1 to two in week 2 and three applications weeks 3-8.  This was 
followed by three intramuscular doses of TA-CIN (1ml of 128g/ml) at weeks 10, 14 
and 18. The primary objective was to measure treatment impact on VIN by lesion size 
and histology and the secondary objectives were to assess lesion HPV status, 
symptoms, immune responses as well as safety, toxicity, and tolerability. Women 
were reviewed at weeks 0, 10, 14, 18, 20, 26 and 52, the primary end-point. Punch 
biopsies were taken for histology and HPV typing at weeks 0, 10, 20 and 52. 
Heparinised blood (40ml) was obtained for immunological assays at weeks 0, 10 and 
20. 
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Clinical response 
Complete regression of VIN on histopathology of an index lesion(s) was designated 
the lesion response. Histological assessment was performed on formalin-fixed punch 
biopsies. Biopsies were analysed for HPV typing by Reverse Line Blot Assay which 
is able to amplify and detect 37 HPV genotypes [Gravitt et al., 1998]. Safety, 
tolerability and toxicity were assessed clinically, supplemented by FBC and serum 
biochemistry at weeks 0, 10 and 20. A full record of adverse events was kept. Patients 
were advised to maintain a symptom diary in a visual analogue scale form. This was 
reviewed at clinic visits when patient assessment of vulval pain, itch, swelling, 
discharge and/or any other symptoms were graded as none, mild, moderate or severe. 
Regression of symptoms from moderate or severe (interfering with life style) to the 
mild or none (not interfering with life style) categories was considered to be a 
symptom response.   
 
Immunofluorescence 
Local immune responses were quantified by assessing the TIL density on 7m 
sections of the punch biopsy frozen in liquid nitrogen and stored at -80C. TILs from 
five representative fields of image were counted for each section. T regulatory cells 
were identified by double immunofluorescence labelling for FoxP3 and CD4. This 
was performed with mouse IgG2a anti-CD4 (Abcam) concentration 1:100, mouse 
IgG1 anti-FOXP3 (eBioscience), concentration 1:50 and respectively detected using 
goat antimouse IgG2a Alexa Fluor 546 3µl/1000µl and goat antimouse IgG1 Alexa 
Fluor 488 at 3 µl/1000µl  (Invitrogen). CD8 labelling was performed  using rabbit IgG 
anti-CD8 (Abcam) concentration 1:100 and was detected using goat anti rabbit-IgG 
Alexa Fluor 488 at 3 µl/1000µl. Nuclei were stained with DAPI. Five microscopic 
 289
fields were imaged in a step-wise fashion for each cellular phenotype investigated in 
the VIN biopsies. In most cases, this covered almost the whole specimen, as the 
sections were small punch biopsies. The TIL counting was then performed using 
Image J image analysis software version 1.36b (http://rsb.info.nih.gov/ij/), using the 
cell counting feature of the software. An independent observer reviewed a range of 
slides and the counts differed by no more than 5%.  Results were reported as density 
per unit area of CD4, CD8 and double stained FoxP3CD4 cells. 
 
Peripheral immune response 
Peripheral immune response to HPV antigens was assessed by lymphoproliferative 
assays. Peripheral blood mononuclear cells (PBMC) alone or PBMC with 25µg/ml 
recombinant HPV antigens:  HPV16 E6E7L2 protein - TA-CIN (Xenova Research 
Ltd.), HPV16 GST E6, HPV16 GST E7[Smyth et al., 2004], HPV16L2 (full length 
HPV16L2 tagged with 6His at N-terminus), TA-GW (HPV 6 L2E7; Xenova Research 
Ltd.) and 2µg/well PHA were performed as previously described [Winters et al., 
2008]. Responses were measured by tritiated thymidine incorporation following a 5-
day incubation of patient PBMC with the different antigens. Results are presented as 
Stimulation Index (SI) defined as the mean number of counts incorporated by the 
antigen stimulated PBMCs divided by the mean number of counts for PBMCs in 
medium alone. A pre-existing proliferative T cell response was defined as SI ≥ 2. A 
post vaccination proliferative T cell response was defined as a 2-fold increase in the 
SI compared with the pre-vaccination value.   
 
Neutralising antibodies to HPV 16 pseudovirions were tested as by the SEAP pseudo 
virus neutralisation based assay as previously described [Karanam et al., 2009]. 
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Statistical analysis 
Analyses were performed using ‘Stats Direct Statistical Software’. Differences 
between responder and non-responder categories (baseline disease duration; HPV 16 
positivity; smoking; symptom response at week 52 compared to baseline) were 
analysed using Fisher’s exact test. The non-parametric Mann-Whitney U was used to 
test for differences in proliferative and lesion T cell density between groups (lesion 
responders and non-responders). The non-parametric Wilcoxon’s signed ranks test 
was used to analyse differences in the responses within groups at different time-
points. All reported P values are two sided and have not been adjusted for multiple 
comparisons. A P value of  0.05 was considered to indicate statistical significance.  
 
 
 291
RESULTS 
Twenty women consented to the trial.  One woman, found to have early stromal 
invasion on the first study biopsy, was withdrawn from the study and excluded from 
the analysis, which is based on 19 women.  Patient demographics are presented in 
Table 1. The group had a mean age of 46 years with average disease duration of 7 
years (range 1-20 yr). Thirteen patients had been previously treated and seven had at 
least three prior treatments. Only 4/19 (21%) never previously smoked cigarettes.  
 
Tolerability 
The majority of women experienced local inflammation, ulceration, malaise and flu 
like symptoms within the initial few weeks of imiquimod.  Side effects were classed 
as severe in 14 and moderate in 5 women. In order to improve tolerance, treatment-
free intervals of no more than a few days were allowed in order to achieve the total 
dose, but let side effects subside. 16/19 (84%) of women completed the prescribed 
course of imiquimod treatment. Three women noted a marked improvement in facial 
acne with fewer spots and smoother skin in general whilst on imiquimod treatment. 
TA-CIN, administered intramuscularly into the deltoid muscle was well tolerated with 
no side effects or adverse events. 
 
Response Rates 
Table 2 reports the VIN lesion size, histology, HPV status and any patient symptoms 
at baseline (week 0), after imiquimod (week 10), after vaccination (week 20) and at 
52 weeks.   Figure 1a stratifies lesion size reduction at weeks 10, 20 and 52 compared 
to week 0. For example, 74, 85 and 79% of women had a  50% reduction in the size 
of lesion at weeks 10, 20 and 52 respectively. However, patient 8 still had a visible 
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VIN like lesion at week 52 but the comprehensive histological analysis indicated 
resolution of VIN (Table 2).  A background of inflammation and pigmentation can 
confound the true assessment of any lesion and emphasises the need for histological 
definition of VIN. Figure 1b summarizes the lesion response and HPV status as well 
as patient symptom responses with time. Complete regression of VIN on histology 
was 32, 58 and 63% at weeks, 10, 20 and 52 respectively.  At baseline, 15/19 (79%) 
women had moderate to severe symptoms compared with 11/19 (58%) at week 10 
with significant reduction at week 20, 5/19 (26%), sustained at week 52, 4/19 (21%), 
(P=0.01).  At weeks 0, 10, 20 and 52; 14, 8, 9 and 10 of the nineteen women were 
HPV16 positive respectively; 16/19 were HPV 16 positive on at least one occasion. 
Three women were consistently HPV 16 negative but two showed other HPV type 
infection at some point. Of the women who showed lesion responses at week 52, 5/10 
also cleared their HPV 16 infection compared to only 1/6 non-responders; this did not 
reach statistical significance. There were no statistical differences in the lesion 
responder and non-responder groups with respect to disease duration (Table 1) at trial 
entry (P=0.58) or HPV16 detection at baseline (P=0.66). 12 out of 19 women were 
active smokers during the trial period. Current smoking habit was not associated with 
lesion response  (P=0.1). 
 
Extended follow-up of these patients for an average of 15 months beyond the primary 
end point of week 52 showed 84% of patients with a  50% reduction in lesion size 
consistent with continuing control of VIN (Figure 1a). Unfortunately, biopsy of any 
index lesion after week 52 was not performed unless clinically indicated. Overall, one 
patient developed microinvasive disease (patient 7), two had new lesions after week 
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52 (patient 8 and 17), one had a recurrence 6 months after the trial endpoint (patient 
14)  (Table 2). 
 
Systemic immune response to HPV 16 
Pre-existing HPV 16 antibodies correlated with documented HPV 16 exposure in 
12/15 cases. Overall patient pre-existing neutralizing antibody levels did not differ or 
alter significantly after imiquimod or vaccination in either the lesion responders who 
cleared VIN histologically nor the non-responders who failed to clear VIN (data not 
shown).  
 
Lymphoproliferation to HPV antigens was used to analyse patient systemic cellular 
immunity to HPV before and after the imiquimod and vaccination steps in the 
protocol.   Sixteen women (84%) demonstrated pre-existing lymphoproliferative 
response to TA-CIN (SI ≥ 2), of whom 14 were HPV16 positive on vulval biopsy on 
at least one occasion. Of these, 11 were lesion responders and 5 non-responders with 
no significant difference in magnitude of pre-existing response (P=0.4). Following 
vaccination, 10/12 lesion responders compared to 3/7 non-responders showed ≥ 2-fold 
SI change compared with baseline.  Figure 2 shows box- plots of the median and 
quartile lymphoproliferative responses of all the patients as well as stratification into 
lesion responders or non-responders to the different antigens, TA-CIN vaccine 
(HPV16 E6E7L2 fusion protein), its component HPV 16 antigens L2, E6 and E7 as 
GST fusion proteins, TA-GW (HPV 6 L2E7 fusion protein) as a negative control and 
PHA as a positive control for lymphocyte proliferation.  Strong PHA responses were 
demonstrated by all the women with median SIs of 12, 10.6, 16.9 at week 0, 10 and 
20 respectively; these responses were not significantly different after imiquimod or 
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vaccination (P=0.4, 0.2 in the group) or when patients were stratified by lesion 
response (P=0.7, 0.5 in responders and P=0.3, 0.3 in non-responders) (Figure 2a). By 
contrast, a significant increase in proliferation to TA-CIN was seen in the patients 
after vaccination compared to pre-treatment (P=0.01) and this was associated with 
lesion responders (P=0.008) but not the non-responders (P=0.7) (Figure 2b).  Similar 
significant patient proliferative responses to each of the individual HPV16L2, E6 and 
E7 antigens after vaccination were seen (P=0.02, 0.01, 0.02 respectively), with this 
increased proliferation associated with lesion responders (P=0.01,0.03,0.03) and not 
non-responders (P=0.5,0.5,0.2) (Figure 2c, d, e).  Specificity of the HPV 16 responses 
was supported by the absence of any significant increase in patient 
lymphoproliferation post-vaccination to TA-GW (HPV6 L2E7), nor in the responder 
(P=0.4) or non-responder (P=0.9) groups (Figure 2f). No significant increase in 
proliferation to any of the antigens was noted post-imiquimod in any of the patient 
groups. Post-vaccination proliferative response to TA-CIN and its components 
appears to correlate with the clearance of VIN on histology.  
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Tumour infiltrating lymphocytes 
To investigate local immune factors in the vulval biopsies pre-treatment, post- 
imiquimod and vaccination, the densities per unit area of CD4, CD8 and double 
stained FoxP3CD4 (T regulatory) cells were assessed. Imiquimod treatment was 
expected to enhance the local immune infiltration. The data are presented in Figure 3 
as median/scatter plots for all the patients as a group or stratified by lesion response. 
In the group as a whole, significant increases in the number of CD4, CD8 and 
FoxP3CD4 T cells were evident by week 20 compared to baseline (P=0.03, P=0.01, 
P= 0.04 respectively); a significant increase in CD8 density was apparent after 
imiquimod (P=0.04). At week 20, the increased CD4 and CD8 density was 
significantly associated only with the lesion responders (P=0.03; P= 0.03) while 
increased FoxP3CD4 density was associated with the patients who do not show lesion 
response (P=0.05). There were no significant pre-treatment differences in the density 
of CD4 or CD8 T cells in lesion responder and non-responders (P=0.2, P=0.5 
respectively) but intralesional FoxP3CD4 density was significantly higher in non-
responders compared to responders (P=0.05).  By week 20, a significant reduction in 
FoxP3CD4 T cell population density was apparent in lesion responders, which was 
significantly different from non-responder densities (P=0.01).  
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DISCUSSION 
This study was designed on the premise that imiquimod and therapeutic HPV 
vaccination could combine to alter the balance of local immunity through inducing a 
local inflammatory environment and enhancing T cell responses to HPV E6 and E7 
proteins. Immunotherapies that tip the balance of immune equilibrium in favour of the 
host effector response and away from regulatory and viral evasion strategies of the 
HPV may be the key to enhancing the cell mediated immunity required to eradicate 
persistent HPV infection and established disease. This study demonstrated that 
imiquimod followed by vaccination achieved histological clearance of VIN at 52 
weeks in almost 60% of a heavily pre-treated cohort of women with high-grade, long-
standing VIN.  
 
With the proviso that the study size was small, the analyses of lesion associated T 
cells showed that higher pre-existing and post-treatment levels of regulatory T cells 
are associated with a lack of lesion response to treatment. As expected in the group as 
a whole, imiquimod treatment induced T cell infiltration, which was most apparent by 
week 20.  However, the increased CD4 and CD8 T cell density was significant only in 
the lesion responder group while a significantly higher regulatory T cell density was 
only seen in the non-responder group. These observations are consistent with immune 
control and therapeutic impact reflecting the balance of useful CD4 and CD8 directed 
effectors against their control by T regulatory activity. Thus, increasing the CD8/CD4 
T cell density may be able to re-establish local immune control which is lost or 
suppressed in chronic VIN [Gul et al., 2004]. Where the T regulatory cells dominate 
the local immunological milieu they can continue to suppress the HPV antigen-
specific cytotoxic T cell response facilitating persistent VIN [Kobayashi et al., 
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2004;Stanley, 2008b]. T regulatory depletion prior to imiquimod or therapeutic 
vaccination, particularly in women with higher proportion of systemic or intralesional 
T regulatory cells pre-treatment might enhance the stimulation and efficacy of the 
useful HPV specific effector T cells. Indeed, there have been several attempts to 
improve the outcome of different vaccination regimes either by down regulating or 
blocking T regulatory cells with anti-CD25 antibodies [Chuang et al., 2009] or IL-2 
diphtheria toxin conjugates [Dannull et al., 2005].  
 
The TA-CIN vaccination component of the protocol was aimed at expanding E6 and 
E7 specific T effectors with the possibility that post imiquimod their entry and activity 
in the VIN lesions would not be limited by local immunosuppressive factors. 
Lymphoproliferation of PBMC established that all patients were immunocompetent 
and that the vaccination was immunogenic and HPV 16 antigen specific. Importantly, 
these systemic immune responses to HPV 16 antigens were significantly associated 
with lesion responders and not the non-responders. There was no influence on 
immunity to HPV as a result of the imiquimod treatment. However, a trend towards 
higher pre-existing responses to HPV16 early antigens in the lesion responder group 
was noted in this study, which was significantly stimulated by the vaccination. By 
contrast, the lesion non-responders showed little pre-existing response and this was 
not boosted by the vaccine.  Previous studies have noted a significant correlation 
between pre-existing systemic HPV 16 specific T cells and regression of HPV 16 
positive lesions [Van Poelgeest et al., 2005;Winters et al., 2008]. The immune 
response to the HPV vaccine used in this study might have additional impact if 
delivered with an adjuvant which can boost both serological and cellular immune 
responses to its HPV 16 antigens [Karanam et al., 2009].  
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Overall, it appears that the natural history of the VIN in the non-responders is related 
to modulation of both local and systemic immune responses allowing persistence of 
HPV infection. The mechanisms underlying this chronic VIN state are not known but 
might include genetic predisposition involving immune and other parameters 
[Davidson et al., 2003b].  In chronic VIN the sub optimal stimulation of HPV 
immunity probably also leads to anergy of HPV specific T effectors. The precise time 
course of immune responses relevant to HPV lesion clearance are completely 
unknown and there is no a priori reason why it would achieve its full potential at the 
arbitrary study endpoint especially for chronic lesions, which have been present for 
many years. Thus, although some of the histological and symptom response noted at 
week 52 was evident from week 10 (post-imiquimod), response enhanced with time. 
It is reasonable to argue that an immunologically challenged chronic condition which 
takes time to establish will equally take time to regress, explaining the continuing 
response noted long after treatment completion. In this study of a heavily pre-treated 
cohort of women with long standing disease, containment of response for two years is 
worthy of note. Patient 5 (40 yrs, VIN for 20 years, 7 surgical excisions) and patient 
19 (35yrs, multifocal VIN for 10 years, 10 surgical treatments) illustrate particularly 
impactful lesion responses achieved by week 52 in this study but which have been 
maintained for a further two years thus far. In both these cases, intralesional pre-
treatment T regulatory cell density was low, with no enhancement following treatment 
contrary to increased density of CD4 and CD8 cells. A pre-existing proliferative 
response to HPV16 with significant increase in proliferation response post-
vaccination was also demonstrated. It would be beneficial if the likelihood of response 
to treatment could be determined using biomarkers either pre-treatment or in the case 
of combined therapy, following imiquimod, in order to avoid subjecting likely non-
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responders to unnecessary treatment. At face value, pre-treatment assessment of 
dominant immunological cell types in the lesion microenvironment and looking at 
pre-existing immunity to HPV could provide the basis for selecting patients most 
likely to benefit from imiquimod with or without vaccination regimes.  
  
In considering the imiquimod treatment, tolerability is a significant issue since the 
majority of women experience local and systemic side effects lasting for the duration 
of imiquimod treatment, which may impact on daily activities. Overall, our regimen 
was feasible but as expected, was associated with considerable imiquimod induced 
discomfort necessitating breaks in treatment. Women with refractory VIN are, 
however, highly motivated to comply with the treatment protocol, and in the event, 
85% persevered with treatment and finished the full course of imiquimod. In this 
study, the lesion response was 63% at week 52 with 8 weeks of imiquimod followed 
by vaccination, which compares very favourably with  imiquimod alone treatment of 
16 weeks assessing histological regression of VIN as 64% assessed soon after 
treatment as VIN1 or better [Le et al., 2007] , 81% [Mathiesen et al., 2007] and  
69%[van Seters et al., 2008b]  with no VIN at 2 months after  treatment.  
 
A recent study of VIN patients treated by 3 or 4 immunizations at 3 weekly intervals 
with a HPV vaccine composed of long HPV16 E6/E7 peptides in adjuvant 
(Montanide ISA-51, Seppic) showed 60% and 79% lesion size response rate ( 50% 
reduction) at 3 and 12 months of follow-up [Kenter et al., 2009]. As suggested by 
Kenter et al., imiquimod might be more beneficial if used after therapeutic HPV 
vaccination as studies indicate that imiquimod treatment may depend on IFN 
producing HPV specific T cells [Kenter et al., 2009].  
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Following another recently published study of imiquimod followed by photodynamic 
therapy[Winters et al., 2008], continued surveillance for up to 3 years (unpublished 
results) has shown a sustained clinical response rate of 65% at follow-up. This 
treatment is now being offered to women in our unit for whom surgical therapy is not 
suitable. Distinguishing the contribution of the individual components of such 
combination regimes and establishing proof of either additive or synergistic effects 
will require further innovative trials. All the recent studies of immunologically driven 
treatments of VIN provide momentum for further multicentre randomised trials with 
consistency in measurement of outcomes and definitions of response. Comparing 
upfront surgical treatment with imiquimod or other potential more potent Toll-like 
receptor agonists [Fahey et al., 2009] or therapeutic HPV vaccination [Karanam et al., 
2009;Kenter et al., 2009], or a combination of Toll-like receptor agonists with 
therapeutic HPV vaccination in a crossover study design will be valuable.  
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Figure legends 
 
Figure 1a. Reduction in Lesion Size. Reduction in lesion size by 100%, >50% but 
less than 100% and <50% at baseline (Wk0), post-imiquimod (Wk10), post-
vaccination (Wk20), primary end-point (Wk52) and follow-up (62 wk after primary 
end-point) in the group (n=19). 
1b. Lesion and Symptom Responses. Lesion response (complete disappearance of 
VIN on histology), symptom response (regression to mild/none symptoms), absence 
of HPV 16 on biopsy) at baseline (Wk0), post-Imiquimod (Wk10), post-vaccination 
(Wk20) and primary end-point (Wk52) in the group (n=19). 
 
Figure 2. Box-feather plots showing median and quartile lymphoproliferation 
responses. The figures show stimulation indices of proliferation in response to PHA 
(a), TA-CIN (b), HPV-16L2 (c), GST-E6 (d), GST-E7 (e), TA-GW (f) in the whole 
group (n=19), lesion responders (R)(n=12), and lesion nonresponders (NR)(n=7) at 
baseline (Wk0), post-Imiquimod (Wk10), post-vaccination (Wk20).  
P values which are statistically significant for stimulation indices (SI) at Wk20 
compared to Wk0 are shown. The Wilcoxon’s signed ranks test was used to determine 
the significance of within group differences pre and post treatment. P value of  0.05 
was considered significant.  
 
Figure 3. Median/Scatter-dot plot of lesion associated immune cells in the group 
(G), lesion responders (R) and non-responders (NR).   
The figure shows median number (density per unit area) of CD4, CD8 and FoxP3CD4 
cells pre-treatment (0), post-imiquimod (W10) and post-vaccination (W20) in the 
group (G), lesion responders (R) and non-responders (NR). P values for statistically 
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significant difference in the number of cells either at week 10 or week 20 compared to 
week 0 are shown. The Wilcoxon’s signed ranks test was used to determine the 
significance of within group differences pre and post treatment. P value of  0.05 was 
considered significant.  
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Figure 3 
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Table 1. Patient Demographics. M, multifocal; U, unifocal; CIN, cervical intraepithelial neoplasia; Hyst, h/o hysterectomy; Ex, Ex-smoker. 
 
 
   
Pt no: Age (yr) Focality 
 
h/o CIN  Smoking  Prev  
Treatment 
Disease  
duration (yr) 
1 51 M Yes No LASER 
Vulvectomy 
Imiquimod 
4 
2 43 M Yes Yes LASER x 4 9 
3 45 M Yes Ex Excision 3 
4 40 M Yes Yes Excision 10 
5 40 M No Yes Excision x 7 20 
6 65 M No Ex None 4 
7 58 M Yes Yes Excision x 3 
Vulvectomy 
15 
8 27 M Yes Yes None 1 
9 51 M Hyst Ex Diathermy 1 
10 55 U Yes Yes Excision 6 
11 51 U No Yes LASER x 2 16 
12 47 U Yes No None 1 
13 56 M Yes Yes None 2 
14 43 M Hyst No LASER x 2 
Excision x 1 
4 
15 48 U No No None 1 
16 34 M No Yes LASER 
Imiquimod 
3 
17 22 M No Yes None 1 
18 66 M Hyst Yes Excision x 5 
LASER x 4 
16 
19 35 M Yes Yes Excisions x 6 
LASER x 4 
9 
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Table 2. Clinical Responses in VIN patients treated by Imiquimod and TA-CIN. neg, negative; n/e, non evaluable. Pt 7 developed ESI () at 
week 30; Pt 1,2,4, 10 underwent LASER treatment () after trial completion, Pt 14 developed recurrence () 6 months after trial completion and 
underwent LASER and surgery. Pt 8 and 17 developed new lesions () after week 52 treated with LASER. Pt 16 repeated course of imiquimod 
()after trial completion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                      Lesion Size in mm                                                  Histology                                                               HPV type                                                         Symptoms 
Pt no Wk 0 Wk 10 Wk 20 Wk 52 Wk 0 Wk 10 Wk 20 Wk 52 Wk 0 Wk 10 Wk 20 Wk 52 Wk 0 Wk 10 Wk 20 Wk 52 
1 80 35 30 40 VIN1/2/3 VIN1/2/3 VIN2/3 VIN2/3 neg neg 16 16 Mild Moderate Mild Moderate 
2 75 60 70 70 VIN3 VIN1/2/3 VIN2/3 VIN2/3 16 16 16 16 Severe Moderate Moderate Severe 
3 90 65 40 30 VIN2/3 VIN2/3 VIN2/3 VIN1/2 42 neg neg neg Moderate Severe Mild Mild 
4 50 40 30 45 VIN2/3 VIN2/3 VIN2/3 VIN2/3 16 16 16 neg Severe Moderate Mild Mild 
9 >100 25 20 10 VIN3 VIN2/3 VIN2/3 VIN2/3 16 16 16 16 Severe Moderate Mild Mild 
16 45 20 30 40 VIN2/3 VIN2/3 VIN2/3 VIN2/3 16 16 16 16 Severe Severe Severe Severe 
18 30 20 10 20 VIN2/3 VIN2/3 VIN2/3 VIN2/3 16 16 16 16 Mild Mild Mild Mild 
5 60 10 0 0 VIN1/2/3 no VIN no VIN no VIN 16 neg neg neg Mild Moderate None None 
6 65 25 5 0 VIN2/3 no VIN no VIN no VIN 16 16 neg 16,53 Severe Mild None None 
7 100 50 50 0 VIN3 no VIN no VIN no VIN 16,33,84 neg n/e 33 Severe Mild Mild Mild 
8 60 25 25 25 VIN2/3 VIN2/3 VIN2 no VIN 16 16,33,81 n/e 16 Severe Severe Severe Severe 
10 25 10 0 0 VIN2/3 VIN1/2/3 no VIN no VIN neg neg neg neg Severe None None Mild 
11 25 0 0 0 VIN3 no VIN no VIN no VIN neg neg 84 84 Moderate Moderate None None 
12 20 0 0 0 VIN3 VIN1/2 no VIN no VIN neg 33 neg 16,33 Moderate Moderate None None 
13 50 40 20 0 VIN3 VIN1/2 no VIN no VIN 16 16 16 16 None Mild None None 
14 90 15 15 0 VIN2/3 VIN1/2 no VIN no VIN 16 neg neg neg Moderate None Moderate Mild 
15 25 3 0 0 VIN3 no VIN no VIN no VIN 16 neg 16 neg Severe None None None 
17 40 3 4 0 VIN2 VIN1/2 no VIN no VIN 16 neg 16 16 Moderate Moderate Moderate Mild 
19 >100 0 0 0 VIN2/3 no VIN no VIN no VIN 16 neg 6 6 Severe Mild Mild None 
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CD4 T lymphocyte density – in the individual participants expressed as 
density – no: of cells /unit area at weeks 0, 10 and 20.  represents treatment 
non-responders and  represents treatment responders 
 
 Week 0 Week 10 Week 20 
IT1 311 160 75 
IT2 109 81 215 
IT3 17 154 350 
IT4 188 139 76 
IT5 63 74 132 
IT8 121 65 110 
IT9 56 186 310 
IT10 68 45 57 
IT11 104 48 301 
IT13 124 136 215 
IT14 133 83 208 
IT15 192 211 42 
IT16 44 26 26 
IT17 237 107 407 
IT18 37 110 88 
IT19 190 43 367 
IT20 66 76 174 
IT21 82 360 170 
IT23 92 103 116 
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CD8 T lymphocyte density – in the individual participants expressed as 
density – no: of cells /unit area at weeks 0, 10 and 20.  represents treatment 
non-responders and  represents treatment non-responders 
 
 Week 0 Week 10 Week 20 
IT1 38 50 30 
IT2 31 145 152 
IT3 15 79 168 
IT4 134 66 37 
IT5 26 47 23 
IT8 64 105 107 
IT9 34 113 97 
IT10 26 22 48 
IT11 60 61 47 
IT13 74 54 89 
IT14 55 30 104 
IT15 70 170 19 
IT16 8 11 19 
IT17 33 21 143 
IT18 47 100 14 
IT19 97 29 170 
IT20 68 111 133 
IT21 22 301 238 
IT23 32 42 55 
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FoxP3 CD4 density – in the individual participants expressed as density – no: 
of cells /unit area at weeks 0, 10 and 20.  represents treatment non-
responders and  represents treatment responders 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Week 0 Week 10 Week 20 
IT1 37 27 19 
IT2 25 19 95 
IT3 2 31 43 
IT4 18 22 15 
IT5 1 37 5 
IT8 14 8 30 
IT9 6 63 60 
IT10 13 8 1 
IT11 28 6 33 
IT13 2 50 2 
IT14 33 29 39 
IT15 14 27 4 
IT16 1 10 6 
IT17 66 8 90 
IT18 11 39 7 
IT19 35 3 120 
IT20 10 8 15 
IT21 18 173 50 
IT23 36 25 9 
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LYMPHOPROLIFERATIVE RESPONSE TO E6 & E7  PEPTIDES 
No significant lymphoproliferative responses were observed for all the E6 
peptides as shown in the tables below. A significant lymphoproliferative 
response to E7I peptide was demonstrated in the responders at both weeks 
10 and 20, however the significance of the change in response was greater at 
week 20.   
 
LYMPHOPROLIFERATIVE RESPONSE TO E6 I PEPTIDE 
Proliferative Responses to E6I 
Responders Pre-treatment 
Post imiquimod 
(Wk 10) 
Post vaccination 
(Wk 20) 
IT5 2.2 2.5 1.4 
IT8 0.5 1.7 1.5 
IT9 0.8  1.9 
IT10 1.3 1.1 1.3 
IT13 1.0 0.8 1.3 
IT14 0.6 1.0 1.1 
IT15 1.3 1.0 0.8 
IT16 1.1 0.8 0.9 
IT17 0.9 0.8 0.9 
IT18 0.9 0.6 1.0 
IT20 2.0 1.5 1.0 
IT23 2.0 1.0 1.2 
Non-responders    
IT11 1.1 2.5 0.9 
IT19 0.4 0.9 1.4 
IT21 3.0 1.5  
Proliferative Responses to E6 I peptide in the responders and non-
responders at weeks 0, 10, 20 Two fold change in the stimulation index (SI) 
was considered as a response, highlighted in grey 
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Wk 
0 
Wk 
10 
Wk 
20 
Wk 0 vs. Wk 10 
(P, WSR) 
Wk 0 vs. Wk 20 
(P, WSR) 
Group (n=15) 1.1 1.0 1.1 P=0.9 P=0.5 
Responders 
(n=12) 
1.1 0.9 1.0 P=0.9 P=0.8 
Non-Responders 
(n=3) 
1.1 1.5 1.2 P=0.2 P=0.3 
Change in the lymphoproliferative responses to E6I peptide in the group, 
responders, non-responders between weeks 0, 10, 20. No significant 
difference in the magnitude of response (median Stimulation Index SI) was 
observed following vaccination treatment; Wilcoxon signed rank test (WSR) 
 
LYMPHOPROLIFERATIVE RESPONSE TO E6 II PEPTIDE 
Proliferative Responses to E6II 
Responders Pre-treatment 
Post imiquimod 
(Wk 10) 
Post vaccination 
(Wk 20) 
IT5 1.6 1.3 3.6 
IT8 0.6 2.0 1.5 
IT9 1.1  1.6 
IT10 1.3 1.0 1.9 
IT13 2.1 0.5 2.4 
IT14 0.6 1.9 1.5 
IT15 1.0 1.1 1.1 
IT16 1.1 0.9 1.3 
IT17 1.3 1.3 0.9 
IT18 0.9 0.8 1.3 
IT20 2.6 1.7  
IT23 1.8 1.3 1.0 
Non-responders    
IT11 2.0 3.1 1.9 
IT19 0.7 0.7 0.7 
IT21 2.6 1.7  
Proliferative Responses to E6 II peptide in the responders and non-
responders at weeks 0, 10, 20 Two fold change in the stimulation index (SI) 
was considered as a response, highlighted in grey 
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Wk 
0 
Wk 
10 
Wk 
20 
Wk 0 vs. Wk 10 
(P, WSR) 
Wk 0 vs. Wk 20 
(P, WSR) 
Group (n=15) 1.3 1.3 1.2 P=0.5 P=0.2 
Responders 
(n=12) 
1.2 1.2 1.3 P=0.4 P=0.5 
Non-Responders 
(n=3) 
2.0 1.7 1.3 P=0.1 P=0.4 
Change in the lymphoproliferative responses to E6II peptide in the 
group, responders, non-responders between weeks 0, 10, 20. No 
significant difference in the magnitude of response (median Stimulation Index 
SI) was observed following vaccination treatment; Wilcoxon signed rank test 
(WSR) 
 
 
LYMPHOPROLIFERATIVE RESPONSE TO E6 III PEPTIDE 
Proliferative Responses to E6III 
Responders Pre-treatment 
Post imiquimod 
(Wk 10) 
Post vaccination 
(Wk 20) 
IT5 0.8 1.0 3.3 
IT8 1.3 1.2 1.2 
IT9 0.8  1.8 
IT10 5.3 1.6 2.3 
IT13 1.5 0.5 2.1 
IT14 0.7 2.1 1.6 
IT15 1.3 0.6 1.2 
IT16 1.4 2.4 0.7 
IT17 2.0 1.2 1.5 
IT18 1.4 0.6 1.1 
IT20 3.2 1.5 0.9 
IT23 2.3 1.0 1.4 
Non-responders    
IT11 1.0 2.2 0.7 
IT19 0.7 1.3 1.4 
IT21 0.6 1.3  
 
Proliferative Responses to E6 III peptide in the responders and non-
responders at weeks 0, 10, 20 Two fold change in the stimulation index (SI) 
was considered as a response, highlighted in grey 
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Wk 
0 
Wk 
10 
Wk 
20 
Wk 0 vs. Wk 10 
(P, WSR) 
Wk 0 vs. Wk 20 
(P, WSR) 
Group (n=15) 1.3 1.2 1.4 P=0.5 P=0.4 
Responders 
(n=12) 
1.4 1.1 1.3 P=0.6 P=0.5 
Non-Responders 
(n=3) 
0.7 1.3 1.0 P=0.5 P=0.8 
Change in the lymphoproliferative responses to E6IIIpeptide in the 
group, responders, non-responders between weeks 0, 10, 20. No 
significant difference in the magnitude of response (median Stimulation Index 
SI) was observed following vaccination treatment; Wilcoxon signed rank test 
(WSR) 
 
LYMPHOPROLIFERATIVE RESPONSE TO E6 IV PEPTIDE 
Proliferative Responses to E6IV 
Responders Pre-treatment 
Post imiquimod 
(Wk 10) 
Post vaccination 
(Wk 20) 
IT5 2.4 1.0 1.4 
IT8 1.8 1.0 1.6 
IT9 1.0  4.5 
IT10 2.9 1.6 2.5 
IT13 1.1 0.7 2.1 
IT14 0.8 2.2 1.1 
IT15 1.6 1.4 1.8 
IT16 1.0 1.7 0.8 
IT17 3.3 4.4 2.0 
IT18 1.0 0.9 1.0 
IT20 3.4 1.5 1.7 
IT23 1.1 1.2 1.6 
Non-responders    
IT11 0.7 1.5 0.6 
IT19 1.2 0.9 1.2 
IT21 1.8 1.5  
Proliferative Responses to E6 IV peptide in the responders and non-
responders at weeks 0, 10, 20 Two fold change in the stimulation index (SI) 
was considered as a response, highlighted in grey 
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Wk 
0 
Wk 
10 
Wk 
20 
Wk 0 vs. Wk 10 
(P, WSR) 
Wk 0 vs. Wk 20 
(P, WSR) 
Group (n=15) 1.2 1.4 1.6 P=0.4 P=0.5 
Responders 
(n=12) 
1.4 1.4 1.7 P=0.4 P=0.6 
Non-Responders 
(n=3) 
1.2 1.5 0.9 P=0.5 P=0.5 
Change in the lymphoproliferative responses to E6IV peptide in the 
group, responders, non-responders between weeks 0, 10, 20. No 
significant difference in the magnitude of response (median Stimulation Index 
SI) was observed following vaccination treatment; Wilcoxon signed rank test 
(WSR) 
 
 
LYMPHOPROLIFERATIVE RESPONSE TO E7 I PEPTIDE 
 
Proliferative Responses to E7I 
Responders Pre-treatment 
Post imiquimod 
(Wk 10) 
Post vaccination 
(Wk 20) 
IT5 1.0 0.8 1.3 
IT8 0.9 1.7 2.1 
IT9 0.8  1.3 
IT10 1.7 0.7 2.0 
IT13 1.0 1.1 1.6 
IT14 2.5 1.1 0.7 
IT15 1.3 0.7 1.0 
IT16 1.3 0.8 0.4 
IT17 1.3 0.6 1.5 
IT18 1.1 0.9 1.4 
IT20 2.0 1.2 3.3 
IT23 1.4 1.0 1.6 
Non-responders    
IT11 1.1 1.8 1.0 
IT19 0.6 0.8 1.2 
IT21 0.8 1.2  
Proliferative Responses to E7 I peptide in the responders and non-
responders at weeks 0, 10, 20 Two fold change in the stimulation index (SI) 
was considered as a response, highlighted in grey 
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Wk 
0 
Wk 
10 
Wk 
20 
Wk 0 vs. Wk 10 
(P, WSR) 
Wk 0 vs. Wk 20 
(P, WSR) 
Group (n=15) 1.1 1.0 1.5 P=0.3 P=0.004 
Responders 
(n=12) 
1.3 1.0 1.5 P=0.03 P=0.008 
Non-Responders 
(n=3) 
0.8 1.2 1.1 P=0.3 P=0.1 
Change in the lymphoproliferative responses to E7I peptide in the group, 
responders, non-responders between weeks 0, 10, 20. A significant 
difference in the magnitude of response (median Stimulation Index SI) was 
observed in the group and responders following vaccination treatment; 
Wilcoxon signed rank test (WSR) 
 
 
LYMPHOPROLIFERATIVE RESPONSE TO E7 II PEPTIDE 
Proliferative Responses to E7II 
Responders Pre-treatment 
Post imiquimod 
(Wk 10) 
Post vaccination 
(Wk 20) 
IT5 0.6 0.5 0.5 
IT8 0.9 1.7 2.1 
IT9 1.3  2.1 
IT10 1.3 0.7 1.7 
IT13 1.1 0.5 0.8 
IT14 1.5 1.6 1.1 
IT15 1.0 0.5 1.1 
IT16 1.3 1.2 0.4 
IT17 2.3 0.4 0.8 
IT18 0.8 0.7 1.1 
IT20 2.9 0.9 1.9 
IT23 1.1 1.6 1.4 
Non-responders    
IT11 1.1 1.8 1.0 
IT19 0.6 0.8 1.2 
IT21 0.8 1.2  
Proliferative Responses to E7 II peptide in the responders and non-
responders at weeks 0, 10, 20 Two fold change in the stimulation index (SI) 
was considered as a response, highlighted in grey 
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Wk 
0 
Wk 
10 
Wk 
20 
Wk 0 vs. Wk 10 
(P, WSR) 
Wk 0 vs. Wk 20 
(P, WSR) 
Group (n=15) 1.1 0.9 1.1 P=0.4 P=0.05 
Responders 
(n=12) 
1.2 0.7 1.1 P=0.2 P=0.2 
Non-Responders 
(n=3) 
0.8 1.2 1.1 P=0.2 P=0.5 
Change in the lymphoproliferative responses to E7II peptide in the 
group, responders, non-responders between weeks 0, 10, 20. A 
significant difference in the magnitude of response (median Stimulation Index 
SI) was observed in the group alone following vaccination treatment; Wilcoxon 
signed rank test (WSR) 
 
 
 
 
 
 
 
 
 
 
